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Abstract
The goal of this thesis was to develop potent tumour cell vaccines that can be used as 
an effective strategy for cancer treatment. Allogeneic tumour cell vaccines hold great 
promise for caiicer treatment. Cytokine modification has been proven effective in 
enhancing the immunogenicity of tumour cell vaccines. This work here shows that 
modification of the allogeneic K1735 cells to express the immunostimulatory 
cytokines GM-CSF, IL-12 or IFN-y, however, was not effective in augmenting the 
immunogenicity of the vaccine and irradiated cytokine-modified vaccines could not 
protect animals from autologous tumour challenge. These data are in agreement with 
recent literature. Similar results were obtained when K1735 cells were modified to 
express heat shock proteins. Analysis of the injection site of irradiated K1735 
vaccine cells demonstrated that clearance of the K1735 cells from the injection site 
correlated well with the induction of proinflammatory cytokines and infiltration by 
non-specific effector cells such as NK cells.
FMG-induced fusion was next investigated as a novel and effective way of releasing 
tumour antigens from allogeneic vaccine cells in an immunostimulatory fashion. 
Expression of the Vesicular Stomatitis Virus G glycoprotein by K1735 or B16 cells 
lead to the formation of extensive syncytia in vitro. Vaccination of mice with 
irradiated 2-day fusing allogeneic K1735 or syngeneic B16 cells showed no 
significant therapeutic benefit relative to irradiated ùnfusêd cells. Interestingly, 
vaccination of mice with a hybrid K1735/B16 fusing vaccine repeatedly lead to 
significant protective and therapeutic immunity against a B16 challenge. Overall, 
VSV-G mediated syncitial death was shown to be a highly immunogenic event that 
promotes the induction of potent specific antitumour immunity in the context of 
allogeneic vaccines. The mechanism of immunogenicity of fusing hybrid vaccines 
was investigated.
Generation of long-term human allogeneic fusing tumour cell vaccines for translation 
of this work into clinical application was next investigated. A human melanoma cell 
line stably transduced with the gene for a hyperfiisogenic form of the Gibbon ape 
leukemia virus FMG gene was generated. The Tet-On system of transcriptional 
control was employed to control gene expression and thus GALV-mediated fusion. 
Very high levels of fusion could be obtained following the addition of doxocycline in 
culture. This cell line could form the basis of human melanoma fusing vaccine.
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Chapter 1 
I n t r o d u c t io n
1.1 Cancer Immunotherapy
The concept of employing the immune system to effectively eliminate any insult to 
the human body, be it a bacterial pathogen, a virus, or cancer, has been continuously 
explored over the course of the last two centuries. Since first described in the late 
1790s by Jenner, the development of effective immunoprophylactic vaccines has 
flourished to become one of the most successful types of medical intervention. In 
contrast to the widespread success of immunoprophylactic vaccination for infectious 
diseases, imunotherapeutic intervention for the treatment of cancer has been less 
successful. One of the first documented reports of tumour immunotherapy in humans 
was in the late 18^ century, when W. Coley used bacterial extracts to boost the 
immune system against tumour cells in cancer patients. This approach was based on 
observations of tumour regression following incidental bacterial infections (Old 
1992). Interest in the field of cancer immunotherapy has dramatically oscillated over 
the course of the last century between overenthusiasm for the applicability of vaccines 
in inducing potent anti-tumour immune responses and severe pessimism for the 
validity of such an approach. The immense complexity of the immune system and the 
diversity of mechanisms underlying tumour development are the principal causes 
behind the relatively slow progress in the development of effective, clinically relevant 
imunotherapeutic vaccination approaches for cancer therapy.
Present enthusiasm for cancer immunotherapy has come as a direct result of advances 
made primarily over the last two decades in understanding the biology of the immune 
system, identifying cellular and molecular components crucial to immune recognition, 
priming and regulation, and new insights in tumour biology. Critical technological 
advances in the field of vector development and gene therapy have also made it 
possible to consider anti-tumour vaccination as a pragmatic approach to cancer 
therapy.
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Most cancer cells have multiple genetic defects. Some gene therapy approaches for 
cancer treatment aim to correct such genetic defects and thus reverse malignant cells 
to a non-malignant phenotype. However, since most cancer cells have an 
accumulation of multiple defects, and restoration of the phenotype must be achieved 
in every single cell in a tumour mass, successful corrective gene therapy is faced with 
great challenges. These challenges arise from limitations in identifying the whole 
spectrum of important genetic defects in each tumour and the current lack of efficient 
gene delivery strategies for targeting and transducing all malignant cells. At present, 
corrective gene therapy can not address the issue of effectively targeting metastatic 
lesions commonly present in cancer patients or the issue of genetic diversity between 
different lesions in the same patient.
Immunotherapy of cancer on the other hand is primarily focused in eradicating cells 
with a malignant phenotype, rather than attempting to revert them to a normal state. 
Many gene transfer strategies have been developed for the in vivo or ex vivo 
introduction of cytotoxic genes or immunostimulatory genes, such as cytokines, into 
tumour cells or cells of the immune system. Here the aim is to directly kill tumour 
cells and/or augment the immune response against them, resulting indirectly in 
tumour cell death.
1.2 Tumour Immunology
A landmark in the development of immune-based strategies for cancer treatment has 
been the realisation that tumour cells express a range of tumour associated antigens 
(TAA) that can present targets for immune cell activation and immune-mediated 
elimination of malignant cells. Tumour infiltrating lymphocytes (TIL) isolated firom 
the stroma of growing tumours in mice could be activated to recognise and eliminate 
tumour cells in in vitro assays (Barth, Bock et al. 1990). Adoptive transfer of these 
TIL to tumour bearing animals could mediate regression of established disease 
(Spiess, Yang et al. 1987). Similar observations have been made in human studies 
where administration of autologous TIL plus interleukin-2 (IL-2) to patients with 
metastatic melanoma resulted in regression of established invasive disease in some 
individuals (Muul, Spiess et al. 1987; Rosenberg, Packard et al. 1988). Identification
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of such tumour-reactive TIL has provided a rational basis for the development of 
strategies aimed at inducing or further augmenting immune responses to tumours.
1.2.1 Identification Of TAA
Identification and ex vivo expansion of tumour-reactive lymphocytes from patients 
provided a useful reagent for the molecular identification of cancer antigens. Using 
lymphocytes from a melanoma patient. Boon and colleagues identified the MAGE 
family of genes, which were expressed on a subset of cancers as well as on gonadal 
tissue (van der Bruggen, Traversari et al. 1991). A tumour reactive cytotoxic T 
lymphocyte (CTL) clone exhibiting cytotoxic activity against autologous tumour cells 
in in vitro assays was expanded from the peripheral mononuclear cells of this patient 
and used to identify an antigen-loss variant of the original tumour that was not lysed 
by the CTL clone. The genes encoding the antigens recognised by the CTL clone 
were then identified by modifying the antigen-loss tumour variant with DNA libraries 
from the original tumour and testing for restoration of recognition by the CTL clone. 
The gene encoding the target antigen recognised by the CTL could then be isolated. 
An improved strategy for identifying target genes encoding relevant TAA involves 
the generation of tumour-derived cDNA libraries, the transient transfection into 293 
or COS cell lines expressing the appropriate Major Histocompatability Complex 
(MHC) gene, and determination of recognition and lysis by autologous CTL or TIL. 
When positive pools are identified they are subcloned and individual genes 
responsible for conferring sensitivity to lysis by the CTLs or TIL are isolated. This 
technique was first successful in identifying the melanoma antigen tyrosinase 
(Brichard, Van Pel et al. 1993; Robbins, el-Gamil et al. 1994).
TAA can also be identified using a biochemical technique in which MHC Class I 
complexes from tumour cell lysates are immunoprecipitated and the bound tumour- 
specific peptides acid-eluted. The eluted peptides are then fractionated and peptide 
fractions are pulsed onto surrogate target cells, expressing the appropriate MHC Class 
I molecules. Specific TAA are identified by purifying and sequencing fractions 
conferring sensitivity to lysis by autologous CTLs or TIL (Van den Eynde, Peeters et 
al. 1995; Rosenberg 1997). A “reverse” method for identifying TAA has also been 
developed in which the sequence of proteins know to be overexpressed in tumour
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cells is screened for the presence of MHC-binding motifs. Peptides within these 
sequences are synthesised and pulsed onto target cells expressing the appropriate 
MHC molecule and tested for their ability to mediate tumour recognition and lysis by 
CTLs and TIL. This approach was used to identify an HLA-A1 -restricted epitope 
derived from MAGE-3 (Celis, Tsai et al. 1994).
Another approach of TAA identification has been developed recently and is based on 
the presence of antibodies against surface or intracellular cancer antigens in sera of 
cancer patients (Old and Chen 1998). In this approach recombinant cDNA expression 
libraries of human tumours are analysed serologically with autologous serum (Sahin, 
Tureci et al. 1997). Using this technique a range of novel as well as previously 
identified cancer antigens, such as tyrosinase and the MAGE antigens, have been 
described (Old and Chen 1998). A further technique for TAA identification has been 
the global expression profiling approaches such as SAGE (Martelange, De Smet et al. 
2000; Riggins 2001). Comparing all genes expressed in tumours compared to their 
normal tissue of origin has identified patterns of gene expression common to tumour 
and distinct from normal cells. Further analysis of these data will identify multiple 
antigen targets that span multiple tumour types and MHC restrictions.
1.2.2 Tumour Antigens Recognised by T cells
Studies of antigens expressed in tumour cells, particularly melanoma, and recognised 
by autologous human T lymphocytes have established several important principles for 
human cancer immunotherapy (Rosenberg 2001). Firstly, cancer antigens can arise 
firom various different proteins (normal differentiation antigens, cancer-testis 
antigens, viral antigens) and intracellular genetic events (alternative open reading 
fi:ames, single base mutations, chromosomal rearrangement, post-transcriptional 
control of expression, intronic sequences, aberrant processing). Secondly, a given 
cancer antigen can contain epitopes that can be presented on many different MHC 
molecules. Tyrosinase for example contains epitopes that can be presented by HLA- 
A l, -A2, -A24, -B44, -DR4 and -DR15, while epitopes fi’om gplOO can be presented 
by HLA-A2, -A3, -A24, -Cw8, -DR4, and -DR15. Thirdly, a given cancer patient can 
develop immune responses to multiple antigenic epitopes as demonstrated by 
observations of reactivity of the same polyclonal TIL population against multiple
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different antigens. Finally, antigens from the same gene can be expressed in multiple 
different tumours. Antigenic epitopes deriving from the MAGE gene for instance 
have been identified in breast, lung, prostate, bladder and oesophageal cancers. 
Although the pool of known TAA is highly heterogeneous in composition, TAA 
recognised by autologous T cells can be generally classified into the following 5 
categories (Table 1.1):
Table 1.1: Tumour Antigens Recognised By The Immune System
CatSQorv of antiaen Tumour
Unique tumour antigens
P-catenin Meianoma
caspaseS Head and Neck
C0K4 Melanoma
Developmental antigens
MAGE-1.-3.-4 solid tumours
GAGE-1,-2 solid tumours
BAGE solid tumours
DAM solid tumours
NY-ESO-1 solid tumours
TIssue-speclfle differentiation antigens
gp100/pmeil7 Melanoma
tyrosinase Melanoma
MelanA/MART-1 Melanoma
TRP-1,-2 Melanoma
PSA. PSMA Prostate
Oncogwe  & tumour suppresor gene products
pS3 50% solid tumours
Ras Melanoma, pancreatic, coloredal
H er-2/neu............. . ............ Breast, ovarian
. VIrally, encoded antigens
EBV. HPV. HTLV-1 Cervical, hepatoma, leukemia, lymphoma
1.2,2.1 Unique Tumour Antigens
Unique tumour antigens have been identified in tumours of individual patients and are 
usually the products of point mutations, gene rearrangements or changes in open 
reading frames that give rise to altered MHC Class I or Class II restricted T 
lymphocyte epitopes. An example of a unique tumour antigen identified in melanoma 
is an epitope generated from a point mutation of the gene for P-catenin (Robbins, El- 
Gamil et al. 1996). A single C to T base mutation gave rise to an HLA-A24 restricted 
nine amino acid peptide with over a million fold greater avidity for recognition by the 
patient’s autologous TIL clone compared to the nonmutated 9-mer. A point mutation
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in the cyclin-dependent kinase 4 (CDK4) gene gave rise to a peptide with altered 
binding affinity for HLA-A2, which constituted a novel T cell melanoma epitope 
(Wolfel, Hauer et al. 1995). Mutation of the CDK4 protein prevents it from 
interacting with the tumour suppressor gene and CDK4 inhibitor, plb'^'^'^^ therefore 
disturbing the normal cell cycle regulation machinery. An example of a TAA 
generated from alteration in an open reading frame is that of caspase 8 in a case of 
head and neck cancer (Old and Chen 1998). A mutation in a stop cpdon resulted in 
the extension of the normal open reading frame by 88 amino acids giving rise to novel 
T cell epitopes. Finally, another interesting type of unique tumour antigens are those 
arising from the idiotypic determinants of immunoglobulins expressed on clonal B 
cell malignancies, which have been explored as vaccines in studies of patients with B 
cell lymphomas (Kwak, Taub et al. 1995) (Hsu, Benike et al. 1996).
Most of the mutations or gene alterations giving rise to unique tumour antigens are 
thought to be critical contributors in the malignant phenotype of cells. The tumour 
specificity coupled with the patient specificity of unique tumour antigens renders 
them unlikely candidates for the development of generic vaccines with large-scale 
clinical application.
1.2.2,2 Developmental Antigens
Also known as embryonic antigens (expressed during embryonic development) or 
tumour shared antigens, developmental antigens are predominantly, but not uniquely, 
expressed by malignant cells. An interesting characteristic of these antigens is that 
their expression is shared by multiple types of cancers, making them attractive 
candidates for vaccination purposes. Expression of such antigens can also be shared 
with normal tissues, such as the testis or placenta, although the levels of antigen 
expression in normal tissues are usually very low. This apparent quantitative 
difference in expression levels between the different tissues sharing expression of 
developmental antigens can be exploited in the development of cancer vaccines. The 
MAGE-T encoded antigen MZ2-E, which%n HLA-Al restricted epitope (van der 
Bruggen, Traversari et al. 1991), is considered a prototype of molecularly identified 
human TAA recognised by autologous CTLs. MAGE-1 encodes an additional 
epitope restricted by HLA-Cw (antigen MZ2-Bb) (van der Bruggen, Szikora et al.
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1994), MAGE-1, located on the X chromosome, is expressed in appoximately 40% 
of melanomas, as well as other tumour types including gliomas, breast cancer, head 
and neck, and non small cell lung cancer. Further cloning revealed a multigene 
family encoding several developmental antigens consisting of at least 12 MAGE 
genes and the closely related gene families of BAGE, GAGE, DAM (Boel, Wildmann 
et al. 1995) (Van den Eynde and Brichard 1995). Antigens expressed by these genes 
are found in melanoma and other cancers, as well as normal tissues such as placenta, 
testis and eye.
1.2,2.3 Tissue-Specific Differentiation Antigens
Tissue-specific differentiation antigens are nonmutated molecules expressed only by 
cells (normal or malignant) of the same lineage. Expression in transformed cells is 
generally upregulated compared to expression in normal counterparts. The best 
examples of this class of tumour antigens have been described in melanoma. 
Tyrosinase, gplOO, melanoma antigen recognised by T-cells-1 (MART-1), tyrosinase 
related protein-1 and -2 (TRP-1 and TRP-2) are all proteins expressed in melanoma as 
well as normal melanocytes, and contain several MHC Class I or Class II restricted 
epitopes recognised by C08^ or CD4^ T cells (Brichard, Van Pel et al. 1993) 
(Topalian, Rivoltini et al. 1994) (Cox, Skipper et al. 1994) (Robbins, el-Gamil et al.
1994). CTLs specific for such antigens that are capable of killing melanoma cells will 
also be able to kill normal melanocytes. Prostate specific antigen (PSA), prostate 
specific membrane antigen (PSMA), and PSH-Pl are similar examples of 
differentiation antigens expressed by normal prostate epithelia and overexpressed in 
prostate cancer and which can be recognised by specific CTLs. Differentiation 
antigens are good candidates for immunotherapeutic treatment of specific cancers 
arising in epithelial tissues not necessary for survival. In clinical studies in melanoma 
patients, adoptive transfer of TIL specific for melanoma differentiation antigens plus 
IL-2 resulted in regression of melanoma lesions (Rosenberg and White 1996). 
Clinical responses were often associated with the appearance of vitiligo, a 
depigmentation of the skin due to destruction of normal melanocytes. The appearance 
of vitiligo is associated with good prognosis and demonstrates that tolerance of the 
immune system to normal self antigens can be overcome. Of course, while less of
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melanocytes can be tolerated, this may not be an acceptable side effect of 
immunotherapy for kidney or brain tumours, for example.
L2.2.4 Oncogene and Tumour Suppressor Gene Products
Overexpression or point mutation of oncogenes or tumour suppressor genes can also 
give rise to TAA that can be recognised by CD4^ or CD8^ T cells. Oncogenes and 
tumour suppressor genes have central role in tumourigenesis and antigens arising 
from such molecules are very interesting targets for antitumour immunity. In addition 
to being recognised by specific TIL and CTL, these antigens can also be recognised 
by antibodies from the serum of patients.
The most commonly altered tumour suppressor gene in cancer is p53. p53 mutations 
are found in more than 50% of solid tumours. More than 120 different mutations 
have been identified in the p53 gene, most of which result in the generation and 
accumulation at very high levels of a non fimctional protein (Theobald, Biggs et al.
1995). The presence of any single p53 mutation in only a very small fraction of 
human cancers makes cancer vaccines aimed specifically at p53 mutations rather 
impractical (Pardoll 1998). Nonetheless, CTL can be generated against either human 
(Yanuck, Carbone et al. 1993) or murine (Noguchi, Chen et al. 1994) mutated p53 
protein. Alternatively, CTLs specific for a wild-type p53 peptide can be created and 
adoptive transfer of these CTLs in animals bearing tumours overexpressing mutated 
p53 has been shown to generate a significant therapeutic effect (Vierboom, Nijman et 
al. 1997).
An oncogene that has been extensively studied as a target for anti tumour immunity is 
the Ras proto-oncogene (Disis and Cheever 1996). Three main activating mutations 
in the Ras gene (in positions 12, 13 and 61) have been identified in melanoma, 
pancreatic and colorectal cancers (Gaudemack 1996) giving rise to novel MHC Class 
I and Class II restricted epitopes recognised by CD4^ and CD8^ T cells (Possum, 
Olsen et al. 1995). Antibody mediated responses to mutated Ras have also been 
identified in patients with gastrointestinal cancer. Her-2/neu, a membrane tyrosine 
kinase receptor, is an oncogene normally expressed in low levels in ovarian, 
mammary and other epithelia, and overexpressed in a number of carcinomas such as
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breast and ovarian. Although not mutated, her-2/neu has been shown to elicit both 
antibody and T cell mediated responses in cancer patients (Peoples, Goedegebuure et 
al. 1995) and her-2/neu expressing tumour cell clones have been shown to be 
susceptible to lysis by autologous CTLs (Yoshino, Peoples et al. 1994).
1.2.2. S Viralfy Encoded Antigens
As several different malignancies have been associated with specific viruses, interest 
in virally-encoded antigens as targets in the design of anti tumour vaccines has 
increased significantly. Although viral proteins can be directly oncogenic or 
indirectly contribute to the accumulation of a malignant phenotype in cancer cells, it 
is not know whether they are necessary for maintenance of the transformed state, an 
important consideration in the development of cancer vaccines. Human pappiloma 
virus (HPV) types -16, -18,-31 and -45 have been strongly associated with cervical 
carcinoma. Approximately 80-90% of cervical cancers express the E6 and E7 
antigens of HPV, which bind to and inactivate the tumour suppressor proteins p53 and 
retinoblastoma respectively. Efforts have been made to identify specific epitopes 
from E6 and E7 that can be presented by MHC molecules and generate a specific 
CTL response (de Gruijl, Bontkes et al. 1996; Ressing, van Driel et al. 1996). Other 
viruses implicated in malignant transformation and which may express potential 
tumour antigens are hepatitis virus (hepatoma), Epstein-Barr virus (lymphomas and 
nasopharyngeal cancer), and human T cell leukemia virus-1 (leukemias). In addition 
to being potentially strong candidates for therapeutic cancer vaccines, virus- 
associated tumour antigens also present a great opportunity for the development of 
prophylactic vaccination strategies (Chang, Chen et al. 1997).
13 Immune Responses to Tumour Cells
The plethora of studies devoted to identifying antigens expressed in tumour cells that 
can function as tumour regression antigens clearly demonstrate that mediators of 
cellular immunity can not only recognise tumour antigens presented to them by MHC 
molecules but can also be licensed to kill cells displaying these target antigens. CD8^ 
or CD4^ T cells isolated from tumour-bearing patients expressing specific T cell 
receptors (TCR) can be activated in vitro upon ligation of the TCR to an MHC Class
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I-, or Class II- peptide complex, respectively, and kill autologous tumour cells both in 
vitro and when adoptively transferred in vivo (Rosenberg, Spiess et al. 1986; Muul, 
Spiess et al. 1987; Spiess, Yang et al. 1987; Barth, Bock et al. 1990). In addition, 
antibody mediated responses against tumour cells have been described (Sahin, Tureci 
et al. 1997; Old and Chen 1998; Bremers and Parmiani 2000). However, in the 
majority of patients tumours thrive in the presence of an intact immune system, 
suggesting that the development of an effective antitumour immune reaction in 
patients is the exception and not the rule. Even in these cases where there is evidence 
of immuneresponsiveness, whether specific TIL or antibodies, the tumours 
progressively grow. Importantly, in most of the previously mentioned studies 
extensive in vitro conditioning with additional immune stimulatory factors, such as 
cytokines was required to activate T cells to produce effector functions (Herin, 
Lemoine et al. 1987) (Rosenberg, Packard et al. 1988). Understanding the 
mechanisms underlying inunune responsiveness to tumour cells is therefore essential 
for designing strategies to modulate immune responses and effectively directing them 
against tumour cells.
The inunune system is a highly complex and gracefully orchestrated network of cells 
and soluble factors. It is the fine-tuning of this system that determines the outcome of 
a reaction -  stimulation, suppression, tolerance or ignorance. Two major branches 
constitute the core of host resistance against invading agents and tumours: innate 
immunity and adaptive immunity. Interaction between the two branches is very close 
and regulated by a variety of cells of the immune system and soluble factors 
(Belardelli and Ferrantini 2002).
1.3.1 Innate Immune Response
The innate immune system is traditionally considered as the first line of defence 
against invading pathogens such as bacteria and viruses. Increasing evidence 
however has revealed that cells of the innate immune response have critical roles in 
the host responses against malignant cells. Two of the main characteristics of innate 
immunity are a lack of immunological memory and antigen recognition via specific 
structurally and genetically conserved pattern recognition receptors. Key players of 
the innate immune system include macrophages, natural killer (NK) cells, neutrophils.
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eosinophils and dendritic cells, although as will be described later, some of these cells 
play significant roles in the adaptive branch of immunity as well. Most of these cells 
recognise non-processed antigen, such as carbohydrates and nucleic acids of 
pathogens, via a spectrum of different pattern recognition receptors. Pattern 
recognition receptors can be expressed on the cell surface, in intracellular 
compartments, or secreted in the bloodstream and tissue fluids and examples include 
the macrophage manose receptor (MMR) expressed on the surface of macrophages 
(Fraser, Koziel et al. 1998), macrophage scavenger receptor (MSR) also expressed on 
macrophages (Pearson 1996) and Toll-like receptors expressed on NK cells, DCs and 
macrophages.
1.3,LI Natural Killer Cells
Key mediators of innate immunity known to have critical roles in anti-tumour 
immunity are NK cells. NK cells are large granular lymphocytes initially identified 
by their ability to kill tumour cells of different origins without prior activation. They 
arise in the bone marrow and comprise approximately 10-20% of the mononuclear 
cell fraction in peripheral blood. Unlike T cells, NK cells do not need to undergo 
thymal education for maturation (Dorshkind, Pollack et al. 1985) and do not express 
any TCR/CD3 complex on their surface (Lanier, Cwirla et al. 1986). They lack 
apparent antigen specificity and lyse tumour cells in a non-MHC-restricted fashion. 
Upon activation by tumour cells or cytokines such as IL-2 and IL-12, NK cells 
produce cytokines including IFN-y and tumour necrosis factor -a  (TNF-a) (Perussia 
1991). Expression of cell surface receptors for IL-2, IL-12 and TNF-a on NK cells 
ensure that cytokines produced by activated NK cells can exert an autocrine effect, 
possibly enhancing their cytotoxic function. Lymphokine activated killer cells, 
predominantly consisting of activated NK cells, can be generated from the blood or 
from tumour-infiltrating lymphocytes upon IL-2 conditioning. These IL-2 activated 
NK cells have a broader specificity and enhanced ability to kill tumour cells.
The most important feature of NK cells for cancer immunity and the most important 
distinction between NK cells and T cells is their ability to recognise and kill tumour 
cells that lack MHC Class I on their surface. This makes them very attractive 
candidates for immunotherapy of tumours that have downregulated surface MHC
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Class I expression to evade T cell recognition. For example, MHC Class I absence on 
lymphoma cells renders them susceptible to NK-cell mediated cytotoxicity (Karre, 
Ljunggren et al. 1986). Thus, Class I downregulation by transformation or infection 
may make cells susceptible to NK cell lysis (Raulet and Held 1995; Lanier, Corliss et 
al. 1997), while IFN-y induced upregulation of Class I expression on tumour cells 
may protect them from NK mediated killing (Piontek, Taniguchi et al. 1985). Class I 
recognition by NK cells in humans is mediated primarily by killer immunoglobulin 
receptors (KIR). KIR are members of the immunoglobulin superfamily (Wagtmann, 
Biassoni et al. 1995) and can signal inhibition or activation upon MHC Class I 
binding depending on motifs present within their cytoplasmic tail. Interestingly, in 
mice MHC Class I binding NK receptors belong to a structurally different class of 
receptors, the type II lectins, capable of recognising sugar moieties on Class I 
molecules (Yokoyama and Seaman 1993).
The best characterised activation receptor on NK cells is the Fey receptor, CD 16, 
which serves to bind soluble or cell bound IgG-complexes during antibody-dependent 
cell-mediated cytotoxicity and facilitate killing of the target cells (Takai, Li et al.
1994). Natural cytotoxicity receptors (NCR) are another type of activation receptors 
expressed on the surface of NK cells. Members of NCR include the recently 
identified NKp46, NKp30 and NKp44 (Mdretta, Biassoni et al. 2000) all of which 
play important roles in the lysis of most tumour cell lines, as suggested by antibody- 
mediated receptor-blocking experiments. NKp46 high expressing NK cells have a 
greater ability to kill autologous, allogeneic or xenogeneic tumour cells than low 
NKp46 expressing NK cells. NKp44 is expressed uniquely on IL-2 activated NK 
cells, contributing to the increased ability of these NK cells to lyse a broad spectrum 
of tumour cells (Cantoni, Bottino et al. 1999).
In addition to their direct anti-tumour cytotoxic effects mediated by ligation of the 
inhibitory and activatory cell surface receptors on NK cells with MHC Class I 
molecules on target tumour cells, NK cells can have indirect, cytokine mediated 
antitumour effects. As mentioned earlier, NK cells can be activated to express a 
plethora of type 1 and type 2 cytokines, including IFN-y, TNF-a, GM-CSF, M-CSF, 
IL-2, IL-3 and IL-8, plus chemokines. All of these may contribute to the activation of
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CD4^ T cells, CD8^ T cells and DCs, thus influencing the development of the 
adaptive immune response to tumour cells (Trinchieri 1995; Kos 1998). NK cells can 
reciprocally respond to cytokines produced by cells of the adoptive immune response, 
suggesting the existence of a very close link between non-specific innate immune 
responses and antigen-specific T cell-mediated responses.
1.3.L2 Macrophages
Macrophages are scavenger cells that are highly phagocytic and can express high 
levels of MHC Class II on their cell surface, thereby functioning as efficient APC able 
of stimulating CD4^ helper T cells. Macrophages can determine the course of 
downstream immune responses to tumours via cytokine secretion (Gough, Melcher et 
al. 2001). Often they are part of the cell infiltrates found in tumours. Expression of 
pro-inflammatory cytokines such as IL-12 by tumour associated macrophages (TAM) 
contributes to the activation of T cells as well as other effector cells such as NK cells 
and promotes recruitment of secondary immune cells, such as neutrophils, to the 
tumour site enhancing local cytotoxicity (Bartholeyns 1993). Like NK cells, 
macrophages play an important role in innate immunity by expressing several PRR 
and immunoglobulin Fc receptors which allow them to recognise pathogen-associated 
molecular patterns and mediate antibody-dependent cellular cytotoxicity respectively. 
The mechanisms of cellular cytotoxicity by activated TAM include secretion of 
reactive oxygen species (ROS), proteases, nitric oxide and cytotoxic cytokines such as 
tumour necrosis factor (TNF)-a and IL-1. ROS release by TAM however has been 
associated with irreversible inhibition of NK cell activity in some instances, leading to 
apoptotic NK cell death (Hellstrand, Asea et al. 1994; Kono, Salazar-Onfray et al.
1996).
Although macrophages can be highly effective at initiating antitumour immune 
responses, there is significant evidence that macrophages recruited to tumours are 
responsible for numerous pro-tumourigenic activities. Macrophages enhance vascular 
remodelling in the tumour environment and can also enhance the metastatic potential 
of primary tumours (Elgert, Alieva et al. 1998). In this way macrophages, while 
potentially a key component of an effective antitumour immune response, are most
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likely to be found in patient tumours as active participants in the tumorigenic
environment.
1.3.2 Adaptive Immune Response
The adaptive branch of host immunity is characterised by antigen specificity and 
immunological memory. Dendritic cells (DCs), CD4^ T cells, CD8^ T cells and B 
cells are the key mediators of adaptive immunity and the close interactions between 
these cells are crucial to the outcome of immune responses. T and B lymphocytes 
have the unique ability to create large numbers of clones expressing distinct antigen 
receptors, TCR, and immunoglobulin respectively, recognising antigens or peptides in 
a highly specific manner. Antigen specific cells do not have the ability to distinguish 
between structures that “require” an immune response and those that do not. Thus, 
selection of specific cells is critical to “elucidate” the repertoire of antigen specific 
clones to minimise immune responses in non-pathogenic circumstances. Moreover, 
antigen recognition by these antigen specific cells is not merely sufficient to instigate 
an effective antigen specific immune response. In fact, antigen recognition in the 
absence of subsequent signals is likely to lead to generation of antigen tolerance. It is 
cells of the innate immune system, particularly DC, which can efficiently provide the 
necessary signals to guide the development of an immune response to specific 
antigens.
1.3,2.1 Dendritic Cells
DC, the most professional type of APC, are an essential link between innate and 
adaptive immunity (Palucka and Banchereau 1999). Originally described by 
Steinman and colleagues (Steinman and Cohn 1973), DC represent a heterogeneous 
cell population encompassing multiple subsets with potentially distinct roles (Vremec 
and Shortman 1997). They reside in most peripheral tissues, particularly skin and 
mucosae, where they can continually take up antigens, process them into peptides and 
load them onto MHC Class I and II for presentation to T cells. There are at least three 
distinct subpopulations of DC, two within the myeloid lineage and one within the 
lymphoid lineage, and three stages of development, including precursor DC patrolling
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through the blood and lymphatics, tissue resident immature DC and mature DC 
primarily found within secondary lymphoid organs (Palucka and Banchereau 1999).
Immature tissue resident DC are very efficient in capturing antigens from the local 
environment, but express very low levels of surface MHC and accessory molecules 
making them very inefficient T cell stimulators. Immature DC possess several 
mechanisms for antigen uptake particularly macropinocytosis (Sallusto, Celia et al.
1995), during which large volumes of extracellular fluid can be sampled for soluble 
antigens, receptor-mediated endocytosis (Guermonprez, Valladeau et al. 2002), which 
allows the uptake of macromolecules through coated pits, and phagocytosis of 
particles and microbes. Mouse and human immature DC express a plethora of surface 
receptors including Fc receptors (Esposito-Farese, Sautes et al. 1995; Fanger, 
Wardwell et al. 1996), which allow the uptake of Ig-coated particles, C-type lectin 
receptors such as DEC-205 (Mahnke, Guo et al. 2000) and MMR (Sallusto, Celia et 
al. 1995), scavenger receptors involved in uptake of apoptotic bodies (Platt and 
Gordon 1998), DC-specific ICAM3-grabbing non-integrin (DC-SIGN) (Geijtenbeek, 
Krooshoop et al. 2000) and Langherin (Valladeau, Ravel et al. 2000). Another class 
of very important receptors expressed by DC are the TLR responsible for recognition 
of pathQgcn-associated molecular patterns such as LPS, bacterial lipoproteins, CpG 
motifs present in bacterial DNA, and double stranded RNA (Medzhitov 2001).
To activate CD8^ cytotoxic T cells, DC must present antigens in the context of MHC 
Class I molecules (Figure 1.1.A). Classically MHC Class I restricted peptides are 
products of endogenously synthesised proteins. Most proteins destined to be loaded 
on MHC Class I molecules are targeted for proteosomal degradation into short 8-10 
amino acid long peptides by the ubiquitin (Ub)-proteasome pathway (Spataro, 
Norbury et al. 1998). The resulting antigenic peptides are transferred to the ER by the 
transporter associated with antigen presentation (TAP) and under the guidance of a 
loading complex composed of endoplasmic reticulum (ER) resident chaperones are 
loaded on newly synthesised MHC Class I molecules (CrcsswcU, Bangia et al. 1999). 
MHC Class I-peptide complexes are rapidly transferred to the plasma membrane 
where they become available for recognition by CD8^ T cells. DC also have the 
ability to process and present exogenously derived antigens, such as tumour-derived 
antigens, through the MHC Class 1 pathway, in a process know as “cross-
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presentation”. Cross-presentation can occur either in a TAP-independent or a TAP- 
dependent manner (Yewdeli, Norbury et ai. 1999). The former mechanism requires 
that MHC Class I molecules are present in the endocytic pathway (Kleijmeer, Escola 
et al. 2001) and is generally insensitive to inhibitors of protein neosynthesis and 
inhibitors of the proteasome. The latter mechanism is better understood and has been 
demonstrated in several different experimental systems (Kovacsovics-Bankowski and 
Rock 1995; Rodriguez, Regnault et al. 1999). Cross presentation is believed to be 
critical to the development of protective antigen-specific immune responses against 
tumour cells that express very low to no MHC 1 molecules (Huang, Bruce et al.
1996). Additionally, cross presentation explains immune responses induced by 
allogeneic tumour cell vaccines that can not productively present tumour antigens on 
their MHC molecules to host T cells.
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Figure 1.1: Antigen processing and presentation pathways.
A: endogenous antigens are degraded by the proteasome and following TAP- 
mediated transport to the rough ER they are loaded on free Class I MHC molecules 
with the help of the chaperoning molecules tapasin, calnexin and calreticulin. 
Binding of antigenic peptides to Class I MHC stabilises this complex and promotes 
release from ER and rapid transport to the plasma membrane. B: following uptake by 
the APC, exogenous antigens are degraded in endocytic compartments and are loaded 
on Class II MHC molecules in late endosomal compartments. Class II MHC 
molecules in the rough ER associate with the invariant chain (li) to prevent premature 
loading and to aid with transport to loading compartments. li becomes gradually 
degraded and its last remaining fragment, CLIP, becomes is replaced by an antigenic 
peptide. Class II MHC-peptide complexes are transported to the plasma membrane.
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CD4^ T cells recognise processed antigen presented on the surface of DC in the 
context of MHC Class II molecules (Figure l.l.B). Exogenous antigens enter the 
endocytic pathway of the cells where they are degraded into 12-15 amino acid long 
peptides and are directed toward the MHC class Il-rich compartments (MIICs), late 
endosomal structures abundant in immature DC (Watts 1997). MHC Class II 
molecules are synthesised in the ER where they associate with invariant chains (li) 
prohibiting their premature loading (Cresswell 1996). Transport signals present in the 
cytoplasmic region of the li chain guide MHC Il-Ii complexes through the Golgi 
apparatus to endosomal and lysosomal compartments leading to the MIICs, where 
amidst an acidic, protease-rich environment, the li chain is degraded by several 
proteolytic enzymes and MHC Class II molecules become free for antigen loading. 
Antigen loading onto MHC Class II molecules is mediated by HLA-DM and HLA- 
DO products (Kropshofer, Hammerling et al. 1999). MHC Class Il-peptide 
complexes are relocated to the cell surface, where they become available for binding 
to TCR on CD4^ T cells (Celia Marina 1997; Santambrogio, Sato et al. 1999).
Antigen presentation through either of the two pathways of processing and 
presentation becomes extremely efficient once DC have received maturation signals. 
Mature DC express higher levels of MHC Class I and II molecules (Cella Marina 
1997; Rescigno, Citterio et al. 1998), and have increased proteosomal activity in the 
lysosomal compartments resulting in more efficient degradation of antigens (Fiebiger, 
Meraner et al. 2001). Additionally, mature DC replace the standard proteasome with 
the immunoproteasome, which may enhance efficiency of processing certain epitopes 
(Macagno, Gilliet et al. 1999; Morel, Levy et al. 2000). DC maturation can be 
triggered by a variety of factors. Maturation of DC is required for effective T cell 
activation as it leads to not only enhanced presentation of antigenic peptides but also 
to enhanced expression of essential costimulatory molecules on the surface of DC, as 
well as production of a variety of immune regulatory cytokines. Typically, microbial 
or viral products such as LPS, CpG DNA motifs and dsRNA can very efficiently 
induce DC maturation, and they do so via TLRs or other pattern recognition receptors 
on DC. Thus TLR provide a mechanism by which DC can link innate and adaptive 
immunity. Pro-inflammatory cytokines such as IL-1, GM-CSF and TNF-a also
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trigger DC maturation, while IL-10 blocks maturation. DC have a unique ability of 
directing the outcome of an immune response, as demonstrated by the influence that 
the cytokine milieu generated by activated mature DC has. Release of cytokines such 
as IL-2, IL-12, IL-15, INF-y, TNF-a and TNF-p can promote activation of T helper I 
(ThI) cells and development of cell mediated immune responses, whereas secretion of 
cytokines such as IL-4, IL-5, IL-6 and ILIO can promote activation of Th2 cells and 
humoral immune responses against tumours (Belardelli and Ferrantini 2002).
Migration and homing of DC to and from tissues or lymphoid organs is tightly 
regulated by chemotactic factors released by target tissues and by modulation of 
adhesion molecules expressed on the surface of DC (Palucka and Banchereau 1999). 
Differential expression of distinct chemokine receptors at various stages of DC 
maturation may play an important role in the migratory capacity of DCs (Sozzani, 
Allavena et al. 1998).
1.3.2.2 T Lymphocytes
T lymphocytes are the crucial mediators of antigen specific cytotoxicity. As 
previously discussed naïve CD8^ and CD4^ T cells can recognise antigens presented 
by APC in the context of MHC Class I and Class II molecules respectively and 
following additional stimulation can be primed to respond against cells expressing 
this antigen on their surface. To avoid inappropriate and potentially harmful 
activation against antigens expressed by normal tissues, the immune system has 
developed several mechanisms for “de-sensitising” T cells against “self’ antigens. In 
the thymus, developing T cells undergo a sequential process of thymic education 
(Mondino, Khoruts et al. 1996). Initially, in a process called “positive selection”, T 
cells expressing a TCR with no affinity for self MHC are deleted, while those with 
moderate TCR reactivity to self MHC are stimulated to continue the maturation 
process. Surviving T cells subsequently undergo “negative selection” during which T 
cells carrying TCR with very high affinity for self peptides presented in the context of 
self MHC by cortical epithelial cells or APC are eliminated. This process, usually 
referred to as “central tolerance”, ensures that circulating mature T cells can 
potentially react efficiently only against non-self antigens presented by self MHC 
molecules. It is clear however, that central tolerance is not absolute and T cells with
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some reactivity to self-antigens presented by self MHC can escape in the periphery. 
This can be the case for antigens not expressed or not presented by APC in the 
thymus during T cell maturation, for “subdominant” epitopes of a self antigen that are 
possibly not adequately presented in the thymus (Cibotti, Kanellopoulos et al. 1992) 
or for antigens expressed only for a short period during development. Potentially 
self-reactive T cells existing in the periphery are believed to be kept in check by a 
mechanism referred to as “peripheral tolerance”. Although the exact mechanisms 
behind peripheral tolerance are not well understood, it is believed that presentation of 
the self-antigens by self MHC molecules in the absence of any additional co­
stimulatory or inflammatory signals (the case in normal physiological conditions) 
leads to T cell non-responsiveness (tolerance).
An alternative model to the self/non-self paradigm described above is provided by the 
“danger” model (Matzinger 1994; Fuchs and Matzinger 1996). This model proposes 
that it is not the nature of an antigen (self or non-self) that is the determining factor in 
the development of an antigen specific immune reaction, but rather that immune 
reactivity to any antigen can develop only if additional danger signals are provided in 
the same context as the antigen. If an antigen-associated signal is presented to a T 
cell in the absence of such danger signals immunological ignorance or tolerance will 
result (Gallucci and Matzinger 2001; Matzinger 2002). Indeed, studies of neonatal 
tolerance of foreign antigens in newborn mice are supportive of this model. In these 
studies, newborn mice can be made responsive to foreign antigens when antigens 
were given in appropriate doses, on appropriate APCs and with suitable adjuvants 
(Mahana, Guilbert et al. 1989; Forsthuber, Yip et al. 1996; Ridge, Fuchs et al. 1996). 
Although the danger model was originally proposed as an alternative to the self/non- 
self paradigm to explain immune responsiveness or tolerance to antigens presented to 
T cells, it is becoming increasingly evident that the two models need not necessarily 
be exclusive or incompatible with each other. The principles of the danger model 
have played a significant role in the design of antitumour vaccination strategies, 
where the goal is to break tolerance to self tumour antigens. Strategies in which cells 
such as DC are employed to provide cellular signals associated with danger, or 
genetic modification with genes that have the potential to directly or indirectly 
promote a dangerous or inflammatory environment in which the tumour antigens are 
presented, have been developed and applied with encouraging results.
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Generation of effective tumour-specific immune responses involves a plethora of 
different cells and events that unfold in a highly synergistic and interactive fashion. 
Immune responses are generally regarded as having two major phases: the induction 
phase and the effector phase. Induction of a successful specific anti-tumour immune 
response requires that T cells receive a first signal (signal one) through ligation of 
TCR with MHC Class I-peptide complex in the case of CD8^ T cells or MHC Class 
Il-peptide complex in the case of CDW T cells (Figure 1.2.A). Presentation of TAA 
can be direct by the tumour cell, in which case the TAA are presented on the cell 
surface in the context of MHC Class I molecules to CD8^ T cells, or indirect by an 
APC such as DC, in which case both MHC Class I and Class II peptides can be 
presented to CD8^ and CD4^ T cells. This initial interaction between T cells and DC 
can be strengthened by high expression of several adhesion molecules such as 
integrins pi and p2 and members of the immunoglobulin super familly. Direct 
presentation of TAA to CD4^ T cells can occur when the tumour cells themselves 
express MHC Class II molecules, as is the case with tumours of lymphoid origin such 
as B cell lymphomas. Signal one on CD8^ T cells is responsible for the antigen 
specificity of an immune response. A second, antigen non-specific, co-stimulatory 
signal (signal two) is required to sustain T cell activation. Signal two involves 
several molecules on APC which are recognised by T-cell surface receptors (Figure 
1.2.B). The most well studied co-stimulatory molecules are the CD80 (B7.1) and 
CD86 (B7.2) on APC binding to CD28 on T cells and the analogous interaction 
between CD40 and CD40L. Finally, a polarisation/proliferation signal (signal three) 
is believed to be required for appropriate recruitment and proliferation of reactive 
lymphocytes (Kalinski, Hilkens et al. 1999). This signal is provided by cytokines or 
growth factors in order to recruit, polarise and propagate tumour reactive lymphocytes 
(Figure 1.2.C). Activated APC can provide such polarising signals. In vitro 
experiments with monocyte derived DC have shown that presence of IFN-y during 
DC maturation induced DC to express high levels of IL-12 and drive CD4^ T cells to 
the T helper I (ThI) differentiation pathway. Thl CD4^ T cells secrete cytokines such 
as IL-2, IL-12, TGF-(3 and IFN-y that promote cell mediated immune responses. In 
contrast, PGE2 promotes low IL-12 production by DC and a Th2 driving capacity.
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A. Signal One
Class I MHC TCR CDS
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Figure 1.2: T cell activation.
A: Signal one of T cell activation involves ligation of the TCR on Tcells with an 
MHC-peptide complex on the APC. B: Signal two or costimulation signal involves 
ligation of costimulatory molecules such as B7.1, B7.2 or CD40 on the surface of the 
APC with the appropriate receptors such as CD28 and CD40L respectively on T cells. 
C: Signal three is a polirisation or proliferation signal provided by cytokines and 
growth factors. All three signals are believed to be essential for efficient I  cell 
activation and proliferation.
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Th2 CD4"^  T cells secrete cytokines such as IL-4, IL-5 and IL-10 that promote B cell- 
mediated humoral immune responses. It is now believed that distinct subsets of DC 
(lymphoid vs myeloid) can induce different class of immune responses (Thl vs Th2). 
DC-stimulated CD4^ T cells up-regulate CD40L that reciprocally activates and 
promotes maturation of DC via CD40 and this renders DC more potent stimulators of 
CD8^ T cells. Activated T cells produce propagation/proliferation signals such as 
cytokines, promoting proliferation of specific CTLs and their effector functions. 
Specifically, IL-2, produced mainly by activated Thl CD4^ T cells, is the major 
helper proliferation signal for CTLs. The effector phase of an anti-tumour immune 
response is mediated by activated CTL, activated NK cells and specific antibodies. 
Importantly, in activated effector T cells signal one suffices for killing of the target 
cells, whereas signal one in the absence of co-stimulatory signals results in anergy of 
naïve T cells. This renders activated effector T cells able to kill target non-APCs that 
do not express appropriate costimulatory signals.
1 3 3  Cytokine Network Linking Innate and Adaptive Antitumour Immunity
Communication between cells of the immune system, including APC and 
lymphocytes, during the course of an immune response is mediated by cytokines. The 
type of host antitumour response is determined by the cytokines present in the tumour 
milieu. Immunostimulatory cytokines can induce or enhance antitumour immunity, 
whereas hnmunosuppressive cytokines can impair the host antitumour response. 
Cytokines linking the innate and adaptive branches of immunity include type IIFN, 
GM-CSF, IL-12, TNF-a, IL-15 and IFN-y. Cells of the innate immune system such 
as macrophages and DC produce a number of these cytokines upon stimulation by 
pathogens or danger signals and thus directly and indirectly affect cells of the 
adaptive immune response.
GM-CSF is mainly produced by monocytes and macrophages and has a wide range of 
effects on cells of the innate and adaptive immune systems. It promotes expansion 
and activation of APC such as macrophages to produce other immunostimulatory 
cytokines such as IFN-y, IL-12 and IL-15, which have an effect on cells of the innate 
immune system such as NK cells and induces migration of DC to lymph nodes 
(Mellstedt, Fagerberg et al. 1999). GM-CSF induces chemotaxis plus phagocytic and
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cytotoxic activity of neutrophils and macrophages, and it has a strong effect in the 
induction of cell-mediated immunity by stimulating naïve T cells. The 
immunomodulatory effects of GM-CSF have made it an attractive candidate for use in 
antitumour vaccinations. GM-CSF can also enhance antibody-dependent cell- 
mediated cytotoxicity and amplify humoral immune responses (Belardelli and 
Ferrantini 2002). GM-CSF-mediated activation of monocytes however can also lead 
to production of an immunosuppresive cytokines, leading to suppression or down- 
modulation of immune responses (Mellstedt, Fagerberg et al. 1999).
IL-12, produced by activated APC, particularly DC, can promote the development, 
growth and cytotoxic activity of NK cells and induces production of IFN-y by NK 
cells, DC, macrophages and T cells. IL-12 is believed to skew the immune response 
towards a Thl type of response and thus enhance CTL responses to tumours 
(Trinchieri and Scott 1999). These effects along with the role of IL-12 in inhibition 
of angiogenesis, are believed to be the predominant components of the IL-12- 
mediated antitumour immune responses observed in mice (Lollini and Fomi 1999). 
Clinical success of IL-12 in antitumour therapy however has been limited by the 
severe toxicity associated with systemic administration of this cytokine. To minimise 
toxic effects observed upon systemic administration and to lake full advantage of the 
immunomodulatory activities of this cytokine, localised production of IL-12 alone or 
in combination with other immune potentiating agents has been exploited as a 
therapeutic antitumour approach with very encouraging preclinical results (Melero, 
Mazzolini et al. 2001) (discussed further section 1.6.3.2.1).
Recently the critical role of type I IFN on DC differentiation and function and the 
potent antitumour effects mediated by these cytokines have become better understood. 
IFN-a, the most extensively used cytokine in the clinic, can exert both direct and 
indirect antitumour effects. Predominantly produced by monocytes, macrophages and 
a specialised subtype of DC, the plasmocytoid DC (also known as IFN-producing 
cells), IFN-a can promote the antitumour cytotoxic effects of NK cells and 
macrophages (LuA, Pang et al. 1998). Importantly, it has been shown that IFN-a can 
provide critical differentiation and maturation signals to DC and promote their 
migration to lymphoid organs. IFN-a can promote B cell proliferation and antibody
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production and enhance the in vivo proliferation and survival of memory T cells, 
thereby leading to an enhancement of both cellular and humoral antitumour immune 
responses (Belardelli and Ferrantini 2002). Most importantly, IFNs enhance antigen 
processing and presentation in all cells in the cytokine environment, enhancing TAA 
presentation for any cytotoxic T cells generated.
1.4 Tumour Escape Mechanisms
Given the complexity of cellular interactions and regulatory signals that mediate the 
induction and maintenance of effective antitumour immune responses, it is anything 
but surprising that tumou^^ells have developed mechanisms to evade humoral and 
cellular immune responses. The main mechanisms tumour cells employ to escape 
immune recognition will be discussed below:
1.4.1 Selection and Outgrowth of Genetically Altered Variants
Naturally arising tumours can be polyclonal in origin and tumour cells develop in 
such a way that antigens previously recognised by the immune system are no longer 
expressed. An effective antitumour immune response constitutes a selective pressure 
on cells and loss of expression of the immune stimulating molecules c ^  thus lead to 
escape from the original immune attack. Expression of tumour antigens such as 
gplOO, tyrosinase and MART -1 /MelanA, commonly used in melanoma 
immunotherapy, is not homogeneous and is often significantly reduced. Suboptimal 
levels of antigen expression may result in inefiBcient T cell recognition. Selective 
survival advantage may also occur in tumours that possess or develop defective 
antigen processing and presentation machineries. Mutations in genes coding for 
crucial antigen presentation and transport molecules, such as TAP, and components of 
the proteosome, often result in selective survival of tumour cells (Maeurer, Gollin et 
al. 1996). So, even though the antigen and MHC molecules are present, the 
recognised antigenic epitope is not presented at the cell surface in the context of the 
MHC molecules, resulting in impaired CTL recognition and selective tumour 
progression (Kageshita, Hirai et al. 1999). Total or partial loss of MHC class I 
expression is another immune evasion mechanism employed by tumour cells 
(Rosenberg, Packard et al. 1988; Nawrocki and Mackiewicz 1999). Inactivation by
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mutation of the p2-microglobulin gene leads to complete loss of MHC Class I 
expression on tumour cells. Since complete loss of MHC Class I expression on the 
surface of tumour cells may make them more susceptible to NK cell-mediated 
elimination, tumour cells may better survive with partial rather than complete loss of 
Class I expression.
1.4.2 Tolerance Induction
Costimulatory molecules are normally expressed by APC, such as DC, B cells and 
macrophages. With the exception of some lymphomas, tumour cells do not normally 
express costimulatory molecules and are therefore incapable of providing the crucial 
signal 2 for induction of an effective antitumour immune response. Interaction of 
TCR on CD8^ T cells with MHC Class I/peptide complexes on tumour cells in the 
absence of costimulation leads to T cell anergy. Naïve T cells meet antigen on cells 
within the peripheral lymphoid organs, most commonly presented by APC. These 
APC may not be fully matured following contact with the tumour environment and 
thus express suboptimal levels of costimulatory molecules and cytokines and be 
tolerogenic (Blankenstein and Schuler 2002). Therefore, in the absence of acute 
pathological challenges, the chronic antigen source generated by the tumour generates 
more tolerance than immune activation despite dominant TAA. Anergy may be 
induced among CTL previously capable of recognition and cytotoxic function 
(Staveley-O'Carroll, Sotomayor et al. 1998). Anergy of CD4^ T cells may lead to 
absence of T cell help, necessary for induction and maintenance of antigen specific 
CTL responses. In addition, lack of immunostimulatory or danger signals in the 
tumour microenvironment may lead to immune tolerance or anergy.
1.43 Suppression of the Immune Response
Tumour cells can secrete inhibitory factors such as tumour growth factor (TGF)-p or 
IL-10 that can directly or indirectly suppress immune effector cells. TGF-P blocks T 
cell activation while IL-10 blocks DC maturation (Torre-Amione, Beauchamp et al. 
1990; Wojtowicz-Praga 1997). In addition, Fas ligand (FasL) expression on the 
surface of tumour cells can lead to apoptosis of T cells upon ligation of Fas on the T 
cell surface. FasL expression has been demonstrated in a number of malignancies
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including melanoma, glioblastoma, colon carcinoma, lung carcinoma and ovarian 
cancer (Bremers and Parmiani 2000).
1.4.4 Impaired T Ceil Function
Analysis of TIL isolated from tumours has demonstrated a general impairment of 
fimction of T cells. Downregulation or complete loss of expression of TCR 
components, such as CD3 Ç, leading to impaired signalling from the TCR/CD3 
complex has been observed in peripheral or intratumoural T lymphocytes isolated 
from cancer patients. Similarly impaired p56 ‘^^  ^ or Zap70 tyrosine kinase function 
leading to impaired T cell proliferative responses has been demonstrated in TIL from 
cancer patients (Tartour, Latour et ai. 1995). Finally, abnormalities in signal 
transduction pathways and transcription factors may also contribute to abnormal 
function of T cells. This is likely caused by the tolerance and suppression 
mechanisms.
1.5 Alloresponse and Tumour Immunity
The immune system has the ability to react to allogeneic MHC molecules on 
transplanted cells in a highly vigorous manner. Several immunotherapeutic strategies 
for cancer treatment, such as adoptive transfer of allogeneic DC or allogeneic tumour 
cell vaccines, have tried to take advantage of this feature to compensate for weak 
responses to tumour antigens and to enhance specific antitumour immunity. Most of 
what is currently known about allogeneic responses comes from transplantation 
immunology and although the potential interaction between transplantation and 
tumour immunology has been occasionally investigated, the full potential of this 
interaction has yet to be vigorously explored.
T lymphocytes are the main cell type involved in tissue rejection. In a phenomenon 
called “alloagression”, unprimed T cells from one individual have the ability to 
potently react against the MHC of an individual from the same species (Fabre 2001). 
Whereas the fi^quency of T cells reactive to conventional antigens is estimated to be 
approximately 1x10 ® to 3x10 ®, the frequency of alloreactive T cells can be as high as 
1x10"^  (Suchin, Langmuir et al. 2001), demonstrating the incredible potency of the
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alloresponse to foreign MHC. T cells can recognise determinants on intact allogeneic 
MHC molecules on the surface of foreign cells in a process called “direct 
allorecognition” (Figure 1.3.A). In addition to recognising allogeneic MHC through 
direct allorecognition, T cells can also recognise alio MHC epitopes presented on the 
surface of host APC complexed to self MHC This presentation occurs following 
uptake and processing via the MHC Class I and Class II pathways in a process known 
as “indirect allorecognition” (Figure 1.3.B). The exact molecular mechanisms behind 
direct allorecognition are still the subject of intense investigation.
A. Direct Allorecognition
TCR.411o Class I or II MHC
Host CD8+ or CD4+ T cells
Allogneic cell
allogeneic
peptide
B. Indirect Allorecognition
TCRSelf Class I or II MHC
Host CD8+ or CD4+ T cells
Host APC
allogeneic
peptide
Figure 1.3: Mechanisms of allorecognition by T cells.
A: Direct allorecogntion involves recognition by host T cells of determinants on 
intact allogeneic MHC molecules on allogeneic cells. B: Indirect allorecognition 
involves uptake and presentation of allogeneic MHC epitopes by host APC. Host T 
cells recognise foreign peptide presented by self MHC molecules.
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In addition to alloresponses to MHC, T cells can react to peptides from gene products 
of non-MHC genes. These polymorphic non-MHC proteins are called minor 
histocompatibility antigens (mHAgs) and T cells can only respond to mHAgs if they 
are presented on the cell surface by self MHC molecules. mHAgs include products of 
sex chromosomes, such as the H-Y antigens in mice and humans, products of 
autosomes, such as the HA-2 in humans, and products of mitochondrial DNA. 
Reactivity against mHAgs plays a significant role in transplantation rejection 
(Simpson and Roopenian 1997).
Tumour immunotherapy aims to generate an antigen specific systemic T cell response 
to tumour antigens presented by self MHC molecules, leading to the destruction of 
metastatic lesions. Direct T cell allorecognition has three main implications in the 
generation of such self MHC restricted responses (Fabre 2001). First, alloresponding 
T cells that can directly recognise intact alio MHC determinants may also have 
specificity for normal environmental peptides presented by self MHC molecules, their 
natural ligands (Figure 1.4.A). Consequently, in a cancer patient there is a random 
chance that alloresponding T cells also have specificity for tumour peptides presented 
by self MHC molecules. Second, vigorous stimulation of CD4^ T cells via direct 
allorecognition responses to alio MHC Class II molecules can lead to very potent T 
cell help for existing responses to tumour peptides (Figure 1.4.B), overriding the need 
for presentation of tumour peptides by self MHC Class II molecules on APC. This 
may be of great significance considering that CD4^ T cell help found in tumours is 
likely to be very weak. And third, alloresponses have the potential of generating an 
immunostimulatory environment at the tumour milieu, rich in cytokines and co- 
stimulatory molecules, leading to effective stimulation of DC, T cells and other key 
players composing an effective immune response.
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Figure 1.4: Implications of direct Allorecognition.
A: Cross-reactivity of CD4+ or CD8+ alloresponding T cells to self MHC-restricted 
peptides. B: Activated alloreactive CD4+ T cells may provide help for the
generation of self-MHC restricted T cell responses to tumour peptides (modified from 
(Fabre, 2001)).
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T cell alloagression has found some clinical application in tumour immunotherapy. 
One example is the adoptive transfer of antigen loaded DC. In this approach, the best 
suited DC for stimulating self HLA-restricted anti-tumour responses would be those 
that share expression of as many HLA Class I and Class II alleles with the patient but 
still are incompatible in at least one HLA Class II molecule. This incompatibility 
would ensure direct allorecognition by the patient’s CD4" T cells and generation of 
potent T cell help promoting the induction of antigen specific HLA-specific CTL 
responses. Genetic modification of the patient’s own DC to express an allogeneic 
HLA Class II allele can potentially result in the effect. Another example of the use of 
alloagression in tumour immunotherapy is the generation of hybrids of autologous 
tumour cells to allogeneic tumour cells or to DC (Gong, Nikrui et al. 2000; Kugler, 
Stuhler et al. 2000). Generation of “semi-allogeneic” tumour cell hybrids has had 
some success in preclinical studies. Recent work using human melanoma cell lines 
engineered to express HLA Class II and CD86 costimulatory molecules fused to 
tumour cells from individual patients has shown that TIL isolated from a patient and 
exposed to semi-allogeneic hybrids from the same patient exhibited better cytolytic 
activity in vitro (Newton, Romano et al. 2000). Subsequent use of such semi- 
allogeneic hybrid vaccines mixed with GM-CSF in a Phase I Clinical trial showed an 
enhanced antitumour response to autologous tumour cells as measured by delayed- 
type hypersensitivity (DTH) responses (Newton, Aciemo et al. 2001). Fusion of 
autologous tumour cells to allogeneic or syngeneic DC has also shown great promise. 
In particular, fusion of autologous tumour cells to allogeneic DC represents an 
approach with great therapeutic potential (Gong, Nikrui et al. 2000; Kugler, Stuhler et 
al. 2000). The fused tumour cell/DC hybrids express all of the DC’s allogeneic HLA 
Class II molecules stimulating CD4^ T cell help via direct allorecognition, as well as 
all the patient specific HLA Class I for self HLA-restricted antigen specific 
stimulation.
1.6 Antitumour Vaccination
The underlying principle behind antitumour vaccination is the effective stimulation of 
the immune system against a specific component of the tumour cells, leading to 
immune-mediated tumour cytotoxicity and persistent immune memory. There are 
several prerequisite factors to stimulation of an efficient systemic antitumour
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immunity. First, at least one tumour antigenic epitope against which a specific 
immune response can be raised need to be provided by the antitumour vaccine. 
Vaccines expressing multiple antigens, such as tumour cell vaccines or multivalent 
antigen vaccines, are better suited to minimise the risk of tumour variants not 
expressing a given antigen escaping immune targeting. Second, the antigens need to 
be released in the tumour milieu in an immunostimulatory manner. In the case of 
tumour cell vaccines, for example, the mechanism of cell death has been shown to 
influence the potency of the vaccine. Necrotic cell death of the vaccine cells, which is 
associated with induction and release of danger signals (Melcher, Gough et al. 1999; 
Basu, Binder et al. 2000), has been shown to provide an environment significantly 
more immunostimulatory than apoptotic cell death (Melcher, Todryk et al. 1998; 
Sauter, Albert et al. 2000). Third, immune cells such as DC and T cells need to be 
recruited at the site of vaccination for subsequent antigen uptake. Release of 
inflammatory cytokines and chemokines in the tumour microenvironment can 
efficiently promote homing and priming of immune cells. Finally, recruited immune 
cells need to be activated to exert their functions, for example antigen presentation 
and T cell activation by DC or cytokine release by cells of the innate immune system 
such as NK cells and macrophages. Activation signals can be provided directly by 
engineered vaccine cells or indirectly by appropriately activated immune cells. An 
effective antitumour vaccine would be one that can provide and/or facilitate all of the 
necessary steps for potent immune stimulation.
Advances in the molecular characterisation of TAA has allowed the development of 
innovative approaches to antigen-specific vaccination. Vaccination against a defined 
immunodominant tumour antigen provides the ability to control and target antitumour 
immune responses.
1,6.1 Peptide Vaccines
As previously mentioned, there is a large number of human tumours for which TAA 
have been identified and characterised and some of these antigens have been the focus 
of peptide vaccine clinical studies in cancer patients. Emerging technology has made 
the synthesis of large quantities of tumour antigen peptides simple, rapid and 
inexpensive. The use of synthetic peptides allows for safer vaccine preparations by
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greatly reducing the potential for bacterial or viral contamination that is possible 
when using tissue for immunisation. MHC restriction of each TAA however, 
restrains the universal applicability of peptide vaccines. Nevertheless, peptide 
vaccination has been shown to be effective against viral antigens (Kast, Roux et al. 
1991) and in tumour challenge experiments in pre-clinical studies (Feltkamp, Smits et 
al. 1993). The optimal peptide vaccine preparation should contain multiple 
immunodominant T and B cell epitopes, including epitopes presented by both MHC 
class I and class II molecules for CTL and T helper cell priming. It should contain 
TAA that cover a wide range of MHC types and are potent tumour rejection antigens 
and should be delivered by the appropriate route or vehicle such that tolerance 
induction is avoided, for example by providing co-stimulation or danger signals along 
with the TAA. Several Phase I and II clinical trial have evaluated immunisation of 
patients with peptides encoding epitopes of different antigens including Melan- 
A/Mart-I (Jager, Ringhoffer et al. 1996; Wang, Bade et al. 1999; Jager, Hohn et al. 
2002), gpIOO (Rosenberg, Yang et al. 1998; Rosenberg, Yang et al. 1999; Stewart and 
Rosenberg 2000), NY-ESO-1 (Jager, Gnjatic et al. 2000; Gnjatic, Jager et al. 2002), 
and MAGE-3 (Marchand, van Baren et al. 1999; Coulie, Karanikas et al. 2002; 
Machiels, van Baren et al. 2002). Vaccination strategies under evaluation include 
direct peptide vaccination with immunologic adjuvants and/or cytokines, lipopeptide 
conjugates, peptide loading onto splenocytes or DC and lysosomal complexes for a 
wide range of cancers (Moingeon 2001; Rosenberg 2001).
1.6.2 Recombinant Viral and Bacterial Vaccines
The development of recombinant techniques that allow the insertion of antigens or 
antigenic epitopes into the genome of attenuated micro organisms, such as bacteria 
and viruses, coupled with the intrinsic immunogenicity of such agents has made the 
development of recombinant viral or bacterial vaccines an attractive cancer vaccine 
approach.
Viruses are among the most interesting vectors since they can induce antibody, as 
well as CTL responses. Recombinant vaccinia and other poxviruses have been the 
most popular vehicles used in such cancer vaccines, but more recently adenoviral and 
other viral vectors have also been utilized. Viral infection and the resulting cellular
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pathology can elicit signals that attract and activate professional APC. Furthermore, 
direct infection of APC by recombinant viruses could result in efficient processing of 
endogenously synthesized antigens in the MHC class I pathway. Improved MHC 
class I and class II presentation and effective introduction of co-stimulatory molecules 
have been shown to enhance antigen presentation and vaccine potency (Minev, 
McFarland et al. 1994). Attachment of lysosomal/endosomal sorting signals to the 
gene encoding tumour antigen has been shown to enhance class II presentation and 
CD4^ T cells activation by recombinant poxviruses (Lin, Guamieri et al. 1996), and 
incorporation of genes for the expression of co-stimulatory proteins and cytokines 
into poxviruses has also been shown to enhance vaccine potency (Bronte, Tsung et al. 
1995). Several Phase I/II clinical trials are ongoing for the evaluation of the 
feasibility of recombinant viral antitumour vaccination in melanoma, breast, prostate 
and lung cancers (Bremers and Parmiani 2000; Moingeon 2001; Rosenberg 2001). 
Exaples include vaccination of melanoma patients with adenovirus expressing gpIOO 
or Melan-A/ Mart-1 with or without IL-2 (Rosenberg, Zhai et al. 1998), prostate 
cancer patients with vaccinia virus expressing PSA (Eder, Kantoff et al. 2000), and 
breast or lung cancer patients with vaccinia virus expressing CEA or MUC-1 (Tsang, 
Zaremba et al. 1995; Cole, Wilson et al. 1996; Bonnet, Tartaglia et al. 2000).
Currently a major limitation of recombinant virus vaccines is the presence of high 
levels of neutralising antibodies against the most commonly used viral vectors, 
vaccinia virus and adenovirus, in most individuals. Strategies to overcome such pre­
existing immunity include engineering novel viruses which normally do not infect 
humans, for example viruses from the Avipoxviridae family such as fowlpox and 
canarypox (Bonnet, Tartaglia et al. 2000; Marshall, Hoyer et al. 2000).
The use of engineered bacteria is another interesting approach to recombinant 
vaccination. Bacterial strains such as Salmonella, BCG and Listeria Monocytogen 
possess two characteristics that make them very attractive tools for vaccination: 
enteric route of infection, providing the possibility for oral administration of the 
vaccine, and endogenous processing of the tumour antigens through direct infection 
of professional APC. Studies in animal models have shown promising results (Pan, 
Ikonomidis et al. 1995).
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1.6.3 DNA Vaccines
Immunisation with DNA vaccines has gained enormous interest following the initial 
report by Liu and colleagues showing that intra-muscular injection of naked plasmid 
DNA encoding influenza nucleoprotein could protect mice from influenza challenge. 
Naked DNA vaccines encoding tumour antigens have been shown to provide some 
degree of systemic tumour protection in animal models (Irvine, Chamberlain et al.
1997). The potency of naked DNA vaccines is generally lower compared to 
recombinant viral vaccines. This is probably due to low in vivo transfection 
efficiencies, leading to low expression levels. In addition, inflammatory or danger 
responses generated by DNA inoculation are usually much weaker than those 
occurring during viral infections. Consequently, repeated administration of the 
plasmid DNA or use of adjuvant in conjunction with plasmid DNA administration is 
generally required for induction of an optimal response. Nonetheless, DNA injection 
has been shown to induce local inflammation and activation of bone marrow derived 
APC (PardoII and Beckerleg 1995). The immunostimulatory activity of plasmid 
DNA vaccines has been associated with the presence of a central CpG motif in the 
sequence PuPuCpGPyPy in the prokaryotic portion of the plasmid. Through 
mechanisms not very well understood, unmethylated forms of such motifs can 
stimulate monocytes and macrophages to produce cytokines such as IL-12, TNF-a 
and INF-y (Chace, Hooker et al. 1997) and enhance CTL responses and anti-tumour 
activity (Davila and Celis 2000). Unmethylated CpG motifs are therefore likely to 
play a crucial role in the ability of nucleic acid vaccines to induce immunity.
1.6.4 Tumour Cell Vaccines
Despite the significant advances that have been made in the field of TAA 
identification the current list of defined tumour antigens that can function as tumour 
regression antigens constitutes only a partial representation of the repertoire of 
immunologically important tumour antigens. Use of whole cells as the source of 
tumour antigens is a widely explored alternative approach in cancer vaccine 
development.
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1.6.4.1 Autologous Tumour Cell Vaccines
The use of autologous tumour cells has the major advantage that the vaccine can 
provide the whole spectrum of unique and shared antigens expressed by the individual 
tumour, reducing the risk of tumour escape. First generation autologous tumour cell 
vaccines consisted of irradiated tumour cells isolated from fresh, cryopreserved tissue 
or a cell line established from autologous tissue (Greten and Jaffee 1999; Moingeon 
2001). Early attempts to induce effective antitumour immune responses using 
irradiated autologous cell vaccines had only limited success. This apparent low 
efficiency could be attributed to the poor immunogenicity characteristic of most 
naturally evolving tumours. As mentioned above, native tumour cells often exhibit 
defects in antigen presentation, expression of MHC or costimulatory molecules and 
may directly express immunosupressive factors that can drastically limit their efficacy 
in inducing specific antitumour immune responses. Initial attempts to enhance the 
immunogenicity of autologous tumour cell vaccines employed non-specific adjuvants. 
Tumour cells were mixed with bacteria such as BCG and Corynebacterium parvum, 
components of bacterial cell walls, oil-containing mixtures such as Freund’s adjuvant 
or aluminum salts (Greten and Jaffee 1999). Clinical trials in melanoma, colon and 
renal cell cancers showed enhanced efficacy (McCune, O'Donnell et al. 1990, 
Floover, 1993 \  Herd, Kairys et al. 1998; Harris, Ryan et al. 2000).
One major current limitation of autologous tumour cell vaccination is that production 
of such customised vaccines is time consuming and technically challenging. Ex vivo 
expansion of tumour cells derived from the patients own tumour is cumbersome and 
is dependant on the quantity of available tumour tissue. This substantially limits the 
use of this approach in treating large groups of patients, patients with minimal 
residual disease, where availability of tumour tissue for in vitro propagation is very 
limited, and also limits the number of consecutive vaccinations a patient can receive.
1.6.4.2 Allogeneic Tumour Cell Vaccine
An alternative approach which eliminates the difficulties associated with generating 
autologous tumour cell vaccines is the use of long term in vitro expanded cell lines. 
These cell lines originate from a different patient than the patient to be treated and are 
therefore called allogeneic cells lines. The use of such allogeneic cell lines for
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antitumour vaccination of patients gained significant popularity following the 
realisation that tumours from different patients, even tumours of different histological 
origin, often share expression of TAA and that TAA can be efficiently cross­
presented by host APC to cross-prime host CD8^ T cells (discussed in earlier 
sections). Allogeneic cell lines can be partially characterised in vitro for expression 
of known shared antigens, offer better standardisation in preparation and quality 
control and are amenable to large scale production and customised modification, for 
example genetic modification to express immunostimulatory factors. Mixture of 
several cell lines of the same type creates polyvalent formulations of a broad range of 
TAA and multiple HLA antigens, limiting the probability of immune escape. As 
previously discussed, expression of allogeneic HLA molecules on the surface of 
allogeneic cells can function as an adjuvant, rendering the cells more immunogenic as 
they can potentially induce both T helper and CTL immune responses to cross­
reacting TAA.
Several Phase I/II clinical studies involving allogeneic tumour cell vaccines have been 
completed and results have triggered more elaborate Phase III studies. Morton and 
colleagues have generated a polyvalent allogeneic melanoma vaccine -  CancerVax 
(Chan and Morton 1998). CancerVax is an antigen enriched melanoma cell vaccine 
developed from three human melanoma cell lines chosen for their rich expression of 
melanoma antigens. It expresses at least II TAA found in melanoma and other 
tumours and eight melanoma associated antigens. Phase II trials of CancerVax plus 
BCG with 157 stage IV melanoma patients (AJCC) yielded an overall response rate of 
15-20% and an increased 5-year survival rate compared to historic controls (25% 
compared to 6%) (Morton and Barth 1996). In another Phase II clinical trial 
treatment of 283 stage III patients with CancerVax plus BCG yielded a 10-year 
overall survival rate of 49% compared to 33% in the non-vaccinated historical control 
patients. Randomised multicentre phase III trials with stage III and IV patients are 
underway to verify the effectiveness of this allogeneic vaccine to induce melanoma- 
specific antitumour immune responses (Chan and Morton 1998).
One variation of the theme of tumour cell vaccines is the use of tumour cell lysates or 
tumour-shed antigens as vaccines. Mitchell and colleagues prepared human 
melanoma lysates from two mechanically disrupted tumour cell lines (Melacine) and
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combined this preparation with a novel adjuvant called DETOX to treat patients with 
metastatic melanoma in an phase I trial (Mitchell, Harel et al. 1993). Vaccination of 
patients with Melacine plus DETOX induced an overall objective clinical responses in 
20 out of the 106 patients. Clinical responses correlated with partial match of HLA 
phenotype between the patients and the vaccine and increases in CTL precursors in 
the patient’s blood. A phase |II study in 140 AJCC stage IV melanoma patients 
however, failed to show clinical benefit from the Melacine vaccine compared to a 
four-drug standard chemotherapy (Mitchell 1998), although significantly lower 
adverse effects were associated with the Melacine vaccine.
Bystryn and co workers prepared a polyvalent melanoma antigen vaccine consisting 
of HLA-depleted antigens from three human and one hamster melanoma cell line 
(Bystryn, Jacobsen et al. 1986). In an uncontrolled, open study with 94 patients with 
surgically resected stage III melanoma an overall 50% 5-year survival was observed, 
and both cellular and humoral anti-melanoma immune responses seemed to be 
associated with a favourable clinical outcome (Miller, Abeles et al. 1995).
1.6.5 Enhancing Immune Response to Tumour Cells by Gene Modification
Advances in molecular biology and gene therapy techniques have allowed the cloning 
and characterisation of immunostimulatory molecules, such as cytokines and heat 
shock proteins, leading to the development of new approaches, based on genetically 
modified tumour cell vaccines, to enhance the immune responses to tumour cells. 
The principle behind cytokine gene modified tumour cell vaccines is that local 
sustained expression of immimostimulatory cytokines by the tumour cells will modify 
the microenvironmental conditions leading to induction of effective innate and/or 
specific antitumour immunity. Although systemic administration of cytokines such as 
IL-2 has been shown to lead to tumour regression, severe toxicity is associated with 
such an approach (Bremers and Parmiani 2000). Local release of cytokines by gene 
modified tumour cells therefore represents a very attractive alternative approach.
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1.6.5.1 Gene-Modifîcation With IL-12
IL-12 is a heterodimeric cytokine that exhibits proinflammatory effects, as well as 
antitumour properties in vivo. Expressed predominantly by activated DC, XL-12 
promotes cellular immunity by supporting the development of Thl responses by 
CD4^ T cells, as well as the production of IFN-y by NK cells, and is an enhancer of 
CTL and NK cell cytotoxic activity (Figure 1.5) (Trinchieri 1995). The antitumour 
and antimetastatic effects of IL-12 have been demonstrated in many mouse models 
(Trinchieri and Scott 1999). The observation that IL-12 deficient mice are more 
susceptible to chemical carcinogens and develop increased number of metastasis 
following injection of transplantable tumours indicates that IL-12 is an essential 
component of efficient tumour surveillance (Smyth, Thia et al. 2000).
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Figure 1.5: Effects of expression of EL-12 by tumour ceils.
IL-12 secreted by modified tumour cells promotes a Thl- type response and 
stimulates the release of Thl-type cytokines by Thl cells. In adition, IL-12 enhances 
cytotoxic activity of T cells and NK cells.
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IL-12 has a potent direct antitumour effect, as tumour cells engineered to express IL- 
12 are not tumourigenic (Tahara, Zitvogel et al. 1995; Cavallo, Signorelli et al. 1997; 
Chong, Todryk et al. 1998) and primary tumours can be eradicated following 
intratumoural administration of recombinant IL-12 (Nastala, Edington et al. 1994) or 
recombinant adenovirus expressing IL-12 (Gambotto, Tuting et al. 1999). 
Furthermore, mice treated with IL-12 develop long-term tumour immunity and mice 
vaccinated with IL-12 secreting tumour cells or fibroblasts show enhanced systemic 
antitumour vaccination (Tahara, Zeh et al. 1994; Meko, Yim et al. 1995; Tahara, 
Zitvogel et al. 1995). The potent antitumour effect observed following gene transfer 
of IL-12 are dependent on T cells, particularly CDS  ^T cells, and IFN-y expression by 
other cells, mainly NK cells. In the absence of IFN-y, CD4^ T cells and GM-CSF 
were required for IL-12 mediated antitumour effects (Zilocchi, Stoppacciaro et al.
1998).
Injection of IL-12-engineered fibroblasts at the site of an established MCA207 
sarcoma could eliminate or suppress tumour growth in a dose-dependent manner, 
while repeated vaccination of animals with IL-12-secreting fibroblasts could 
effectively treat a pre-established sarcoma and induce long term protective antitumour 
immunity (Zitvogel, Tahara et al. 1995). Tumour regression was associated with 
infiltration of CD4^ and CDS^ T cells and macrophages. Similar systern^antitumour 
therapeutic effects were observed in mice vaccinated with tumour cells expressing IL- 
12 (Tahara, Zitvogel et ai. 1995; Cavallo, Signorelli et al. 1997).
In addition to the direct cellular and humoral antitumour effects, IL-12 has been 
shown to promote the destruction of the tumour vasculature and inhibit angiogenesis 
(Voest, Kenyon et al. 1995; Duda, Sunamura et al. 2000; Strasly, Cavallo et ai. 2001), 
which may contribute to its potent antitumour effects. Finally, synergistic antitumour 
effects have been observed when IL-12 is combined with other cytokines, such as IL- 
18 (Oshikawa, Shi et ai. 1999) or GM-CSF (Aruga, Tanigawa et ai. 1999), 
costimulatory molecules (Zitvogel, Robbins et ai. 1996; Chong, Todryk et ai. 1998) or 
chemokines.
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Several phase I clinical trials using IL-12 gene modified tumour cell or fibroblast 
vaccines have demonstrated the safety and feasibility of such vaccines for cancer 
treatment (Sun, Jurgovsky et al. 1998; Kang, Park et al. 2001). Kang et al. (Kang, 
Park et al. 2001) initiated a phase I clinical study in 9 cancer patients with 
disseminated cancer using peritumoural injection of IL-12 gene engineered 
autologous fibroblasts. This was a dose escalation study where patients received four 
injections at intervals of 7 days. Transient reduction of tumour size was observed at 
the injection sites in four out of nine cases, and at noninjected distant sites in one 
melanoma patient. Tumour regression was associated with TNF-a expression and 
CD8^ T cell infiltration at the local sites (Kang, Park et al. 2001).
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1.6.5.2 Gene-Modifîcation With GM-CSF
GM-CSF is one of the most extensively studied cytokines in gene modification of 
tumour cell vaccines. Several preclinical studies have demonstrated the potent ability 
of this cytokine to enhance antitumour immunity. The underlying mechanisms 
mediating this effect involve the augmentation of tumour-antigen presentation by 
recruited host APC (Figure 1.6). GM-CSF enhances expansion, maturation 
activation and migration of DC (Dranoff, Jaffee et al. 1993; Mellstedt, Fagerberg et 
al. 1999) leading to enhanced T cell reactivity to tumour cells as well as enhancement 
of primary antibody responses.
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Figure 1.6: Effects of expression of GM-CSF by tumour cells.
GM-CSF secreted by modified tumour cells stimulates maturation and expansion of 
APC, such as DC, leading to enhanced T cell reactivity.
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In a study comparing the efficacy of gene engineering of tumour cells to express 
different cytokines in inducing antitumour immunity, Dranoff et al. found that 
introduction of the gene for GM-CSF in B16 melanoma cells was superior to the 
insertion of other genes (Dranoff, Jaffee et al. 1993). Irradiated GM-CSF expressing 
tumour cells stimulated a potent, long-lasting and specific antitumour immunity 
against the autologous tumour. This effect was shown to be mediated by both CD4  ^
and CD8^ T cells. This study was significant as one of the first studies comparing the 
efficacy of irradiated gene-modified tumour cell vaccines to the efficacy of irradiated 
unmodified tumour cells. Further analysis of the mechanisms underlying the efficacy 
of such a vaccine revealed that GM-CSF expression by the vaccine tumour cells 
attracted a greater number of host APC which took up antigen from the dying tumour 
cells and cross-presented to host T cells (Dranoff, Jaffee et al. 1993; Huang, 
Golumbek et al. 1994; Chiodoni, Paglia et al. 1999). Expression of GM-CSF by renal 
cell carcinoma cells lead to complete abrogation of the tumourigenicity of primary 
tumours and vaccination of mice with GM-CSF-expressing tumour cells led to 
induction of systemic protective immunity, as demonstrated by retardation of tumour 
growth and prolonged survival (Kinoshita, Kono et al. 2001).
Previous work in our laboratory showed that expression of GM-CSF alone by B16 
tumour cells had no effect in the growth of primary tumours while expression of 
herpes simplex virus-thymidine kinase (HSVtk) plus ganciclovir (GCV) alone 
completely abrogated growth of primary tumours (Castleden, Chong et al. 1997). 
When GM-CSF was combined with HSVtk/GCV treatment a significant abrogation 
of primary tumour growth was observed. GM-CSF release by tumour cells lead to the 
best levels of long-term systemic protection. Importantly, coexpression of GM-CSF 
with HSVtk in a tumour prevention model lead to significantly enhanced long-term 
protection compared to either modification alone demonstrating the ability of GM- 
CSF to act as a potent adjuvant in tumour immunotherapy.
The efficacy of GM-CSF modification in inducing protective systemic immunity has 
also been demonstrated in allogeneic tumour cell vaccination models (Kayaga, 
Souberbielle et al. 1999; Chang, Chen et al. 2000) with the effects dependent on both 
CD4^ and CD8^ T cells. In a study directly comparing the efficacy of cytokine 
modified autologous to allogeneic tumour cell vaccines, Todryk et al. showed that the
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efficacy of GM-CSF transduction was significantly lower for an allogeneic vaccine 
compared to an autologous vaccine (Todryk, Birchall et al. 2001).
Two phase I clinical trials involving autolgous tumour cells genetically engineered to 
secrete GM-CSF have been reported. Soiffer et al. vaccinated patients with stage IV 
metastatic melanoma with GM-CSF-transfected autologous melanoma cells (Soiffer, 
Lynch et al. 1998). In all of the 21 evaluable patients an initially negative DTH 
reaction to non-transfected, autologous tumour cells was converted to a strong 
positive response after several vaccinations. Biopsy of metastatic lesions in 11 out of 
16 patients showed dense infiltration of both T cells and plasma cells and extensive 
tumour destruction, and seven showed increased anti-melanoma antibody response 
(IgG-type). Anti-melanoma CTL and antibody responses were associated with 
tumour destruction, though these antitumour immune responses resulted in clinically 
relevant responses only in one case. Simons and co-workers conducted a similar trial 
with an autologous, irradiated GM-CSF expressing vaccine in renal cancer patients 
(Simons, Jaffee et al. 1997). In this randomised dose escalation study patients were 
treated with equivalent doses of autologous cells with or without GM-CSF transfer. 
No dose-limiting toxicity was found in the 16 evaluable patients, while an intense 
eosinophil infiltrate was detected at the site of DTH responses to GM vaccine but not 
in patients receiving non-transduced cells. One objective partial response was 
observed in a patient treated with GM-CSF gene transuced cells.
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1,6,5.3 Gene-Modifîcation With IFN-y
IFN-y is predominantly expressed by activated T cells and can significantly enhance 
the ability of T cells and macrophages to lyse tumour cells (Figure 1.7). In addition 
IFN-y can activate NK cells to exert their effector functions. IFN-y expression leads to 
upregulation of MHC Class II molecules in MHC Class II non-expressing cells such 
as epithelial cells (el-Asrar, van den Oord et al. 1989), which may lead to enhanced 
interaction with and activation of CD4 T cells, promoting the development of 
cytotoxic effector cells (Figure 1.7). Furthermore, IFN-y can upregulate expression 
of MHC Class I molecules (Trinchieri 1994) and adhesion molecules such as ICAM-1 
and LFA-3, that are important in the interaction of both MHC-restricted and non- 
MHC restricted effector cells with target cells. It also enhances expression of 
molecules involved in antigen processing and presentation including TAP and 
components of the proteosome complex, thereby enhancing presentation of tumour 
antigens (Boehm, Klamp et al. 1997).
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Figure 1.7: Effects of expression of IFN-y by tumour cells.
EFN-y secreted by modified tumour cells enhances MHC Class I and II expression and 
thus improves antigen presentation by cells. In addition, EFN-y augments the 
cytotoxic activity of T cells as well as the effector functions of NK cells and 
macrophages.
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Transduction of a weakly immunogenic fibrosarcoma cells line with the gene for IFN- 
y significantly enhanced surface expression of MHC Class I and Class II molecules 
and reduced the in vivo growth rate of a primary tumour (Yang, Vervaert et al. 1999). 
In a protective vaccination model, an irradiated IFN-y transduced tumour cell vaccine 
generated systemic immunity leading to significantly enhanced protection of animals 
against tumour challenge. These therapeutic effects were primarily dependent on 
CD8^ T cells and partly dependent on CD4^ T cells. In renal cell carcinoma, IFN-y 
gene transfer enhanced tumour cell recognition by MHC-restricted, tumour antigen 
specific CTL but suppressed recognition by non-MHC-restricted cytotoxic cells such 
as LAK cells (Schendel, Falk et al. 2000). Overall, animal studies have shown that 
the efficacy of IFN-y in inducing significant antitumour effects varied widely 
depending on the tumour model used, with some studies showing an increase in 
tumour metastasis following administration of an IFN-y expressing tumour vaccine 
(Ferrantini and Belardelli 2000).
In a phase I clinical trial, Abdel-Wahab and colleagues treated 20 stage III-IV 
melanoma patients with IFN-y secreting autologous tumour cells and demonstrated 
complete response in two patients and transient shrinkage of subcutaneous nodular 
disease in two additional patients (Abdel-Wahab, Weltz et al. 1997). Thirteen out of 
the twenty patients completed the protocol and eight out of those thirteen, including 
those that exhibited an objective clinical response, showed humoral IgG responses 
against autologous and allogeneic melanoma cells.
1,6.5.4 Gene-Modification With Other Cytokines
In addition to IL-12, GM-CSF and IFN-y, several other cytokines have been explored 
in preclinical animal models as well as some human clinical trials for use as adjuvants 
in effectively inducing antitumour immunity. Local delivery of IL-2 provides a 
strong helper signal for CD8^ T cells, possibly bypassing CD4^ T helper function, 
leading to activation, tumour antigen recognition and enhanced tumour cell killing 
(Karp, Farber et al. 1993) (Russell, Eccles et al. 1991). Transfer of the gene for IL-2 
into tumour cells results in inhibition of tumour growth in vivo, while vaccination 
with IL-2 expressing autologous or allogeneic tumour cells or fibroblasts has been
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shown to induce an effective systemic immunity against weakly immunogenic 
tumours (Cavallo, Giovarelli et al. 1992; Kim, Russell et al. 1992; Kim, Russell et al. 
1993; Kircheis, Kupcu et al. 2000). Tumour immunity has also been augmented by 
immunisation with tumour cells modified to express IL-4, IL-6, IL-7, TNF-a and 
IFN-a (Dranoff, Jaffee et al. 1993; Sun, Paschen et al. 1999; Kinoshita, Kono et al. 
2001; Todryk, Birchall et al. 2001).
1.6.5.5 Gene-Modification With Hsp70
Fleat shock proteins (HSPs) such as the cytoplasmic hsp70 and the endoplasmic 
reticulum-based gp96 are natural biologic adjuvants that have been explored in cancer 
vaccination strategies. HSPs are a highly conserved group of proteins most of which 
are present in abundant levels in living organisms under normal conditions 
(constitutively expressed HSPs). Expression of HSPs can be greatly induced by heat 
shock, glucose deprivation and other forms of cellular stress (inducible HSPs). Under 
normal physiological conditions the main functions of HSPs(%^  ^ binding to other 
cellular proteins, ensuring their correct folding and assisting in their transport to the 
ER and the cytoplasm. HSPs are believed to constitute potent danger signals of 
mammalian cell origin and thereby play a pivotal role in the development of innate 
and adaptive immunity (Anderson and Srivastava 2000). Accordingly, non-apoptotic 
(necrotic), but not apoptotic cell death, has been associated with the expression and 
release of high levels of immunogenic HSPs from cells (Melcher, Todryk et al. 1998; 
Basu, Binder et al. 2000). Release of HSPs in the extracellular milieu can lead to 
stimulation of macrophages and DC to secrete cytokines and upregulation of MHC 
and costimulatory molecule expression on DC (Suto and Srivastava 1995; Anderson 
and Srivastava 2000), providing a mechanisms whereby the immune system can 
perceive and respond to immunogenic types of cell death.
Previous work in our laboratory has demonstrated that when tumour cells are killed in 
a non-apoptotic manner (mediated by HSVtk plus GCV) high levels of the inducible 
form of hsp70 are expressed by the dying tumour cells (Melcher, Todryk et al. 1998). 
In vivo, this mechanism of cell death was associated with increased immunogenicity 
as demonstrated by immune protection conferred by vaccination with autologous 
HSVtk-killed cells against a subsequent challenge with unmodified tumour cells.
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CMT93, a poorly immunogenic colorectal tumour cell line that died by HSVtk- 
induced apoptosis could be rendered immunogenic by overexpression of the 
apoptosis-blocking agent bcl-2, and this enhancement of immunogenicity was 
associated with increased HSP expression (Melcher, Todryk et al. 1998). 
Furthermore, when poorly immunogenic tumour cells were modified to overexpress 
hsp70 their immunogenicity could be significantly enhanced (Melcher, Todryk et al. 
1998; Todryk, Melcher et al. 1999). It was therefore proposed that HSP
overexpression may provide immunostimulatory signals in vivo, similar to those 
obtained by immunogenic cell death such as necrosis, which may help break tolerance 
to tumour antigens. These findings are consistent with those of other groups which 
have demonstrated that biochemically purified hsp for tumour cells can effectively 
stimulate a potent immune response and lead to immune protection against the 
parental cells (Udono and Srivastava 1994; Tamura, Peng et al. 1997; Janetzki, 
Blachere et al. 1998).
Although the mechanism of immunogenicity of HSPs is not completely understood, it 
has been suggested that endogenous heat shock proteins are not immunogenic per se 
but rather chaperone antigenic peptides generated during antigen processing and that 
it is the peptides rather that the HSPs that function as the immunogens. Evidence to 
support this suggestion comes from observations that HSPs stripped of their 
associated peptides lose their immunogenicity (Suto and Srivastava 1995). Several 
studies have shown that immunogenic HSP-peptide complexes can be reconstituted in 
vitro and that these reconstituted complexes are immunologically active, as 
demonstrated by their ability to elicit antitumour immunity and CD8^ CTL responses 
(Blachere, Li et al. 1997). HSP-peptide complexes generated in vivo or in vitro can 
directly induce macrophages and CTL to secrete inflammatory cytokines such as 
TNF-a (Chen, Syldath et al. 1999) and can be used to effectively immunise mice 
against autologous tumour cells. Follow up studies in our laboratory have shown that 
radio-labelled lysates from tumour cells engineered to overexpress hsp70 were taken 
up by immature DC in vitro to a far greater extent than lysates of unmodified tumour 
cells and this effect was characteristic of immature but not mature DCs (Todryk, 
Melcher et al. 1999). Furthermore, experiments using tagged hsp70 demonstrated 
that DC specifically took up this molecule. Importantly, hsp70-expression by
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tumours induced a heavy in vivo infiltration of T cells, macrophages and 
predominantly DC and expression of Thl cytokines (Todryk, Melcher et al. 1999), an 
environment that is likely to promote an effective cellular immune response. These 
data suggest that induction of hsp70, and possibly of other HSPs, can serve to alert the 
immune system to an immunologically dangerous situation against which an immune 
reaction should be raised. These findings are in agreement with work from other 
laboratories that shows that HSP-peptide complexes can be taken up by APC such as 
macrophages, processed by the MHC Class I pathway of the APC and cross-presented 
on the cell surface where they can stimulate CTL (Suto and Srivastava 1995; 
Castellino, Boucher et al. 2000). A specific receptor, CD91, has recently been 
identified on the surface of APC as a common receptor for binding of several HSPs 
including hsp70, gp96 and hsp90 (Basu, Binder et al. 2001). The identification of this 
receptor may help explain the unique ability of HSPs as peptide chaperones to induce 
potent antigen specific CD8^ T cell immune responses even in the presence of only 
nanomolar amounts of HSP-peptide complexes.
Collectively these observations support the use of HSPs for cancer immunotherapy. 
In a pilot phase 1 clinical study, Srivastava and colleagues treated sixteen patients 
with advanced malignancies refractory to established therapies with autologous 
tumour derived gp96 vaccines (Janetzki, Palla et al. 2000). No adverse toxicity or 
auto-immune reactions were associated with vaccination in any of the fourteen 
evaluable patients. Immunisation elicited MHC 1-restricted, tumour-specific CD8^ T 
cells in six out of twelve patients immunised, and NK cell expansion in eight of 
thirteen patients immunised. This study demonstrates the feasibility and safety of 
utilising HSPs in therapy protocols for the induction of antitumour immune responses 
in humans.
1.7 Fusogenic Membrane Glycoproteins
Enveloped viruses such as the orthomyxoviruses (e.g. influenza), paramyxoviruses 
(e.g. Sendai), rhabdoviruses (e.g. vesicular stomatitis virus), retroviruses (e.g. human 
immunodeficiency) and alphaviruses (e.g. Semliki Forest virus) contain the viral 
genome and core proteins within a membrane that has been acquired from the host 
cell during virus assembly and bWding. Entry of enveloped viruses involves fusion of
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otherwise called viral fusogenic membrane glycoproteins (FMGs). Membrane fusion 
is a frequent reaction in eukaryotic cells, including for example the formation and 
consumption of vesicles transporting molecules between intracellular organelles.
Enveloped viruses in general utilise one of two mechanisms for viral entry. Viruses 
belonging to the Retrovihdae, Paramyxoviridae, Herpesviridea and Coronaviridae 
families typically initiate fusion in a pH-independent manner, where following initial 
attachment of the virion to the cell surface by virtue of interaction of the FMG on the 
virus surface with the appropriate viral receptor on the host cell surface, fusion 
between the viral and cellular membranes occurs at neutral pH at the cell surface 
(Figure 1.8.B) (Hernandez, Hoffman et al. 1996).
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Figure 1.8; Routes of enveloped virus entry into cells.
A: Virus is endocytosed and fusion between the viral and cellular membranes takes 
place in a pH dependent manner in the in the endocytic compartments. B. Fusion 
between viral and cellular membranes takes place in a pH independent manner at the 
cell surface.
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Viruses belonging to the Rhabdoviridae, Orthomyxoviridae, and other families 
typically utilise a more complex route of entry that requires a low-pH-mediated event 
for efficient fusion of viral and host cellular membranes (Figure 1.8.A). During this 
pathway of entry, initial attachment of the virion on the cell surface is followed by 
endocytosis and transport to the endosomal and lysosomal compartments, where the 
viral FMGs are activated by exposure to the low pH environment of these 
compartments. Although the exact mechanisms underlying fusion are not entirely 
understood, it is believed that in the pH-independent route of entry, binding of the 
receptor binding domain of the viral FMG is the stimulus that triggers a 
conformational change in the FMG molecule leading to the fusion event, whereas in 
the pH-dependent route, it is the lowering of the endosomal pH that triggers the 
conformational change.
1.7.1 Vesicular Stomatitis Virus G Glycoprotein
Vesicular stomatitis virus (VSV), a member of the Rhabdoviridae family of viruses, is 
an enveloped virus with the characteristic bullet-shaped form and contains a single 
stranded RNA genome of negative polarity that encodes for five viral proteins. VSV 
entry into the host cells involves receptor-mediated endocytosis of the viral particle 
into acidic endocytic organelles, where the low-pH environment of the endosomes 
induces fusion of the viral envelope to the cellular membrane and facilitates release of 
the viral core and genome in the cytoplasm (Hernandez, Hoffman et al. 1996). A 
single glycoprotein in the virion membrane, the G glycoprotein (VSV-G), is
responsible for viral attachment and virus-cell fusion (Florkiewicz and Rose 1984; 
Riedel, Kondor-Koch et al. 1984). VSV-G is a transmembrane protein that exists as a 
non-covalently linked homotrimer on the surface of VSV particles. Glycosylation of 
VSV-G is critical for proper folding, assembly and transport to the cell surface (Coll
1995). It is believed that exposure to low-pH, such as that present in endosomal 
compartments following uptake of the virus, triggers a conformational change in the 
G protein allowing it to induce virus-cell or cell-cell fusion (Figure 1.9).
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Figure 1.9: A model for VSV-G-mediated fusion.
Work on influenza HA protein has allowed the development of a model for HA- 
mediated fusion that can also be applied to VSV-G-mediated fusion. Conformational 
changes in the VSV-G protein are believed to drive the conformational transitions 
required to fuse two membranes (Hernandez 1996). Conformational changes of the 
VSV-G trimer following binding at the target lipid bilayer and clustering at the fusion 
site (steps 1 and 2) is proposed to promote hemifusion (step 3). During this stage of 
the fusion process the VSV-G trimers are thought to bend and bring the two 
membranes into close proximity. It is proposed that this is then followed by the 
formation of a small pore (step 4) and subsequent dialation of this pore (step 5) 
(modified from (Hernandez, 1996)).
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Unlike FMGs of many other enveloped viruses the conformational change of the 
VSV-G has been shown to be reversible (Coll 1995). VSV-G can also initiate cell­
cell membrane fusion between cells expressing the viral glycoprotein on their cell 
surface in the absence of any other viral proteins in a low-pH-dependent manner 
(Florkiewicz and Rose 1984; Riedel, Kondor-Koch et al. 1984). Cell-cell fusion leads 
to the formation of multinucleated syncytia (Florkiewicz and Rose 1984; Riedel, 
Kondor-Koch et al. 1984; Blumenthal, Bali-Puri et al. 1987). This is not however a 
typical cytopathic effect in the life cycle of VSV, as the G glycoprotein reaches the 
cell surface in a fusion incompetent form during the normal replication cycle. VSV- 
G-mediated fusion can be inhibited by treatment with lysomotropic agents, such as 
ammonium chloride and chloroquine, which accumulate in the lysosomal 
compartments and function by raising the lysosomal pH and thus inhibiting the 
conformational change in the G molecule.
Effective viral infection requires that the host cell expresses the appropriate receptor 
on its cell surface for VSV-G attachment and entry. Similarly, for effective cell-cell 
fusion to occur, a cellular receptor for the FMG must be expressed. The cellular 
receptor for VSV is believed to be phosphotidylserine (Schlegel, Tralka et al. 1983) 
(Konieczko, Whitaker-Dowling et al. 1994). Binding of phosphotidylserine to the G 
glycoprotein has been demonstrated in several rabdoviruses (Coll 1995). The 
utilisation of such a generic molecule on the surface of cells as the cellular receptor 
probably accounts to some extent for the extremely broad host range of rabdoviruses. 
It is not clear however if phosphotydilserine U the sole receptor for VSV or if it 
constitutes only a part of a larger protein-lipid receptor.
The G protein of VSV is a single polypeptide of approximately 500 amino acids long 
and is composed of a surface unit (SU), a transmembrane (TM) domain, and a 
hydrophilic cytoplasmic carboxy (C)-terminal peptide tail (Coll 1995). The SU 
contains two putative glycosylation amino acid consensus sequences and a short 
stretch of hydrohpobic amino acids called the signal peptide responsible for directing 
the nascent envelope glycoprotein through the secretory pathway of the infected cell. 
Near the C-terminal domain is another hydrophobic stretch of amino acids that stops 
the translocation process, anchors the molecule in the membrane and causes it to span 
the lipid bilayer (anchoring domain). Unlike FMGs of other enveloped viruses, such
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as the hemagglutinin (HA) of influenza virus or the envelope of murine leukemia 
virus (MLV), VSV-G reaching the cell surface is an intact molecule that does not 
undergo proteolytic cleavage into separate subunits during transport from the ER to 
the cell surface (Coll 1995). For such noncleaved fusion proteins identification of the 
fusion domain, a peptide believed to be responsible for mediating fusion between 
different membranes, has been more challenging. Typically the fusion peptide is a 
peptide segment composed of hydrophobic amino acids that is usually located near or 
at the TM unit. Initial examination of the primary amino acid sequence of the G 
protein of VSV of different strains did not reveal the presence of any obvious 
hydrophobic sequence other than the signal sequence and the carboxy-terminal 
membrane anchoring domain. Subsequent insertional and site-directed mutagenesis 
studies revealed that a region of uncharged amino acids between amino acids 117 to 
137 may represent a putative internal fusion peptide of VSV-G (Zhang and Ghosh
1994) (Whitt, Zagouras et al. 1990). This region is conserved between VSV 
serotypes.
To further support this hypothesis and to identify specific regions within this potential 
fusion peptide, Whitt and colleagues generated mutant VSV-G molecules by 
performing site directed mutagenesis and studied the folding, assembly, surface 
expression and fusion activity of these proteins (Fredericksen and Whitt 1995). These 
studies revealed at least two mutant VSV-G proteins with significantly altered fusion 
activities. The pH threshold for fusion activity of the wild-type VSV-G is 
approximately 6.3 and extensive syncytia formation in cells expressing the wild type 
VSV-G occurs after treatment with pH 5.7. Both VSV-G G-124-> E, which has an 
acidic glutamic acid instead of the non-polar glycine at position 124, and VSV-G P- 
127^D, which has an acidic aspartic acid instead of a non-polar proline at position 
127, were fusion defective at pH 5.7 and had a greatly reduced pH threshold for 
fusion activity, with significant fusion observed only at pH 5.2. The extent of fusion 
induced by either mutant proteins was greatly reduced compared to that induced by 
wild type VSV-G. It is important to mention that both of the mutant VSV-G proteins 
were correctly folded, assembled and transported to the surface similarly to the wild 
type VSV-G. Collectively these studies support the existence of a critical internal 
fusion peptide between amino acids 117 and 137 of the VSV-G glycoprotein with an 
important role in the low-pH-induced virus-cell or cell-cell fusion. Fusion activity of
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VSV-G can also be influenced by regions distal to the fusion peptide, suggesting that 
the conformation of the fusion peptide may be regulated by the three-dimensional 
structure of the G protein obtained after low-pH exposure (Shokralla, He et al. 1998).
VSV infection can induce both CTL and Ab responses. Although the MHC Class I- 
restricted CTL responses to VSV are predominantly specific for the nucleoprotein, 
MHC Class Il-restricted CTL responses could be generated in mice defective for the 
Class I gene. Furthermore, Th responses, capable of enhancing both CTL and Ab 
responses, can be induced by epitopes on VSV-G (Burkhart, Freer et al. 1994; Coll
1995).
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1.7.2 Gibbon Ape Leukemia Virus Envelope Glycoprotein
Gibbon ape leukemia virus (GALV) is a C-type retrovirus that shares many 
similarities in genome organisation, structure and function of viral gene products with 
other C-type retroviruses such as murine leukemia viruses (MLV) and feline leukemia 
viruses (FeLV) (Hunter and Swanstrom 1990). GALV, like many other enveloped 
retroviruses, enters the cells in a pH-independent manner. Fusion of the virus 
membrane with the cell membrane occurs at the cell surface at neutral pH (Figure 
1.10). Viral attachment and subsequent fusion is mediated by the envelope gene 
product of GALV.
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Figure 1.10: Model for the fusion process for C-type retroviruses including
GALV.
A critical step for the maturation and acquisition of the fusion competent state of the 
envelope protein is the cleavage of the R peptide off the cytoplasmic tail. Receptor- 
SU binding promotes conformational changes that lead to the exposure of the fusion 
peptide. The fusion process following this step is similar to that proposed for VSV-G. 
Reproduced by kind permission of Dr D. Lavillette and Dr F-L. Cosset.
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The GALV envelope shows very high homology to other C-type retrovirus envelopes 
such as those of MLV and FeLV and many of the characteristics of the extensively 
studied MLV envelope are therefore believed to be applicable to the GALV envelope. 
The nascent GALV envelope gene product is composed of a single 85 kDa 
polypeptide which is proteolytically cleaved shortly after translation into two distinct 
polypeptides non-covalently linked to each other. The larger subunit, which 
corresponds to the N-terminal region of the precursor protein, is a 70 kDa polypeptide 
(gp70 or surface, SU) that is completely extracellular and contains the receptor 
binding domain (RBD) responsible for receptor specificity and binding, a proline rich 
region (PRR) and a C-terminal domain. The smaller subunit, a 15 kDa polyprotein 
(pl5E or TM) corresponding to the C-terminal region of the precursor protein, is a 
membrane spanning protein that plays a very important role in post-binding effects, 
notably fusion. TM contains an external domain, a membrane spanning domain and a 
cytoplasmic domain. A hydrophobic anchoring domain is contained between the 
membrane spanning and the cytoplasmic domain that serves to stop translocation of 
the polyprotein and anchor it to the membrane. TM also contains a hydrophobic 
region in the N-terminal region corresponding to the fusion peptide, which is 
important in the fusion process, and the so-called R peptide at the C-terminal end of 
the protein.
The R peptide is a short peptide, 16 amino acids long, which is cleaved from the TM 
by viral-encoded proteases during virion maturation (Sutcliffe, Shinnick et al. 1980). 
Cleavage of the R peptide from the TM of the envelope heterodimer is necessary to 
render the envelope molecule capable of triggering membrane fusion. Infection with 
a Moloney MLV (MoMLV) lacking the R peptide or transfection with a plasmid 
expressing a similarly truncated MoMLV envelope glycoprotein results in 
considerable cell-cell fusion (Jones and Risser 1993; Januszeski, Cannon et al. 1997; 
Thomas, Gray et al. 1997). The R peptide is believed to have an inhibitory role in 
fusion since introduction of an R peptide from another retrovirus is capable of 
reversing the hyperfusogenic state of a truncated envelope (Yang and Compans
1996). In addition, the R peptide is believed to play an important role in the 
incorporation of the envelope into the budding virions.
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Shortly after translation in the ER the envelope protein is modified by N-linked 
glycosylation and oligomerises into trimeric structures. Oligomerisation is likely to 
be a prerequisite for transport from the ER to the Golgi compartment. In the Golgi 
the trimeric envelope precursor is further modified by trimming of the core 
carbohydrate side chains and cleavage by host-derived proteases into the individual 
SU and TM proteins. Cleavage occurs immediately after a highly conserved region of 
basic amino acids, placing the fusion peptide close to or at the N-terminus of the TM 
(Hunter and Swanstrom 1990). Following this complex series of modifications, the 
envelope protein is transported to the plasma membrane where it can be incorporated 
into assembling virions.
The cellular receptor for GALV {Glvr or PiTl) is a widely expressed integral 
membrane protein that normally functions as a sodium-dependent inorganic 
phosphate symporter (O'Hara, Johann et al. 1990). PiTl has ten transmembrane 
regions and 5 extracellular loops. Receptor interference and superinfection resistance 
studies revealed that Pitl is a receptor shared between GALV and FLV (Sommerfelt
1999). By studying differences in sequence homology between the relatively 
functional human Pitl and the non-functional murine PiTl molecules the binding sites 
on the receptor for GALV and FLV have been localised to the fourth extracellular 
loop, clustered within a region of nine amino acids termed “Region A” (Johann, van 
Zeijl et al. 1993). The amino acid sequence within this region was polymorphic 
between species, resulting in altered susceptibility to these viruses and differences in 
tropism between viruses. A closely related sodium-dependent phosphate symporter, 
Pit2, has been identified as the receptor for the amphotropic MLV (MLV-A) (Miller, 
Edwards et al. 1994).
1.7.3 Use of Viral FMGs As a Novel Class of Cytotoxic Genes
Several recent reports from our group and others have demonstrated that FMGs can 
be used as novel genes for the local control of tumour growth (Bateman, Bullough et 
al. 2000; Diaz, Bateman et al. 2000; Galanis, Bateman et al. 2001). Expression of a 
hyperfusogenic version of GALV that is lacking the R peptide, or the measles virus F 
and H genes, in a wide panel of human tumour lines or freshly resected human 
tumour explants lead to very high levels of cytotoxicity, demonstrating the great
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efficacy of these genes (Bateman, Bullough et al. 2000). Similarly, expression of the 
VSV-G led to high levels of cell death following a drop of the ambient pH below 6.0. 
Direct comparison of FMG-mediated killing to the classical HSVtk/GCV- or cytosine 
deaminase (CD)-mediated killing demonstrated that direct and bystander killing of the 
three different FMGs were at least one log more potent than that of HSVtk or CD 
suicide genes (Bateman, Bullough et al. 2000). FMG expression led to the formation 
of large multinucleated syncytia, which subsequently died by sequestration of cell 
nuclei and nuclear fusion in a non-apoptotic mechanism. Syncytia remain stable and 
metabolically and transcriptionally active for a period of approximately 2 days and 
then lose viability by day 5 (Bateman, Bullough et al. 2000; Higuchi, Bronk et al.
2000). Expression of the hyperfusogenic GALV FMG in hepatoma cells showed that 
syncytial death is associated with a bioenergetic form of cell death involving necrosis 
and mitochondrial failure with ATP depletion (Higuchi, Bronk et al. 2000). 
Hyperfusogenic GALV FMG expression in human tumour cell lines was also 
associated with upregulation of expression of immunostimulatory signals such as 
hsp70 and gp96, while specific antitumour immunity could be generated in 
immunocompetent mice by vaccination with G AL V-expressing tumour cells (GALV 
expression in murine cells does not lead to syncytia death as murine cells lack the 
appropriate Pitl receptor) (Bateman, Bullough et al. 2000). Finally, transduction of 
human tumour xenografts with plasmid DNA encoding the hyperfusogenic GALV 
cDNA lead to significant prevention of tumour outgrowth, and cytotoxicity could be 
controlled using transcriptional targeting through a tissue specific promoter (Bateman, 
Bullough et al. 2000).
In a similar study Galanis et al. showed that expression of FMGs such as the 
hyperfusogenic GALV and the measles virus F and H proteins could lead to 
significant levels of cell killing both in vitro and in vivo in gliomas (Galanis, Bateman 
et al. 2001). Overall, these studies demonstrate the great potential FMGs have as 
potent cytoreductive agents for the local and possibly the immune-mediated control of 
tumour growth.
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1.8 Transcriptional Control of Gene Expression for Cancer Gene Therapy
The development of gene therapy approaches for cancer treatment, particularly 
cytotoxic gene therapy approaches, has clearly indicated the need for the development 
of strategies that would maximise the beneficial effects of a given treatment and 
minimise the potential side effect or adverse effects. Where gene expression products 
are directly or indirectly toxic to the cells, restricted and highly controllable 
expression of the therapeutic genes to the target tissue of interest would be desired to 
avoid severe toxicity associated with expression in normal tissues. Control of gene 
expression at the level of gene transcription is one of the most widely studied 
approaches to targeted gene therapy, and has multiple facets due to the wide variety of 
promoters and transcription regulation factors that have been characterised. For the 
purposes of this Introduction several different promoter systems will be discussed 
with particular emphasis on drug-inducible promoter systems.
1.8.1 Tissue Specific Promoters
Certain tissues express proteins which are to a large degree specific to that tissue, for 
example tyrosinase in melanocytes and PSA in prostate cells. The promoters that 
regulate these genes are known as tissue specific promoters (TSF) and have been 
greatly exploited for the use in targeted gene expression. In the context of cancer 
treatment, an ideal TSF should meet the following criteria: (1) its activity should be 
reliably restricted to the target tissue; and (2) the normal tissue (in which it will also 
be active) should either be expendable, replaceable or located far from the site of gene 
delivery/expression. For example, a gene therapy strategy using a TSF driving a gene 
that ablates melanocytes, prostate or thyroid tissue is tolerable, whereas a similar 
approach that caused significant damage to liver or neuronal tissues would have 
potentially disastrous consequences. In addition, the degree of tissue specificity of a 
TSF is of considerable importance and will have a direct bearing on the therapeutic 
index of the gene therapy approach. Placing a therapeutic gene under the control of a 
TSF does not guarantee that its expression will be exclusively limited to the target 
tissue. Depending on the gene being used, low level background gene expression in 
other tissues may be associated with toxic side effects.
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A considerable amount of work has concentrated on the use of TSP with preferential 
activity in melanocytes. Vile and Hart (Vile and Hart 1993) reported that inclusion of 
small elements of the 5’ flanking sequences of the tyrosinase and TRP-1 genes in 
plasmid and retroviral constructs was sufficient to drive tissue specific expression of a 
lacZ reporter gene in a wide range of murine and human melanoma cell lines in vitro. 
In addition, tissue specific expression was seen in a melanoma, but not colorectal, 
tumour in vivo after direct injection of plasmid DNA (Vile and Hart 1993). In a 
subsequent study, tissue specific expression of cytokine genes was demonstrated 
under the control of the tyrosinase promoter and cells expressing these genes were 
shown to have reduced tumourigenicity in vivo (Vile and Hart 1994). However, direct 
intratumoural injection of plasmid DNA with cytokines expressed from the tyrosinase 
promoter led to gene expression but no tumour regression. Further refinement of this 
approach has been achieved by engineering Moloney murine leukemia virus-derived 
RV vectors with the tyrosinase enhancer/promoter replacing the 3’ long terminal 
repeat viral enhancer (Vile, Diaz et al. 1995; Diaz, Eisen et al. 1998). Therapeutic 
studies in vitro and in vivo, using localised and metastatic melanoma models, have 
confirmed the ability of plasmid DNA and RV vectors containing suicide transgenes 
to selectively kill melanoma cells (Vile and Hart 1994; Cao, Kuriyama et al. 1999; 
Park, Brown et al. 1999).
Other TSP under development for cancer gene therapy strategies include the PSA 
promoter restricting expression in prostate, the albumin promoter restricting 
expression in liver and the ostecalcin promoter restricting expression in osteoblast 
(Harrington, Linardakis et al. 2000).
1.8.2 Tumour Specific Promoters
The dividing line between tissue and tumour specific promoters is rather blurred. 
Essentially, the definition of tumour specific promoter relies on the fact that certain 
promoters are either silent or have very low background levels in normal tissues, but 
are highly active in tumours. A number of promoters can be included within this 
rather heterogeneous group: (1) promoters that are specific for the malignant process 
but that show no particular tissue specificity -  so-called “cancer-specific promoters”; 
(2) promoters of genes that encode oncofetal antigens and which have very well-
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defined patterns of tissue specificity -  so-called “tumour-type specific promoters”; (3) 
promoters responsive to pathophysiological conditions which predominate in tumour 
areas, for example hypoxia responsive promoters; and (4) promoters that are specific 
to cells of the tumour environment, such as the tumour vascular endothelium.
Classical examples of a tumour specific promoter utilised in the development of 
cancer gene therapy approaches include the carcinoembryonic antigen (CEA) and the 
alpha fetoprotein (AFP) promoters. CEA is expressed by a number of 
adenocarcinomas including colorectal, breast and lung cancers, while AFP is 
expressed by hepatocellular carcinomas and malignant testicular teratomas. The 
promoters of these genes have been characterised and their essential elements have 
been identified. A number of authors have used the CEA promoter to drive 
expression of either reporter or therapeutic transgenes in gastric, lung and colorectal 
tumour systems. In most of these studies, adenoviral vectors have been used with the 
CEA promoter controlling the expression of a suicide gene (HSVtk or CD). Such 
vectors have been shown to confer selective gene expression both in vitro and in vivo 
after intraperitoneal (Lan, Kanai et al. 1997) or intratumoural (Brand, Loser et al. 
1998) injection. However, when compared to the highly active viral CMVI/E 
promoter, the CEA promoter was shown to have relatively weak transcriptional 
activity. A similar body of work exists for the treatment of hepatoma with AFP- 
regulated gene therapy systems. Again, many of the studies have focused on the use 
of TSP-driven suicide gene approaches (Harrington, Linardakis et al. 2000).
1.8.3 Inducible Promoters
Over the last ten years considerable progress has been made in the development of 
inducible systems. In these systems transcription of exogenous genes introduced into 
cells can be controlled by the administration of inducing or repressing agents by 
means of their actions on inducible transcription factors and specific promoters. A 
number of agents, including drugs, radiation and heat have been used to control such 
“gene switches”, with particular progress being made in the development of drug- 
inducible systems. Three characteristics are necessary for the generation of the 
optimal inducible system: (I) specificity, as there should be no responsiveness to 
endogenous activators or interference with cellular regulatory pathways; (2)
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efficiency, as there should be very low to no basal levels of gene expression in the 
uninduced state and high levels of expression upon induction, with rapid and efficient 
conversion between the two states; (3) dose responsiveness, allowing for adjustment 
of the levels of gene expression to meet the needs for the therapeutic requirements 
(Rossi and Blau 1998). In the case of drug inducible systems, the inducing 
agents/drug would ideally be a small, non-toxic, orally bioavailable and cell- 
permeable molecule capable of reversibly modulating the activity of the transcription 
factor. Initial small molecule inducible systems were based on endogenous 
transcription factors inducible by metals or steroids. These systems however suffered 
from the pleiotropic effects of the inducers leading to modification of expression of 
non-target host genes, as well as from interference from endogenous inducers such as 
other hormones. Efficient systems based largely on exogenous transcription factors 
have been developed and some of the most successfully applied systems will be 
discussed below.
1.8.3.1 Tetracycline Inducible Allosteric Off System
The first widely used drug-inducible system to be discussed is an entirely prokaryotic 
allosteric system described by Gossen and Bujard (Gossen and Bujard 1992) where 
gene expression is suppressed by the addition of the non-toxic antibiotic tetracycline 
(tet). In this system a constitutively expressed DNA binding moiety, the tetracycline 
controlled transactivator (tTA), consisting of the E. coli tet repressor (tetR) fused to 
the activating domain of virion protein 16 (VP 16) of HSV, binds to an engineered tet 
responsive element (TRE) placed upstream of the TATA box of target genes and 
activates transcription. Addition of tet, or its more efficient analogues such as 
doxycycline (Dox), leads to a conformational change in the tetK DNA binding 
domain of the tTA such that it dissociates from the promoter element leading to 
abrogation of gene expression (Figure 1.11.A). The TRE is composed of seven 
tandem repeats of tetR binding sites and is located just upstream of a minimal CMV 
promoter that lacks the strong enhancer elements normally associated with the CMV 
immediately early promoter. In the initial study performed in HeLa cells stably 
expressing tTA, expression of luciferase (luc) in the presence of ng/ml quantities of 
tet were very low and withdrawal of tet resulted in induction ratios of as much as 100 
000-fold (Gossen and Bujard 1992). Moreover, luc levels could be varied by titrating
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the concentration of tet in the growth media and maximal, steady-state levels of 
activity were achieved in about 24 hrs. Subsequent studies however have failed to 
reproduce those initial impressive induction ratios, mainly due to high basal levels of 
gene expression. Nonetheless, the allosteric tet-off system has found very wide 
application in tissue culture as well as transgenic mouse studies.
A. Allosteric OFF switch
VP16
TetR
TRE Minimal Coding sequence 
CMV
B. Allosteric ON switch
VP16
rTetR
TRE Minimal Coding sequence 
CMV
Figure 1.11: Diagramatic representation of the Tet inducible systems.
A: The allosteric Off system in which transcription proceeds in the absence of the 
regulating drug, tetracycline (Tet) or analoques such as doxocycline (Dox). B: The 
allosteric ON system in which transcription occurs in the presence of the Tet or Dox .
Hwang et al. developed a retroviral vector in which HSVtk was placed under the 
control of a tet-responsive expression system (Hwang, Scuric et al. 1996). In the 
absence of tet, the tk enzyme levels were 400-fold greater than in control cells but thèt>c 
levels returned to normal after addition of tet. Yu et al. placed the gene for IL-lp- 
converting enzyme, which forms part of the apoptosis signalling pathway, under the 
control of the tet-off system in a RV coexpressing the tTA (Yu, Sena-Esteves et al.
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1996). Introduction of this retroviral vector in glioma cells led to complete death of 
the cells in vitro or when implanted into rat brain, within 4-9 days of removal of tet. 
In contrast, Baasner et al. expressed HER2/c-erbB2 in fibroblasts under the control of 
tet/tTA and showed that tumour formation could be reversibly induced in vitro and in 
vivo by administration of Dox (Baasner, von Melchner et al. 1996). The basic tTA 
system has also been used to generate transgenic mice reversibly expressing luciferase 
or P-galactosidase in a variety of fetal and adult tissues (Shockett, Difilippantonio et 
a l 1995).
The allosteric tet off system has served as a valuable model system but it has a 
number of potential disadvantages for clinical application. Chief amongst these is the 
fact that steady state levels of the modulating agent are required to keep the 
therapeutic gene inactive. This is inconvenient but also exposes the patient to the 
potential toxicities of prolonged drug administration and unplanned gene expression 
after inadvertent drug withdrawal. An additional problem is presented by the fact that 
the time course of gene activation is dependent upon pharmacokinetic parameters 
such as metabolism and excretion which dictate the rate of drug clearance.
1.8.3.2 Tetracycline Inducible Allosteric On System
Subsequent to the development of the original tet-off system, Gossen et al. described 
a modified system in which a reverse transactivator (rtTA) could bind TRE efficiently 
only in the presence of the tet analogues, Dox or anhydrotetracycline (Figure 1.1 l.B) 
(Gossen, Freundlieb et al. 1995). rtTA contains a mutated TetR that has four amino 
acid exchanges at positions 71, 95, 101 and 102 leading to its reversed binding 
properties and phenotype. Transfection of plasmids containing luciferase or p- 
galactosidase under the control of the tTA-dependent promoter in HeLa cells stably 
expressing the rtTA demonstrated the expression of the reporter genes could be 
induced more than 1000-fold upon administration of Ipg/ml Dox. Luciferase 
expression could be induced 100-fold after 5.5 hrs and reached maximal levels in less 
than 24 hrs. One of the main advantages this modified system has over the original 
tTA system is that the kinetics of induction of gene expression do not depend on the 
biological half-life of the effector drug, leading to much more rapid activation of gene
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expression. In addition this system is particularly attractive for use in situations 
where repression of gene expression is desired for long periods of time and long term 
exposure to tet or its derivatives is undesirable or inconvenient, for example in 
transgenic animals or long-term gene therapy approaches).
Several groups have described technical improvements to the original tet-off and tet- 
on systems. To overcome technical difficulties associated with the generation of 
stable cell lines expressing both components of the system (tTA or rtTA plus the gene 
under the control of the tTA-responsive promoter) and to make the cloning process 
more rapid and efficient, several groups have developed single vectors containing 
both components for the simultaneous modification of cells. Plasmid, lentiviral, 
adenoviral, retroviral and adeno-associated viral vectors have been explored in this 
strategy (Hofmann, Nolan et al. 1996; Paulus, Baur et al. 1996; Bohl, Salvetti et al. 
1998; Huang, Spinella et al. 1999; Rubinchik, Ding et al. 2000; Vigna, Cavalieri et al. 
2002). To incorporate tissue specificity in the tet system several studies have 
developed strategies for the tissue-specific expression of the transactivators directed 
by tissue-specific promoters. Examples include the cardiac-specific expression of 
tTA and subsequently luciferase by utilising the rat a  myosin promoter in rats and 
mice (Fishman, Kaplan et al. 1994; Passman and Fishman 1994) and pancreatic p cell 
restricted expression of SV40 large T antigen achieved using the rat insulin promoter 
(Effat, Fusco-DeMane et al. 1995). Furthermore, vectors containing two minimal 
promoters in opposite orientations on either side of the TRE have been developed that 
allow tet-regulated expression of two genes in equal amounts from a single vector 
(Baron, Freundlieb et al. 1995). In an effort to activate higher levels of gene 
expression and to prevent possible toxic effects of constitutive expression of tTA, 
Shockett et al. placed tTA under the control of a tet-responsive promoter, resulting in 
an autoregulatory inducible gene expression system in which tTA is autoactivated in 
the absence of tet and expression of tTA is suppressed in the presence of tet 
(Shockett, Difilippantonio et al. 1995). Using this system substantially higher levels 
of target gene expression could be achieved in vitro, as well as higher frequency of 
resulting inducible clones. In addition, transgenic mice were produced in which 
expression of luciferase was 1 -2 orders of magnitude higher than those reported with
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the constitutive transgenic system (Furth, St Onge et al. 1994), although the levels in 
the uninduced state were also greater.
An important addition to the tet-on regulation system has been the incorporation of tet 
controlled transcriptional silencers (tTS), which are fusions between a TetR variant 
and domains known to function as repressors of transcription. Freundlied et al. tested 
several such domains and found the KRAB domain deriving from the human kidney 
protein Kid-1 to be the most efficient (Freundlieb, Schirra-Muller et al. 1999). The 
resulting TetR-fusion tTS*^ '^  can be coexpressed with rtTA and in the absence of Dox 
tTs* '^d can bind to the TRE and actively repress any basal activity. Addition of Dox 
leads to conformational change in the tTS*^ '^  releasing it from the TRE, while at the 
same time rtTA is activated to bind TRE and strongly activate transcription from the 
promoter. Heterodimer formation between the tTS^“^ and rtTA molecules is avoided 
due to modification of the dimérisation surface of the TetR moiety of the tTS*^ '^  that 
allows the tTS' '^  ^ monomers to only bind to each other. This modification results in 
significantly lowered background levels of gene expression in the absence of Dox and 
hence significantly enhanced induction ratios upon Dox administration.
It is important to note that the efficacy of the tet inducible systems has varied widely 
between cells or tissues of different type. Since the properties of minimal promoters 
are critical for low background expression and high induction it is generally proposed 
that the success in any given cell or tissue milieu might require alternative minimal 
promoters and careful choice of constitutive or tissue-specific promoters for 
transactivator expression (Shockett and Schatz 1996).
1.8.3.3 Dimérisation On Switch
An alternative to the allosteric switch systems is provided by strategies based on drug- 
induced dimérisation of separate DNA-binding and activating proteins. Such systems 
using immunosuppressive agents such as cyclosporine A, FK506 and rapamycin that 
bind to members of the immunophilin protein family have been extensively 
investigated. Initially, in a manner analogous to that described above for tetracycline- 
regulated systems, two chimeric fusion proteins were constructed (one a fusion 
between a Gal4 DNA-binding domain and FKBP12, the other between cyclophilin
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and the VP 16 transactivator) (Belshaw, Ho et al. 1996). In this study, addition of a 
cyclosporine-FK506 fusion compound strongly promoted heterodimerisation between 
these two fusion proteins and subsequent transcriptional activation. Attempts have 
recently been made to improve this system by substituting the non-eukaryotic 
elements with mammalian equivalents in an attempt to reduce the potential for 
immune reactions. Therefore, Gal4 has been replaced by the ZFHDl DNA binding 
domain and VP 16 has been replaced by the p65 subunit of NFkB. A further 
modification involved replacing the cyclophilin element with the FKBP-rapamycin 
binding (FRB) domain from the FKBP12-rapamycin associated protein (FRAP) 
(Magari, Rivera et al. 1997). With this system, rapamycin is able to control the 
expression of transgenes in vivo in a predictable fashion. However, the 
immunosuppressive effects of the modulating compound has been seen as a 
significant potential disadvantage to clinical application of this system. Therefore, 
rapamycin analogues (so-called rapalogs) have been identified which do not interact 
efficiently with wild-type FRAP but which are capable of binding to mutant FRB 
proteins. The rapamycin has been shown to yield regulated expression of human 
growth hormone in nude mice (Rivera, Clackson et al. 1996; Rivera, Ye et al. 1999), 
and regulated production of cytotoxic genes and gene therapy vectors for cancer 
therapy (Chong, Ruchatz et al. 2002).
1 ^ B 4  Customised Promoter
The perceived limitations of many of the natural promoter systems have fuelled the 
search for means of improving available wild-type sequences to derive so-called 
customised or designer promoters (Nettelbeck, Jerome et al. 2000). The simplest of 
these strategies involves the attempt to identify mutant promoters with increased 
ability to drive transcription but with preserved tissue/tumour specificity (Ishikawa, 
Nakata et al. 1999). More benefit has accrued from attempts to generate minimal 
enhancer/promoter sequences that retain the characteristics of the wild-type elements. 
Such studies involve generating a range of deletion and amplification mutants of the 
enhancer/promoter sequence driving a convenient reporter gene such as lacZ or 
chloramphenicol acetyltransferase (CAT). The DNA sequences that are derived from 
these studies are invariably smaller than the wild-type sequence, a feature that is of 
considerable significance to the issue of generating viral vectors. Such studies have
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identified the crucial transcriptional control sequences for a number of genes and have 
led to the construction of a number of new smaller modular versions of previously 
identified promoters. Another strategy involves the construction of chimeric 
promoters composed of regulatory elements from different promoters with the same 
tissue specificity. This tactic seeks to exploit the advantages of each of these 
promoters and to tighten the tissue specificity. This has been applied for the AFP and 
albumin promoters with some success in a hepatoma models (Su, Chang et al. 1996; 
Su, Lu et al. 1997). Alternatively, TSP have been used to drive the expression of 
exogenous bacterial or viral transcription factors which can subsequently transactivate 
constructs containing therapeutic genes downstream of the appropriate DNA binding 
sites (Segawa, Takebayashi et al. 1998). It is likely that further developments will 
occur rapidly in this exciting arena.
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1.9 Aims of the Thesis
Work presented in this thesis focused in the design of effective allogeneic vaccines 
for enhancing the immune responses against tumour cells. The first part of the thesis 
will investigate genetic modification of allogeneic tumour cells with genes expressing 
cytokines (specifically lL-12, GM-CSF and IFN-y) or hsp70 as a means of 
transforming a poorly immunogenic allogeneic melanoma vaccine to a potently 
immunogenic one. The aim is to test whether expression of immunogenic cytokines 
by allogeneic cells can modify the vaccine microenvironment and thus significantly 
augment specific anti-tumour immune responses. This will be followed by studies 
aiming at understanding the mechanisms by which the immune system responds to 
allogeneic cells (chapters 3 and 4).
In the second part of the thesis, a novel class of cytotoxic genes, the viral FMGs, will 
be investigated as a novel means of inducing fusion and subsequently killing vaccine 
cells in a highly immunostimulatory fashion (chapter 5). Following on from previous 
work in the laboratory, the immunostimulatory mode of syncytial cell death, 
combined with the immunogenic component of allogeneneic cells is tested as a potent 
inducer of specific anti-tumour immune responses. The mechanisms of 
immunogenicity of FMG induced cell death will also be investigated (chapter 6).
Finally, the third part of the thesis will involve the development of strategies for the 
control of FMG expression for the purpose of generating “off-the-shelf’ fusing 
allogeneic vaccines. The Tet-On drug-inducible gene expression system will be 
utilised for the development of human allogeneic melanoma cell lines stably 
expressing the GALV envelope gene. Such cell lines can find significant clinical 
application as they can form the basis of an allogeneic fusing tumour cell vaccine for 
use in human clinical studies.
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Chapter 2 
M a t e r i a l s  a n d  M e t h o d s
2.1 Molecular Biology
2.1.1 General Procedures
All solutions employed for the preparation and manipulation of nucleic acids were 
made up using distilled water (dH20). All solutions were autoclaved before use or, in 
the case of thermolabile substances, filter-sterilised using a 0.2 pm filter and stored in 
a sterile container. Unless stated otherwise, all chemical reagents were supplied by 
Sigma (St. Louis, MO) and all enzymes used were purchased from New England 
BioLabs (Beverly, MA). To reduce the chances of RNA degradation by 
contaminating RNAses, all solutions used for RNA work were treated overnight with 
diethylpyrocarbonate (DEPC) as a 0.1% v/v solution and then autoclaved.
4.1.2 Concentration of nucleic acids
Solutions containing nucleic acids were adjusted to 0.3M with respect to monovalent 
cations by addition of 3M sodium acetate (pH 5.0) stock solution. Nucleic acids were 
precipitated by adding 2.5 volumes of ethanol and chilled at -70°C for 30 minutes 
followed by centrifugation at 12,000g for 20 minutes. The pelleted nucleic acid was 
then washed with 70% v/v ethanol and then air dried before resuspension in distilled 
water or Tris-EDTA buffer (TE buffer: 10 mM Tris-HCl pH 8.0, ImM EDTA pH 
8 .0).
2.1.3 Determination of nucleic acid concentrations
The absorbance of an aqueous solution of the nucleic acid was measured at 260 nm 
(LTV-1601, Spectrophotometer, Shimadzu Corporation, Kyoto, Japan). The 
convention was used that an absorbance of one unit is equivalent to a double stranded 
DNA concentration of 50pg/ml and an RNA concentration of 40pg/ml.
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2.1.4 Transformation of bacteria
The plasmid DNA was added to lOOpl of competent E.coli. The suspension was 
cooled on ice for 45 minutes, warmed at 42°C for 1 minute and then returned to ice 
for 2 minutes. 400pl of L-broth was then added to the samples followed by 
incubation in a shaking incubator at 37°C for 60 min to permit expression of the 
antibiotic resistance gene on the plasmid. The bacteria were then plated out onto 
90mm petri dishes (Becton Dickenson Labware, NJ) containing L-agar (L-broth with 
1.5% w/v agar) with ampicillin (final concentration of lOOpg/ml). The plates were 
incubated overnight at 37°C.
2.1.5 Small scale preparation of plasmid DNA (“miniprep")
Plasmid DNA was prepared from small cultures of bacteria using a QlAprep Spin 
plasmid minipreparation kit (Qiagen, Valencia, CA), following the protocol supplied 
by the manufacturer. This procedure was based on the alkaline lysis method for rapid 
extraction of plasmid DNA from bacterial cells followed by the adsorption of DNA 
onto silica in the presence of high salt.
Single bacterial colonies were inoculated into 5 ml of L-broth containing ampicillin 
and incubated overnight in a shaking incubator at 37°C. 1.4 ml of the overnight
cultures were centrifuged at 10,000g for 5 min and the bacteria were then resuspended 
in 250 pi of resuspension buffer PI (50 mM Tris-HCl pH 8.0, 10 mM EDTA, 100 
pg/ml RNAse). 250 pi of lysis buffer P2 (200 mM NaOH, 1% SDS) was then added 
and mixed, followed by adding 350 pi of neutralisation buffer N3 which adjusts the 
sample to high salt binding conditions and causes precipitation of denatured proteins, 
SDS, cellular debris and chromosomal DNA. The samples were then centrifuged at 
10,000^ for 10 min and the supernatants were then applied QIAprep spin column and 
centrifuged for 30-60 sec for the samples to flow through the silica membrane which 
forms the floor of the spin column. After washing with 0.5 ml of buffer PB to remove 
trace nuclease activity and 0.75 ml of buffer PE to remove salts, the samples were 
centrifuged for an additional 1 min to remove any residual wash buffer and the DNA 
was eluted by applying 50 pi of distilled water to the silica membrane and 
centrifuging for 1 min.
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2.1.6 Large scale preparation of plasmid DNA (**maxiprep”)
Qiagen Plasmid Maxi kit was used which is based on the modified alkaline procedure 
followed by binding of plasmid DNA to an anion-exchange resin. A single bacterial 
colony was used to inoculate a 2 ml volume of L-broth containing ampicillin which 
was incubated for 8 hrs in a shaking incubator at 37°C. 1ml of this culture was used 
to inoculate 100 ml of L-broth containing ampicillin which was then incubated 
overnight. The bacteria was pelleted by centrifugation at 6,000g for 20 min (J2-HS 
centrifuge, Beckman) and resuspended in 10 ml of resuspension buffer PL 10 ml of 
lysis buffer P2 was then added and left at room temperature for 5 min. 10 ml of 
neutralisation buffer P3 (3M potassium acetate pH 5.5) (pre-chilled to 4"C) was added 
and the lysate poured into a QIAfilter Maxi cartridge and incubated at room 
temperature for 10 min. The cell lysate was then filtered onto a QIAGEN-tip which 
had been pre-equilibrated with 10 ml buffer QBT (750 mM NaCl, 50 mM MOPS 
pH7.0, 15% ethanol, 0.15% Triton X-100) and allowed to enter the anion-exchange 
resin by gravity flow. Under these conditions, the plasmid DNA binds to the anion- 
exchange resin. The resin was then washed with 60 ml of medium-salt buffer QC (1 
M NaCl, 50 mM MOPS, pH 7.0, 15% ethanol) to remove RNA, proteins and low 
molecular weight impurities. The DNA was eluted with 15 ml of high salt buffer QF 
(1.25 M NaCl, 50 mM Tris-HCl pH 8.5, 15% ethanol) and was then desalted by 
precipitation with 10.5 ml isopropanol. The DNA was pelleted by centrifugation at 
15,000g for 30 min at 4®C ,washed with 70% v/v ethanol, air dried and then dissolved 
in TE buffer.
2.1.7 Agarose gel electrophoresis of DNA
Gels were prepared by adding agarose (0.7 to 1.5% w/v) to 150 ml 1 x TAE (Tris- 
acetate-EDTA) buffer (diluted ftom 50X TAE stock solution: 2 M Tris base, 2 M 
glacial acetic acid, 50 mM EDTA) and boiled in a microwave cooker for 5 min. On 
cooling to below 50®C, 2 pi of ethidium bromide stock solution (10 mg/ml) was 
added. Gels were poured into a gel former with a well-comb in place. After setting, 
the gel was submerged in an electropheresis tank containing 1 x TAE buffer. Loading 
buffer (1/6 volume of 6X stock solution: 0.25% bromophenol blue, 40% w/v sucrose
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in (IH2O) was added to the DNA solutions which were then transferred into the wells, 
and electropheresis was performed using a voltage between 70 and 110 volts. The gel 
was transilluminated with short wave ultraviolet light and the DNA was visualised by 
2 UV transilluminator (UVP, Upland, CA) and Alpha Ease 5.04 Software (Alpha 
Innotech Corporation, San Leandro, CA). DNA fragments were sized by reference to 
a 1 kb DNA ladder (New England BioLabs, Beverly, MA) or a 100 bp DNA ladder 
(New England BioLabs, Beverly, MA).
2.1.8 Digestion of DNA with restriction enzymes
Plasmid DNA was digested in volumes of 30 pi using 1-2 units of enzyme per pg of 
DNA, buffers supplied by the manufacturer and incubated for 60 min at the 
appropriate temperature; BSA was added when indicated.
2.1.9 Removal of 5’ terminal phosphate groups
Re-ligation of the vector DNA in cases where cohesive ends were present was 
reduced by treatment of the restriction enzyme digestion products with calf intestinal 
alkaline phosphatase, to remove the 5’ phosphate groups of linear double stranded. 
The 30 pi reaction sample from the digestion reaction was mixed with 1 unit of CLAP 
(Promega, Madison, WI), 5 pi of 1 Ox reaction buffer (50 mM Tris-HCl pH 9.3, 1 mM 
MgCl2, 0.1 mM Zn CI2 and 1 mM spermidine) and the reaction mixture made up to 50 
pi with dH20. This was then.incubated for a further 60 min at 37°C and the sample 
was run on an agarose gel and the appropriate fragment was purified as described 
below.
2.1.10 Purification of DNA restriction fragments
DNA purification j&om an agarose gel was performed using the QIAquick gel 
extraction kit (Qiagen, Valencia, CA) following the manufacturer’s instructions. The 
method is based on the binding of DNA to silica under high salt conditions. Agarose 
gels were visualised by UV transillumination and the bands of interest excised using a 
scalpel blade. The excised portion of gel was dissolved in 3 volumes of buffer QG 
and incubated at 50®C until the gel has completely dissolved. 1 volume of
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isopropanol was then added if the DNA fragment being purified was between 500- 
4000 base pairs and the sample was then added to the QIAquick column and 
centrifuged at >10,000g for 1 min. The column was then washed once with 500 pi of 
buffer QG and centrifuged as before. Salts were removed by washing with 750 pi of 
buffer PE. The DNA was eluted from the column by the addition of 30 pi TE, 
waiting 1 minute before recentrifugation. Ipl of the eluate was run on an agarose gel 
to confirm successful purification of the DNA fragment.
2.1.11 Ligation of DNA fragments into vectors
DNA fragments were ligated into vectors by overnight incubation at 14°C in the 
presence of T4 DNA ligase (Boerhinger Mannheim Roche, Indianapolis, IN). The 
molar ratio of vector to insert was in the range of 1:3 to 1:10. The appropriate 
volumes of DNA fragment and vector were mixed with 1 unit of T4 DNA ligase, 1.5 
pi ligase buffer (50 mM Tris-HCl pH 7.8, 10 mM MgCli 10 mM DTT, 1 mM ATP, 
25 pg/ml BSA) and the reaction mixture was made up to 15 pi with dHiO. Reaction 
samples were such that the concentration of the 5’ termini was O.l-l.OpM
2.1.12 Automated sequencing of DNA
Automated DNA sequencing was performed at MAYO Sequencing Core facilities 
using Perkin Elmer ABI Prism 377 DNA sequencer and read with Sequencher 
software (Gene Codes Corporation, Ann Arbor, MI).
2.1.13 Genomic DNA preparation from eukaryotic cells
Qiagen genomic DNA minipreparation kit was used kit (Qiagen, Valencia,CA), 
following the protocol supplied by the manufacturer. Approximately 5x10^ cultured 
cells were pelleted by centrifugation at 1500g for 5 min, washed twice with 0.5 ml of 
phosphate buffer saline (PBS, pH7.4) and resuspended in 0.5 ml of cold PBS (4°C). 
Cells were lysed by adding 0.5 ml of ice cold buffer Cl (1.28 M sucrose, 40 mM Tris- 
Cl, pH 7.5, 20 mM MgCb, 4% Triton X-100) and 1.5 ml of ice-cold dHzO, mixing 
and incubating on ice for 10 min. The lysate was then centrifuged at 1300g at 4°C for 
15 min and the nuclear pellet washed by adding 0.25 ml of ice-cold buffer Cl and
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0.75 ml of ice-cold dHiO, vortexing to resuspend and centrifuged at 1300g at 4°C for 
15 min. The nuclei were lysed by adding 1 ml of buffer G2 (800 mM guanidine HCl, 
30 mM Tris-Cl, pH 8.0, 30 mM EDTA, pH 8.0, 5% Tween-20, 0.5% Triton X-100), 
containing 25 pi of QIAGEN Protease and incubating at 50°C for 60 min. Samples 
were vortexed thoroughly and applied on a previously equilibrated QIAGEN 
Genomic-tip 20/G column and allowed to enter the resine by gravity flow. Under 
these conditions the DNA selectively binds to the column, while degraded RNA, 
cellular proteins and metabolites are not retained. The DNA is then washed with 3 x 
1 ml of the medium-salt buffer QC (1 M NaCl, 50 mM MOPS, pH 7.0, 15% 
isopropanol) to remove any remaining contaminants and eluted with 2 x 1 ml of 
buffer QF (1.25 M NaCl, 50 mM Tris-Cl, pH 8.5, 15% isopropanol). The eluted 
DNA is precipitated by mixing with 1.4 ml room-temperature isopropanol to the 
eluted DNA and centrifuged immediately at 6000g for 30 min at 4°C. The DNA 
pellet was washed with 1 ml of cold 70% ethanol, centrifuged at 6000g for 10 min 
at4°C, air-dried for 10 min and dissolved in TE buffer (10 mM Tris-Cl, pH 8.0, 1 mM 
EDTA, pH 8.0).
2.1.14 Analysis of genomic DNA by Southern blot
2.1.14.1 Preparation and electrophoresis o f DNA samples
DNA samples were quantified as described previously and 5 pg were digested with 
the restriction enzyme Xhol. 10 units of enzyme were initially added in a 40 pi 
reaction containing 10% Xhol buffer and incubated at 37°C for 2 hrs. 10 more units 
of enzyme were added to this mixture every 2-3 hrs for 5 hrs and the reaction was 
incubated at 37°C overnight. The digested samples were run on a 1% (w/v) agarose 
gel containing ethidium bromide at 80-90 V for approximately 2 hrs as previously 
described. The DNA on the gel was fragmented by incubating the gel in 500 ml of
0.25 N HCl at room temperature with gentle agitation until bromophenol blue indictor 
turned yellow. The gel was then incubated in denaturing buffer (3 M NaCl, 0.4 M 
NaOH) for 30 min at room temperature with gentle agitation and then washed in 
transfer buffer (3 M NaCl, 8 mM NaOH) until bromophenol blue indicator turned 
from yellow to blue.
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2.1.14.2 Capillary transfer of DNA from agarose gels
Transfer on the DNA to a nylon transfer membrane (Nytran supercharge, Schleicher 
and Schuell, Keene, NH) was performed overnight by downwards transfer using the 
TurboBlotter apparatus and Turboblotter blotter pack (Schleicher and Schuell, Keene, 
NH) according to the manufacturer’s instructions. Following transfer the membrane 
was neutralised in 0.2 M sodium phosphate, pH 6.8 for 3 min and the nucleic acid 
immobilised on the membrane by UV cross-linking using UVC UV Crosslinker 
(Hoefer Pharmacia Biotech Inc, San Francisco, CA).
2.1.14.3 Generation of radio-isotope labelled DNA probe
The DNA probe was produced using (a-^^P)dCTF and the Prime-It II Primer 
Labelling kit (Stratagene, La Jolla, CA) according to manufacturer’s instructions. 
The appropriate template DNA fragment was obtained from a suitable plasmid by 
restriction enzyme digest or by PCR, run on a gel and then gel extracted as previously 
described. This process yielded at least 250 ng of DNA fragment. 25 ng of DNA 
template was mixed with dHzO to a volume of 23 pi in a microcentrifuge tube. 10 pi 
of random oligonucleotide primers was added and the mixture incubated at 100°C for 
5 min. The tube was then centrifuged briefly and kept at room temperature. 10 pi of 
5x dCTP primer buffer was added along with 5 pi (a-^^P)dCTP and Ipl Exo (-) 
Klenow enzyme. This was then incubated at 37°C for 30 min before 2 pi stop mix 
was added. The probe was purified by loading on to a NucTrap probe purification 
colunm (Stratagene, La Jolla, CA) and centrifuged for 10 min at 4,000 ipm. The 
recovered probe activity was confirmed by aliquoting Ipl into a scintillation vial 
containing 9 ml of Opti-fiuor (Packard Instrument company, Meriden, CT) and read 
on a p counter LS-6000 SC (Beckman Coulter, Fullerton, CA).
2.1.14.4 Hybridisation of KNA immobilised on membrane
The membrane was placed in a hybridisation glass cylinder, 20 ml of pre-waimed 
(65°C) hybridisation buffer added (Rapid-hyb, Amersham Pharmacia Biotech, 
Pistcataway, NJ) and incubated in a hybridisation oven (Hybaid, Robbins Scientifie, 
Sunnyvale, CA) at 65°C for 2 hrs with steady rotation. The DNA probe was heat-
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denatured by boiling for 5 min and immediately placing in ice and added in pre­
warmed hybridisation buffer to a final concentration of 1-5 x 10  ^ cpm/ml. The 
hybridisation buffer in the hybridisation cylinder was replaced with the probe- 
containing buffer and hybridisation was allowed to proceed for 2 hrs at 65°C.
2,1.14.5 Washes and stripping ofprobe from membrane
The blot was washed in 100 ml of 2x SSC (20x SSC stock solution: 3 M NaCl, 0.3 M 
Na citrate, adjust pH to 7.0, bring to 1 L with dHiO) at room temperature for 20 min, 
followed by two 20 min washes in 0.2x SSC, 0.1% (w/v) SDS at 65°C with rotation. 
The membrane was then placed in a plastic protector and placed against Kodak film, 
stored at —70®C and exposed for 1 -24 hrs prior to developing.
Stripping of the membrane was performed using stripping buffer (1% (w/v) SDS, O.lx 
SSC, 40 mM Tris-Cl pH 7.5 made up to 1000ml with dHzO) heated to ~95 °C and 
poured over the membrane followed by gentle shaking for 10 minutes. This was 
repeated 3 more times. If additional stripping was required this was performed using 
the previously mentioned stripping buffer at 50%, with 50% formamide, heated to 
65°C and poured over the membrane followed by gentle shaking for 10 minutes. 
Again this was then repeated 3 further times. The membrane was then able to be 
stored at room temperature or re-probed with a different DNA probe.
2.1.15 Total RNA preparation from cultured eukaryotic cells
RNA was obtained fi’om adherent cell lines by employing an RNeasy Mini kit 
(Qiagen, Valencia,CA) which uses the selective binding properties of a silica-gel- 
based membrane. 1-5x10^ cells were trypsinised and pelleted and then lysed in 350 
pi buffer RLT solution (containing guanidinium isothiocyanate). The lysate was then 
homogenized by passing it through a 20-G needle fitted to a syringe. One volume of 
70% ethanol was then added and mixed well. The mixture was then added onto a 
RNeasy mini spin column and centrifuged for 15 seconds at >8000g. The RNeasy 
column was then washed with 700 pi buffer RWl and centrifuged as before. Next, 
500 pi of buffer RPE was added to the colunm and centrifuged twice. After
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centrifugation the RNA was eluted by addition of 30pl Rnase-free dH]0 directly onto 
the RNeasy membrane and centrifuged as before.
2.1.16 Total RNA preparation from frozen animal tissue
RNA was prepared from snap-frozen animal tissue using the RNeasy Mini kit 
(Qiagen, Valencia,CA). Frozen tumour tissue was minced using sterile scalpel blades 
and placed in 350 pi of lysis buffer RLT. From this point onwards the protocol was 
the same as described above.
Total RNA prepared for analysis with reverse-transcriptase-PCR or Northern Blot 
was treated with DNase I to remove chromosomal DNA contamination for the RNA. 
This was carried out by incubating 5 pg of RNA with 10 units of DNAse (RNAse 
free) (Boerhinger Mannheim Roche, Indianapolis, IN) at 37°C for one hour.
2.1.17 Quantitative analysis of mRNA by Northerm blot
The Northern blot protocol followed for analysis of RNA was similar to the Southern 
blot protocol previously described for DNA analysis.
2.L17.1 Preparation and elecrophoresis of RNA samples
10 pg of DNase-treated RNA samples were made up to 20 pi with diethyl 
pyrocarbonate (DEPC) treated dHzO and 2.5 pi of 5x RNA loading buffer was added 
(16 pi saturated bromophenol blue solution, 80 pi 0.5 M EDTA, pH 8.0, 720 pi 37% 
(=12.3 M) formaldehyde, 2 ml 100% glycerol, 3.084 ml formamide, 4 ml 1 Ox 3-(N- 
morpholino)propanesulfonic acid (MOPS) buffer (200 mM MOPS, 50 mM sodium 
acetate, lOmM EDTA, pH 7.0), 100 pi DEPC water). The samples were heated to 
65°C for 4 m in  and kept on ice until loading on a 1.2% (w/v) agarose gel (3.6 gr 
agarose, 30 ml lOx MOPS buffer, made up to 300 ml with DEPC dHiO, heated in 
microwave oven until agarose fully dissolved, cooled to ~65°C, 2.7 ml formaldehyde 
and 5 pi ethidium bromide added and poured to solidify). The gel was run at 80 V for 
30 m in  in Ix running buffer (100 ml lOx MOPS, 20 ml 37% formaldehyde, 880 ml 
DEPC water) to equilibrate and was loaded with the RNA samples and run at 80 V for
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2-3 hrs. The gel was then imaged under UV light, washed four times with DEPC 
water and maintained in 20x SSC (3 M NaCl, 0.3 M Na citrate, pH 7.0, made up to 1 
L with DEPC water).
2.1.17.2 Capillary transfer o f RNA from agarose gels
Transfer on the RNA to a nylon transfer membrane (Nytran supercharge, Schleicher 
and Schuell, Keene, NH) was performed overnight by the downwards transfer method 
previously described using 20xSSC as the transfer buffer. Following transfer the 
membrane was neutralised in 2x SSC for 3 min and the nucleic acid immobilised on 
the membrane by UV cross-linking using UVC UV Crosslinker (Hoefer Pharmacia 
Biotech Inc, San Francisco, CA).
2.1.17.3 Generation of radio-isotope labelled DNA probe
Same as section 2.7.74.3.
2.1.17.4 Hybridisation of RNA immobilised on membrane 
Same as section 2.1.14.4.
2.1.17.5 Washes and striping ofprobe from membrane
Same as section 2.7.14.5.
2.1.18 Complemeotaiy DNA preparation for analysis with PCR
The RNA concentration was estimated by absorbance at 260 nm as previously 
described. cDNA was generated from an RNA template using a First Strand cDNA 
Synthesis Kit supplied by Boerhinger Mannheim Roche (Indianapolis, IN). For each 
RNA sample two aqueous solutions containing Ipg of total RNA were made up to 
lOpl with sterile dH20. To one sample lOpl of the ‘Reaction Mixture’ containing 
RNAase inhibitor, magnesium chloride, dNTPs, aqueous buffer and 2pl 01igo-p(dT)is 
primer was added; this was the rt negative control. To the other sample was added the 
same reaction mixture plus Ipl AMV reverse transcriptase; this was the rt positive
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sample. All samples were then incubated at 25°C for 10 minutes and then at 42°C for 
60 minutes. For analysis with polymerase chain reaction (rtPCR) 2pi of the reaction 
mixture was used in each PCR sample. Both rt positive and rt negative samples were 
first analysed for glyceraldehyde phosphate dehydrogenase (GAPDH) to confirm a 
lack of DNA contamination of the mRNA and identify equal quantities of input RNA 
to the rtPCR procedure.
2.1.19 Amplification of DNA sequences by the polymerase chain reaction
Polymerase chain reaction (PCR) was performed by cycling samples containing 
template DNA mixed with sequence-specific oligonucleotide primers through three 
temperature incubations in the presence of Thermus aquaticus {Taq) DNA 
polymerase; AmpliTaq (Perkin Elmer, CA, USA) was used. These cycles were:
1. Dénaturation of double stranded DNA.
2. Annealing of primers to DNA.
3. Extension of target sequences by Taq DNA polymerase.
The PCR was carried out in a Biometra TRIO-thermoblock (Biometra, Gottingen, 
FRG). The optimal cycle number and exact annealing and extension conditions were 
as described in Table 2.1. Primers were synthesised by the Molecular biology Core 
Facility, Mayo Foundation, on an Applied Biosystems 380B Synthesiser and are 
listed in Table 2.2. The reaction mixtures were prepared in a laminar flow hood 
isolated firom normal areas of DNA handling. Each reaction sample consisted of: 
template DNA (1 pg of genomic DNA or 0.1-0.5 pg of plasmid DNA; for semi- 
quantitative rtPCR the cDNA equivalent of 0.1 pg RNA was used), 8 pi dNTPs 
(40mM), 5 pi of 1 Ox PCR buffer, 0.2 pg 5’ primer, 0.2 pg 3’ primer, 0.5 pi Taq DNA 
polymerase (5 units/pl) and dHzO added to a total volume of 50 pi. The reaction was 
then heated to 94®C for 10 min and then allowed to proceed through 20 to 30 cycles 
of dénaturation, annealing and extension to produce the required degree of 
amplification. If the PCR product was required for cloning experiments a final 10 
min extension cycle at IT^C was added. The amplified PCR products were evaluated 
by mixing 12 pi of the reaction mixture with 2 pi of 6x loading buffer stock solution 
and run on an agarose gel.
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2.1.20 Ligation of PCR products
A TA cloning kit (Invitrogen, Carlsbad, CA) was used to ligate PCR products into 
pCR3.1 vector. This system takes advantage of the nontemplate-dependent activity of 
Taq polymerase which adds a single deoxyadenosine to the 3’ termini of the double 
stranded DNA molecules. The pCR3.1 vector is provided in a linearised form 
possessing single overhanging deoxythymidine residues at the 3’ termini, thus 
allowing the PCR product to ligate efficiently with the vector. The ligations were 
performed according to the manufacturer’s instructions; 1 pi of PCR reaction mixture 
was mixed with 1 pi of lOx ligation buffer, 1 pi T4 DNA ligase, 2 pi of linearised 
vector (60 ng pCR3.1) and 5 pi distilled water and incubated overnight at 14°C. The 
ligation mixture was then transformed into competent E.coli (TOPIGF’ strain for 
pCR3.1 ) and plated onto L-agar containing ampicillin.
2.2 Cell Biology
2.2.1 Eukaryotic cell culture -  general procedures
All manipulations involving cell culture were carried out in a sterile environment 
provided by a laminar flow hood. All tissue culture reagents were filter sterilised by 
passage through a 0.22 pm filter and stored in sterile autoclaved containers.
The cell lines used in this work are listed in Table 2.2. Adherent cell lines were 
grown as monolayers in plastic tissue culture flasks or dishes (Nunc, Nalge Nunc, 
Naperville, IL) in DMEM or RPMI supplemented with 10% v/v heat-inactivated fetal 
calf serum ( Gibco BRL, Life Technologies, Grand Island, NY) and incubated at 37°C 
in 5 or 10% CO2. For culture of cells used in the Tet-On system studies Tet system 
approved fetal bovine serum (Clontech Laboratories Inc, Palo Alto, CA) was used. 
Cells were grown until just subconfluent (approximately 2 to 4 days) and were 
subcultured 1:10, using trypsin (0.05% w/v)/5 mM EDTA to detach the cells. Cell 
counts were performed using an Improved Neubauer haemocytometer and an inverted 
microscope (Olympus 1X70).
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2.2.2 Storage and recovery of cells stored in liquid nitrogen
Cells were trypsinised, pelleted and resuspended at approximately 10^  cells/ml in 
filter-sterilised medium containing 10% v/v dimethylsulphoxide (DMSO). 1ml 
aliquots were transferred to 1.5ml Nunc cryotubes which were then placed within a 
1°C Freezing Container (Nalgene) and stored in a -70°C freezer. Using this 
apparatus, the cells cooled at approximately 1®C per min. Frozen cells were then 
transferred to liquid nitrogen tanks (-196°C) the following day.
Recovery of cells from liquid nitrogen storage was performed by rapid thawing in a 
37®C water bath. Thawed cells were washed in 5 ml of medium, harvested by 
centrifugation (1 lOg for 5 min) and were then transferred to 25 cm  ^flasks containing 
fresh culture medium.
2.2.3 Gene transfer into eukaryotic cells
2,23,1 Growth selection systems
i) Geneticin (G418 sulphate) (Gibco, Life Technologies, Scotland).
Geneticin is an aminoglycoside antibiotic related to Gentamicin and is toxic to both 
prokaryotic and eukaryotic cells. Introduction of the neomycin phosphotransferase 
gene into eukaryotic cells can confer resistance to Geneticin added to normal medium. 
Geneticin was added to DMEM to concentrations previously determined to be optimal 
for selective growth of each cell line.
ii) Puromycin (Gibco, Life Technologies, Scotland)
Puromycin inhibits protein synthesis in eukaryotic cells by acting as an analogue of 
aminoacyl-tRNA thus causing premature chain termination. The puromycin-N- 
acetyl-transferase gene from Streptomyces alboniger may be expressed in mammalian 
cells and used as a selectable marker for puromycin resistance.
iii) Hygromycin B (GibcoBRL Life Technologies, Scotland)
Hygromycin B is an aminoglycoside antibiotic produced by Streptomyces 
hygroscopicus and is toxic to both prokaryotic and eukaryotic cells by inhibiting 
protein synthesis. Cloning and expression of the hygromycin resistance gene
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encoding for a kinase that inactivates Hygromycin B through phosphorylation allows 
selection for resistance to Hygromycin B in both prokaryotic and eukaryotic cells.
2,23.2 Effectene transfection
Transfer of plasmid vectors into eukaryotic cells was performed using the Effectene 
Transfection kit by Qiagen (Valencia, CA) according to the manufacturer’s 
instructions. This method is based on condensing DNA with a non-liposomal lipid. 
The day before transfection 2-8 x 10^  cells were seeded per 25 cm  ^ flask in 5 ml of 
fresh medium such that the following day cells were 60-80% confluent. On the day 
of transfection 1 pg of DNA was made up to 150 pi with the DNA-condensation 
buffer, Bufer EC. 8 pi of Enhancer were added, the reaction was mixed by vortexing 
for 1 sec and incubated at room temperature for 5 min. 25 pi of the Effectene 
Transfection Reagent were then added to the mixture, the mixture vortexed for 10 sec 
and incubated at room temperature for 5-10 min. 800 pi of cell culture media was 
then added to the reaction and added in the flask containing 4 ml of fresh medium.
Cells were incubated at 37°C, 10% CO2 for 48 hrs and were then split in 6 cm plates 
in selection medium containing the appropriate growth selection antibiotic. 10-14 
days later individual single cell clones were lifted off the plates using trypsin-soaked 
sterile filter paper microsquares, transferred to individual wells of a 24-well plate, and 
expanded into larger cell culture flasks.
2.2.4 Murine dendritic cell culture
DCs were cultured from bone marrow of C57BL mice according to a protocol 
modified from that of Inaba et al. (Inaba, Inaba et al. 1992). Briefly, femurs and tibias 
were extracted from mice freshly-killed by CO2 inhal^on, stripped of muscle and the 
ends excised. Bone marrow was flushed from the bones, pipetted until single cell 
suspensions were obtained, filtered through a cell strainer to remove muscle or bone 
fragments and centrifuged at 1500 rpm for 10 min. Red blood cells were removed by 
resuspending the pellet in 9 ml of cold (IH2O and adding 1 ml of 1 Ox PBS. 1 volume
i.e. 10 ml of RPMI medium was added and the mixture filtered and centrifuged as 
before. The cells were resuspended in 1 ml of medium containing a mixture of
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monoclonal antibodies for the depletion of a range of cells types (see Table 23) and 
incubated for 20 min on ice. Cells were washed twice in media, resuspended at a 
final concentration of Ix 10^  cells/ml in diluted baby rabbit serum (Cedarlane, 
Ontario, Canada) and incubated at 37°C for 45 min. Cells were washed twice in 
media and resuspended at a final concentration of Ix 10^  cells/ml in culture medium 
(90% (v/v) RPMI, 10% (v/v) PCS, 10 ng/ml recombinant murine GM-CSF (R&D)) 
and plated in 75 cm  ^flasks. Cells were cultured for a total of 7 days with 2/3 of the 
media being replaced on day 3 of the culture. At the end of the culture, non-adherent 
and loosely adherent cells were harvested, counted and resuspended in appropriate 
medium for subsequent use.
2.2.5 Murine peritoneal macrophage culture
C57BL/6 mice were euthanised, the abdominal skin was retracted to expose the 
peritoneal wall and 8 ml of DMEM containing 10% FCS were injected into the 
peritoneal cavity. Approximately 6 ml of fluid were withdrawn, containing resident 
peritoneal marophages. The cells were washed and resuspended in medium 
containing penicillin and streptomycin for further analysis.
2.2.6 Cell staining for p-gal expression
Adherent cells transduced with p-gal were washed twice in PBS and fixed in 1ml 
fresh formaldehyde solution (4% in PBS) for 10 min at 4°C. After 2 further washes 
in PBS cells were overlaid with 1ml filter-sterilised (0.45pm) X-gal stain (100 mM 
sodium phosphate pH 7.3, 1.3 mM MgCli, 3 mM K3Fe(CN)6, 3 mM K4pe(CN)6, 1 
mg/ml X-gal). After incubation overnight at 37°C cells were examined for blue 
staining by light microscopy.
2.2.7 Immunohistochemistry
Injection sites were surgically excised, fixed in 10% neutral buffered formalin for a 
minimum of 24 hrs and the Mayo Histology Core facilities performed paraffin 
embedding, sectioning (5 pm thick sections) and staining with hematoxylin and eosin 
(H&E).
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2.2.8 Analysis of immune cell infiltrates at vaccination site using gelfoam 
gelatin sponges.
Gelfoam absorbable gelatin sponges (Pharmacia, Upjohn, Kalamazoo, MI) (size 100, 
precut to 1.5 X 1.5 X 0.5 cm) were hydrated in HEPES buffer and surgically implanted 
under sterile conditions in the subcutaneous space at the back of C57BL/6 mice (two 
sponges per mouse). The animals were allowed to recover from the procedure for 
three days and 5 x 10\ lOOGy irradiated, tumour cells were directly injected into each 
sponge. 48 hrs later the sponges were surgically removed, chopped into small pieces 
using sterile scalpels and incubated in a collagenase-containing buffer (170 pg/ml 
collagenase, 20 mg/ml bovine serum albumin (BSA), 1% v/v pennicillin/streptomicin 
in Saline G) at 37°C for 3 hrs in a rotating incubator (225 rpm). (Saline G: 0.11% 
glucose, 0.13 M NaCl, 5.3 mM KCl, 1 mM Na2HP0 4  7 H2O, 1.1 mM KH2PO4, 0.62 
mM MgS0 4 , 0.1 mM CaCh 2 H2O). The dissolved sponges were filtered through a 
100 |im cell strainer to remove remaining pieces of sponge and tissue and the cells in 
suspension were centrifuged at 1500 rpm for 5 min. Red blood cells were removed 
by incubating the cells in 5 ml of red blood cell lysis buffer (156 mM NH4CI, 9.5 mM 
Na2C0]) for 2 min and adding 10 ml of Ix PBS Cells were counted centrifuged as 
before and resuspended in FACS wash buffer (see flow cytometry section) for further 
analysis.
23  Assays
23.1 Flow Cytometry
Adherent cells were trypsinised and washed once in culture medium. Cells were then 
washed twice in ice-cold wash buffer (PBS with 0.1% w/v BSA and 0.1% sodium 
azide) and separated into 1 x 10* cells/sample. The cells were then suspended in 
lOOpl wash buffer containing the appropriate conjugated mouse monoclonal antibody 
(dilution 1:50) and incubated at 4°C for 60 minutes (for list of antibodies used see 
Table 2.4). As a negative control, mouse IgG was used. After washing and spinning 
down the cells three times with wash buffer, the cell pellet was resuspended in 500pl
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of fresh formaldehyde solution (4% in PBS) and stored overnight at 4°C. The cells 
were then analysed using a Becton Dickinson FAC Scan and Cellquest software 
(Becton Dickinson Immunocytometry systems, San Jose, CA).
2.3.2 Murine GM-CSF Enzyme-Linked Immunosorbent Assay (ELISA) 
GM-CSF ELISA was performed using OptEIA™ GM-CSF kit from PharMingen 
(San Diego, CA) according to the manufacturer’s instructions. Briefly, microwell 
plates (Rainin) were coated with 100 pi of capture antibody/well (antibody provided 
in the kit) diluted to 2 mg/ml in coating buffer (0.1 M Carbonate, pH 9.5) and 
incubated overnight at 4°C. Plate was washed three times with 300 pl/well wash 
buffer (PBS with 0.05% Tween-20) and blocked with 200 pl/well assay diluent (PBS 
with 10% FBS, pH 7.0) by incubating at room temperature for 60 min. The washing 
procedure was repeated as described above and 1 0 0  pl/well of test sample and 
standards were added in triplicate and incubated for 2  hrs at room temperature. 
Standards were made up from a stock of 118 ng/ml recombinant mouse GM-CSF: 20 
pi of stock was added to 2.36 ml of assay diluent giving an upper standard value of 1 
ng/ml. Serial dilutions of 1:2 were then performed down to 15.625 pg/ml. The plate 
was washed again as described above with a total of 5 washes and 1Û0 pi of working 
detector (1:1 mixture of detection antibody (diluted 1:250 in assay diluent) and 
avidin-horseradish peroxidase conjugate (diluted 1:250 in assay diluent)) was added 
and incubated for 60 min at room temperature. The plate was washed again as 
described above with a total of 7 washes and 100 pi of substrate solution 
(tetramethylbenzidine and hydrogen peroxide, provided in the kit) were added and 
incubated for 30 min at room temperature in the dark. 50 pi of stop solution (2 N 
H2SO4) were added to each well and the absorbance at 450 nm was read within 30 
min of stopping the reaction.
2.33 BL-12 (p70) ELISA
IL-12 (p70) ELISA was performed using OptEIA^ IL-12 (p70) kit from PharMingen 
(San Diego, CA) according to the manufacturer’s instructions. The procedure used 
was same as the one used for the murine GM-CSF ELISA described above. Capture
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antibody used was an anti-mouse IL-12 antibody diluted 1:250 in coating buffer. The 
detection antibody used was a biotinylated anti-mouse IL-12 antibody diluted 1:250 in 
assay diluent. Standards were made up from a stock of 77 ng/ml recombinant mouse 
IL-12: 20 pi of stock was added to 0.75 ml of assay diluent giving an upper standard 
value of 2 ng/ml. Serial dilutions of 1:2 were then performed down to 31.3 pg/ml.
2.3.4 IFN-y ELISA
IFN-y ELISA was performed using OptEIA™ IFN-y kit from PharMingen (San 
Diego, CA) according to the manufacturer’s instructions. The procedure used was 
same as the one used for the GM-CSF ELISA. Capture antibody used was an anti­
mouse IFN-y antibody diluted 1:250 in coating buffer. The detection antibody used 
was a biotinylated anti-mouse IFN-y antibody diluted 1:250 in assay diluent. 
Standards were made up from a stock of 77 ng/ml recombinant mouse IFN-y: 20 pi of 
stock was added to 0.75 ml of assay diluent giving an upper standard value of 2 
ng/ml. Serial dilutions of 1:2 were then performed down to 31.3 pg/ml.
23.5 Luciferase Assay
Detection of luciferase activity was performed using Promega’s Luciferase Assay 
System (Promega, Madison, WI) according to manufacturer’s instructions. All 
solutions were equilibrated to room temperature prior to use. Growth medium was 
removed from cells and cells were gently washed twice with Ix PBS. 100 pi of Ix 
cell culture lysis reagent (25 mM Tris-phosphate, pH 7.8, 2 mM DTT, 2 mM 1,2- 
diaminocyclohexane-N,N,N’,N’-tetraacetic acid, 10% glycerol, 1% Triton X-100) 
was added per well of a 6 well plate, the cells were scraped free from the culture dish 
and transferred with the solution to a microfuge tube. Following a brief (5 sec) 
centrifugation at 12,000 g, 20 pi of the cell-free supernatant were mixed with 100 pi 
of Luciferase Assay Reagent and the reaction was immediately read in a luminometer 
(Turner Designs TD-20/20, Sunnyvale, CA) by measuring the light produced for 10 
seconds.
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2.3.6 Western Blot
23,6,1 Preparation of samples
Adherent cells were harvested by trypsinisation and washed twice with Ix PBS. The 
cells were lysed by adding 200 pi of lysis buffer (425 mM NaCl, 50 mM Tris-HCl pH 
8.0, 10 ml Nonidet P-40, 0.4% DOC, 0.1% SDS, 714 pi p-mercaptoethanol, in 1 L of 
dHiO, 10 pl/ml protease inhibitors) and incubating on ice for 10 min. The cells were 
then sonicated for 15 sec, centrifuged at 14,000 rpm at 4°C for 30 min and the 
supernatant transferred to a clean microfuge tube. Protein concentration was then 
determined. Protein was then mixed with an equal volume of Laemmli 2x Sample 
buffer (0.65 M Tris/HCl pH 6.8, 2.1% SDS, 0.38% glycerol, 0.01 % bromophenol 
blue, 20% P-mercaptoethanol), heated at 95°C for 5 minutes and cooled on ice for 2 
minutes.
2,3,6,2 Determination of protein concentration
Protein concentration was determined using a colorimetric assay, DC protein assay 
(Bio-Rad, Hercules,CA). This assay was conducted as per the manufacturer’s 
instructions in a microplate and is based on the reaction of protein with an alkaline 
copper tartrate solution followed by the reduction of a Folin reagent; producing a blue 
colour, measurable at an absorbance of 750 nm using the SPECTRAmax 190 
(Molecular Devices) spectrophotometer. Briefly a protein standard was prepared 
using 1:2 dilutions of BSA; range 1.4 mg/ml-0.088 mg/ml. ‘Working reagent A’ was 
produced by adding 20 pi of reagent S (SDS) to 1ml of reagent A (1-5% sodium 
hydroxide, <1% sodium tartrate, <0.1% copper sulfate). Next 5 pi of standards and 
samples were pipetted into wells of a microtitre plate and 25 pi of working reagent A 
added. This was followed by the addition of 200 pi of reagent B (Folin reagent), the 
plate agitated and incubated for 15 minutes at RT. The absorbance was then read at 
750 nm and sample values obtained from the standard curve. All samples were 
adjusted to 1 mg/ml with lysis buffer.
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2.3,63 Electrophoresis o f samples
10 pg of protein was loaded onto a Tris-HCl precast gel (Bio-rad) and the gel was run 
in Ix running buffer (1.5 M Tris base, 1.4% w/v glycine, 0.4% w/v SDS, pH 8.0) for
1 hr at 150 V.
2.3.6.4 Transfer of protein onto nitrocellulose membrane
The gel was placed on top of three sheets of Whatmann 3mm paper pre-soaked in Ix 
transfer buffer (3 M Tris Base, 0.3% w/v glycine, 0.0375% w/v SDS) on the positive 
electrode of a semi-dry blotting aparatus (Trans-blot SD, Bio-Rad). A sheet of 
Hybond-C + nitrocellulose membrane (Amersham pharmacia biotech, 
Buckinghamshire, UK), pre-soaked in dHiO followed by Ix transfer buffer, was 
placed in direct contact with the gel, followed by 3 more sheets of 3MM paper pre- 
soaked in Ix transfer buffer and the negative electrode plate. Transfer was allowed to 
take place for 30-40 min at a constant current of 20 V.
2.3.6.5 Blocking, antibody and chemiluminescence
The membrane blot was blocked in 40 ml of 10% w/v milk in Ix TBS-Tween (lOx 
TBS: O.IM Tris-HCl pH 7.4, 1.5 M NaCl) (diluted TBS to Ix with dHzO and added 
0.05% v/v Tween-20/500 ml) by incubating at room temperature for 2 hrs with gentle 
shaking. The blot was then washed twice with Ix TBS-Tween, diluted primary 
antibody added to it and incubated with gentle shaking for 3 hrs at room temperature 
or overnight at 4°C. Primary antibody was prepared in Ix TBS-T, 1% BSA, 0.1% Na 
Azide, For antibodies used see Table 2,5. The blot was washed with three times with 
Ix TBS-Tween by gentle shaking at room temperature, diluted secondary antibody 
added to it and incubated with gentle shaking for 2 hrs at room temperature or 
overnight at 4°C. Secondary antibody was prepared in Ix TBS-Tween. Following 
extensive washing with Ix TBS-Tween, bands were revealed using the enhanced 
chemiluminescence (ECL) system (SuperSignal West Pico Chemiluminescent 
substrate. Pierce, Rockford, IL). This system requires the mixing of equal volumes of 
a stable peroxide solution and luminol/enhancer solution prior to covering the blot 
and incubating for 5 minutes. The blot was then removed, placed in a plastic
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protector and placed against Kodak film for an exposure of 30 seconds to 5 minutes 
prior to developing.
2.3.7 Syncytia Formation Induced by FMG Expression
2-5x 10^  cells were plated per well of a 6 well plate. The following day, the cells 
were transfected with 1 pg of plasmid expressing the VSV-G or GALV genes using 
the Effectine transfection protocol described previously. In the case of VSV-G, 24 
hrs later the cells were incubated in 2 ml medium of pH 5.5-5.7 for 2 min, washed 
three times in PBS and returned to normal culture medium. 24-48 hrs following the 
pH drop in the case of VSV-G or transfection in the case of GALV extensive syncytia 
formation was observed by light microscopy.
Percent of syncytia formation was determined by dividing the number of cells 
involved in syncytia by the total number cells per visual field. For each sample, at 
least 6 different visual fields were examined and the average % of fusion was 
determined. A + and - grading system was created to indicate the extent of fusion:
0 % fusion 
+ < 20% fusion
++ ^ 40% fusion
+-H- < 60% fusion
-H-K- ^ 80% fusion
I I I I I ^ 100% fusion
2.4 Animal Studies
All animal studies presented in this thesis were approved by the Institutional Animal 
Care and Use Committee at the Mayo Foundation.
2.4.1 Mice
6-8 week old female C57BL/6 mice (Jackson Laboratory, Bar Harbor, Maine) and 4-5 
week old NCr (nu/nu) nude female mice (Taconic, Germantown, NY) were used in
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this thesis and were housed in the biological resources units at Mayo Foundation 
(Rochester, MN). Mice were matched for age and sex for individual experiments. 
Standard food and water vvere provided ad libitum. Between 8 and 10 mice were used 
per group in each experiment. For challenge with live tumour cells, all groups of 
mice in any one individual experiment were rechallenged on the same occasion using 
the same preparation of cells. A naive group of mice was also injected with these 
cells at the same time.
2.4.2 Vaccination of mice using irradiated tumour cells
On day 1 tumour cells were prepared, y-irradiated to lOOGy and resuspended in ice-
cold PBS at the desired concentration. Mice were injected subcutaneously at the 
flank with 100 pi of the irradiated cell suspension. This vaccine was repeated on day 
8 and 15, and on day 22 mice were challenged on the opposite flank with live parental 
cells as described in Results for individual experiments. The diameter of tumours, in 
2 dimensions, was measured tvrice weekly using callipers and mice were killed if 
tumour size progressed to 1.0 x 1.0cm.
2.4.3 Therapy of animals carrying 3 day pre-established tumours
On day 1 tumour cells were prepared in ice-cold PBS and 100 pi of the cell 
suspension was injected subcutaneously at the flank of mice. Three days later mice 
were vaccinated subcutaneously with 100 pi of irradiated cells, prepared as previously 
described. The vaccination was repeated on days 5 and 6 for a total of 3 vaccines. 
Tumour growth was monitored as above and mice were killed if tumour size 
progressed to 1.0 x 1.0cm.
2.4.4 Statistical analysis
Data from animal experiments were analysed by plotting Kaplan-Meier curves using 
the ‘occurring event’ as the time at which tumour size was equal to or exceeded 1cm 
in diameter. A tumour was considered present when a palpable mass >0.2cm was 
noted. Different groups of mice were compared using the logrank test (Altman 1991).
105
Table 2.1: List of primers and conditions used for PÇR amplification of DNÀ 
sequences
Amplified Forward Primer ’ Annealing
Sequence R em sePrim er Temperature Cycles
Tyr CAATGGGTCAACACCCATGTTTA
GATCCCTGTACrrGGGACATTGTTC
54 30
TRP-1 GTGAGAAGGGAtTAGTGAGAGCTGG
GAGAAGACAGGGGTGCTCAGATG
58 . 30
TRP-2 CCATTGATTrCTCTCACCAAGGG
TCTCTrGCTGCTGAGACCrGTCTC
55 30
gplOO ACATTTCATCACCAGGGTGCC
CAGGAACAAGTTGGGTGCr
54 30
Mage A1 CTATCCÀGCCTACTGTTACC
CACTCAGTACÂGCTATGAGG
51 30
Mage A2 GAGTGCTCAGGCCCAAGAGG
GGGTACAGCAATGGAATCAGTGAC
57 30
Mage A4. CTATACTGTCCATTGTTACAGGAA 51 30
CGTGAAAATAGCACCAAGAACAA
Mage A7 CTCTTCTCCCTGTGTGATGA
CTCTCAGTGAGGATACrnTCTG
51 30
IFN-y TCTGAGACAATGGCCGCTACACACTGC 56 3Ô
GTCGACTCITATrGGGACAATGTCIT
TNF-a TTCTATGGÇCÇAGACCCTCACA
GATGAACACCCATCCCCTTCÀC
54 30
Neo AGACAATCGGCTGCTCTGAT
CGGCCAXnTCCACCATGAT
51 30
GAPDH TGAAGGTCGGTGTGÀACGGATTTGCG
CATGTAGGCCATGAGGTCCACCAC
58 30
GALV {BamlS) GGATCCGGATCCGGTGGCCCTCCTATAGTGAG
GGATCCGGATCCTAAGCCTGGTACCGTAACAA
58 35
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Table 2.2: List of cell lines used in this thesis
Cell Line Reference
K1735 murine melanoma [Kripke, 1979]
K1735-IL-12 murine melanoma R. Vile
K1735-GM-CSF murine melanoma R. Vile
K1735-IFN-Y murine melanoma R. Vile
K1735-hsp70 murine melanoma R. Vile
K1735-neo murine melanoma R. Vile
B16-F1 murine melanoma [Fidler, 1975]
A375M human melanoma [Giard, 1973]
293-On human kidney embrional Clontech
Hela human cervical carcinoma R. Vile
Hela-On human cervical carcinoma Clontech
Mel624 human melanoma R. Vile
Mel888 human melanoma R. Vile
Table 2.3: List of monoclonal antibodies used for immune cell depletion
Monoclonal Antibody Antigen source
KH74 I-Ab Pharmingen
145-2C11 CD3e Pharmingen
M3/84 Mac3 Pharmingen
53-6.7 CD8a Pharmingen
RB6-8C5 Gr-1 Pharmingen
RA3-6B2 CD45R Pharmingen
107
Table 2.4: List of monoclonal antibodies used for cell surface staining
Monoclonal Antibody Type Antigen source Coniugation
AF6-120.1 mouse I-Ab FITC Pharmingen
AF6-120.2 mouse I-Ab PE Pharmingen
11.5.2 . mouse I-Ak PE Pharmingen
KH95 mouse H-2Db FITC Pharmingen
15-5-5 mouse H-2Dk FITC Pharmingen
AF6-88.5 mouse H-2Kb FITC Pharmingen
AF6-88.6 mouse H-2Dk PE Pharmingen
36-7-5 mouse H-2Kk PE Pharmingen
145-2C11 hamster CD3 FITC Pharmingen
RM4-5 rat CD4 PerCP Pharmingen
55-5.8 rat CD8a PE Pharmingen
HL3 hamster C D llc FITC Pharmingen
HL4 hamster C D llc PE Pharmingen
M5È2 mouse CD14 PE Pharmingen
30-Fll rat CD45 PerCP Pharmingen
16-lOAl rat CD80 FITC Pharmingen
GLl rat CD86 FITC Pharmingen
3 E2 hamster ICAM-1 FITC Pharmingen
RB6-8C5 rat Ly6-G PE Pharmingen
M3/84 rat Mac3 PE Pharmingen
PK136 mouse N K l.l PE Pharmingen
H-2.65 mouse H-2Ld - Cedarlane
Table 2.5: List of antibodies used in Western Blotting
Anibody Type Antigen source
primary
SPA-810 mouse hsp-70 . StressGen
SC-8432 mouse actin Santa Cruz
Biotech.
secondary
NA931V sheep ct-mouse Ig AmerSham
Pharmasia
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Chapter 3
M o d u l a t i o n  o f  t h e  Im m u n e  R e s p o n s e  A g a in s t  B16 M e l a n o m a  by  c y to k i n e -  
OR H sp70- E x p r e s s in g  A l l o g e n e i c  K 1735 T u m o u r  C e l l  V a c c in e s
The use of whole tumor cells in cancer vaccine preparation has been extensively 
explored in recent years. The primary advantage of such vaccines is their potential to 
be a single and direct source of the entire spectrum of tumor associated antigens 
(Dranoff, Jaffee et al. 1993; Simons, Jaffee et al. 1997; Soiffer, Lynch et al. 1998; 
Schadendorf, Paschen et al. 2000; Jaffee, Hruban et al. 2001). However, the technical 
difficulties and high cost of production currently associated with the production of 
individualized cancer vaccines have hindered the widespread clinical use of 
autologous cancer vaccines. On the other hand, increasing interest has been 
developed in using well established, well characterized, easily modifiable and 
standardized cell lines in cancer vaccines (Chan and Morton 1998; Fabre 2001). Such 
generic vaccines can be optimally designed to share expression of significant amounts 
of immunologically important tumor antigens with the target tumour (Morton, Hoon 
et al. 1993; Habal, Gupta et al. 2001). The use of allogeneic vaccines is supported by 
the finding that antigens from allogeneic cells can be processed and presented by host 
APC to activate host T cells (Huang, Golumbek et al. 1994; Mitchell, Nair et al. 1998; 
Ochsenbein, Klenerman et al. 1999). Furthermore, the allogeneic nature of such 
vaccines may in itself offer an immunological advantage in the form of an adjuvant 
effect, where the allogeneic component of the cells (predominantly the allogeneic 
MHC molecules) may stimulate a non-specific immune response, which can enhance 
the immune response to the tumor antigens in the vaccine (Fabre 2001).
To investigate potential mechanisms of enhancing the efficacy of allogeneic vaccines 
in melanoma, K1735 melanoma cells were used as an allogeneic vaccine against the 
development of B16 melanoma. K1735 is an MHC class I low expressing melanoma 
derived from H-2'  ^C3H/He mice (Kripke 1979) and B16 is a MHC class I negative 
melanoma which grows in H-2** C57BL/6 mice (Fidler 1975). This model was chosen 
because we, and others, have previously shown that K1735 cells by themselves are 
only very poor immunogens against B16 tumor growth in C57BL/6 mice (Figure 3.1 
and (Kayaga, Souberbielle et al. 1999; Melcher, Todryk et al. 1999; Todryk, Birchall
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et al. 2001), allowing significant scope for improvement by manipulation of the 
cellular vaccine. The autologous B16 cells are only weakly immunogenic against 
B16 tumour growth (Figure 3.1, P= 0.0018 compared to PBS group).
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Figure 3.1: Irradiated allogeneic K1735 cells as a vaccine against the 
development of B16 melanoma.
Groups of 8 C57BL/6 mice received 3 sequential subcutanous injections of 5x10^ 
irradiated (lOOGy) K1735 cells or PBS at days 1, 8 and 15. At day 22 (day 0 on the 
graph) mice received an injection of 2x10^ live B16 cells on the opposite flank and 
tumour size was followed. Animals were sacrificed once tumour size exceeded 1cm in 
diameter. Percentage of animals surviving the tumour challenge are shown.
Genetic modification with immune stimulating cytokines as well as HSPs has been 
shown to augment vaccine efficacy in the B16 and other models (Dranoff, Jaffee et al. 
1993; Chong 1996; Rakhmilevich, Turner et al. 1996; Chong, Todryk et al. 1998; 
Nawrocki and Mackiewicz 1999). Therefore, as a first step K1735 cells were 
modified to express a selection of immunostimulatory cytokines (IL-12, GM-CSF, 
IFN-y), or hsp 70, and the effect of these proteins on the efficacy of the allogeneic 
vaccine to generate immune protection against the syngeneic B16 tumour challenge 
was studied (For extensive discussion on IL-12, GM-CSF, IFN-y and hsp70 please see 
Introduction and Discussion).
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3.1 Genetic modification of K1735 cells to express IL-12 does not enhance the 
efficacy of the allogeneic vaccine against a B16 challenge
IL-12 is a pro-inflammatory cytokine that has been shown to stimulate DC, as well as 
CD4^ and CD8^ T cells and to induce cell mediated immunity. K1735 cells 
expressing IL-12 had been previously established in the laboratory using retroviral 
mediated gene transfer (Chong 1996). The IL^12 secretion levels by the K1735-IL-12 
cells was determined by ELISA to be approximately 8.3 ng/4xl0^ cells/48hrs, 
comparable to levels described elsewhere in the literature. The K1735-IL-12 cells 
were used in prophylactic vaccination experiments where groups of 8 C57BL/6 mice 
were subcutaneously vaccinated with 5x10^ cells, irradiated with lOOGy, on days 1, 8 
and 15. 7 days following the last vaccination the mice were challenged on the 
opposite flank with 2x10^ live B16 cells, previously determined as a lethal dose 
(Figure 3.2). All of the mice vaccinated with K1735 unmodified cells succumbed to 
tumour growth, as did the mice vaccinated with the control cell line K1735-pBabeNeo 
and the naïve mice. In addition, three vaccinations of K1735-IL-12 cells were unable 
to protect any animals from the lethal challenge in this experimental model 
(difference between any of the survival curves did not reach statistical significance).
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Figure 3.2: Irradiated allogeneic K1735-IL12 cells as a vaccine against the 
development of B16 melanoma.
Groups of 8 C57BL/6 mice received 3 sequential subcutanous injections of 5x10^ 
irradiated (lOOGy) K1735, K1735-IL12, 1735-Neo or PBS at days 1, 8 and 15. At day 
22 (day 0 on the graph) mice received an injection of 2x10^ live B16 cells at the 
opposite flank and mice survival was followed.
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3.2 Genetic modification of K1735 cells to express GM-CSF does not enhance 
the efficacy of the allogeneic vaccine against a B16 challenge
A similar set of experiments was conducted to study the effect of GM-CSF on the 
immunogenicity of the K1735 vaccine. GM-CSF can attract host APC to the tumor 
site and lead to upregulation of MHC and co-stimulatory molecules on APC, and has 
been previously shown by our laboratory, and others, to efficiently stimulate 
protective antitumour immunity (Dranoff, Jaffee et al. 1993; Castleden, Chong et al. 
1997; Soiffer, Lynch et al. 1998; Kayaga, Souberbielle et al. 1999; Todryk, Birchall et 
al. 2001). A Kl 735 cell line expressing GM-CSF was previously developed in the 
laboratory (Chong, Todryk et al. 1998). The level of GM-CSF secretion by the 
K1735-GM-CSF were determined by ELISA to be approximately 1.4ng/4xl0^ 
cells/48hrs. In a prophylactic vaccination experiment identical to the one described 
above for Figure 3.2, repeated vaccination of C57BL/6 mice with irradiated K1735- 
GM-CSF had no therapeutic effect against a lethal B16 challenge (Figure 3.3). These 
results are in agreement with other studies of GM-CSF modified allogeneic vaccines 
(Todryk, Birchall et al. 2001).
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Figure 3.3: Irradiated allogeneic KI735-GM-CSG cells as a vaccine against the 
development of BI6 melanoma.
Groups of 8 C57BL/6 mice received 3 sequential subcutanous injections of 5x10^ 
irradiated (lOOGy) K1735, K1735-GM-CSF, 1735-Neo or PBS at days 1, 8 and 15. 
At day 22 (day 0 on the graph) mice received an injection of 2x10^ live B16 cells at 
the opposite flank and survival of mice was followed.
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3.3 Genetic modification of K1735 cells to express IFN-y does not enhance the 
efficacy of the allogeneic vaccine against a B16 challenge
IFN-y is a cytokine that is associated with Thl cell mediated immunity, and has been 
shown to upregulate expression of MHC and co-stimulatory molecules in a range of 
cell types. IFN-y-secreting K1735 cells previously developed in the laboratory 
(Chong 1996) were used as an allogeneic vaccine in vaccine/challenge experiments 
identical to the ones described above. Levels of cytokine secretion were determined 
by ELISA to be approximately 3.7 ng/4xl0^ cells/24hrs. Figure 3.4 shows that IFN-y 
release at the vaccine site had no significant effect on the immunogenicity of the 
K1735 vaccine and conferred no significant survival advantage to the animals over 
the parental, unmodified, K1735 vaccinated group or the untreated group.
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Figure 3.4: Irradiated allogeneic K1735-IFNy cells as a vaccine against the
development of B16 melanoma. ^
Groups of 8 C57BL/6 mice received 3 sequential subcutanous injections of 5x10
irradiated (lOOGy) K1735, K1735-IFN-Y, or PBS at days 1, 8 and 15. At day 22 (day 
0 on the graph) mice received an injection of 2x10* live B16 cells at the opposite 
flank and animal survival was followed.
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The beneficial effect of cytokine secretion by autologous tumour cell vaccines has 
been well documented in the literature (Cavallo, Di Pierro et al. 1993; Allione, 
Consalvo et al. 1994; Nawrocki and Mackiewicz 1999; Schadendorf, Paschen et al. 
2000). In the melanoma model, expression of GM-CSF, amongst other cytokines, by 
B16 tumor cells has proven particularly effective in raising a specific and long lasting 
immune response against B16 tumour growth (Dranoff, Jaffee et al. 1993; Castleden, 
Chong et al. 1997; Chong, Todryk et al. 1998; Todryk, Birchall et al. 2001). Our 
findings in the allogeneic vaccination model for melanoma suggest that cytokine 
modification does not have the same effect on the therapeutic potential of an 
allogeneic vaccine as that seen with autologous vaccines. As all of our vaccines had 
to be irradiated due to safety reasons prior to injection in the mice, one possible 
reason for the apparent lack in generating protective immunity in our model could be 
the loss of cytokine expression after lethal irradiation of the cells. To test for this 
possibility, levels of cytokine secretion were determined post irradiation for the 
K1735 cytokine secreting cell lines studied above. 4x10^ cells per well were plated in 
6 well plates and the cells were exposed to a total of lOOGy irradiation. Cytokine 
secretion was followed for a period of 96-144 hrs by harvesting the supernatants from 
each well and replacing with fresh media every 24 hrs. ELISA for each cytokine was 
used to determine cytokine levels (Figure 3.5). Irradiation did not affect the levels of 
secretion of IL-12 or GM-CSF by the K1735-IL12 and K1735-GM-CSF cells 
respectively. Although levels of IFF-y secretion by irradiated K1735-IFN-y cells 
were lower compared to levels obtained from un-irradiated K1735-IFN-y cells, they 
remained stable up to 96hrs post irradiation.
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Figure 3.5: Levels of cytokine secretion by genetically modified K1735 cells 
following irradiation.
A: 4x10^ cells/well of K1735-IL12 or K1735 cells were plated in 6 well plates and 
exposed to 0 (live) or lOOGy irradiation. Supernatants from each well were harvested 
every 24 hrs (replacing with fresh media) for a total of 144 hrs and concentration of 
cytokine determined by ELISA. All samples prepared in triplicates. B: Same as A for 
K1735-GM-CSF. C: Same as A for K1735-IFNy. IFN-y secretion followed up to 96 
hrs (*f<0.03).
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3.4 Generation of allogeneic tumour cell line overexpressing the inducible 
form of hsp70 and up-regulation of hsp70 expression in parental cell by heat 
shock
Previous studies in the laboratory have shown that hsp70 over-expression by B16 
tumour cells is associated with increased tumor cell infiltrates, a THl profile of 
intratumoural cytokine production, enhanced antigen uptake by DC and enhanced 
immunogenicity of a B16 tumour cell vaccine (Melcher, Todryk et al. 1998; Todryk, 
Melcher et al. 1999). Furthermore, hsp70 has been shown to efficiently chaperone 
tumour antigens for effective anti-tumour immune responses (Blachere, Li et al. 1997; 
Castellino, Boucher et al. 2000). Based on these findings, we decided to investigate 
the effect of hsp70 on the immunogenicity of K1735 cells in our allogeneic 
prophylactic vaccination model.
K1735 cells were retrovirally transduced with pBabe-hsp70 and a stable pooled 
population was generated by Puromycin selection (K1735-rhsp70). Hsp70 expression 
of the Puro resistant pooled population was verified by Western Blot analysis using an 
anti-hsp70 antibody specific for the inducible form of hsp70. Figure 3.6A confirms 
the expression of high levels of hsp70 by the K1735-rhsp70 cell line (lanes3 & 4), 
while no detectable hsp70 protein was expressed by the parental K1735 cells (lane 1) 
or the control K1735-pBabePuro (lane 2).
Hsp expression is upregulated in cells in response to heat stress. Therefore, in 
addition to generating a stable hsp70-expressing cell line, hsp expression was induced 
in K1735 cells by heat shock, as described in the Materials and Methods. Briefly, 
2x10^ cells were plated per well in a 6 well plate, and were exposed to either 42^C for 
20min or 45^C for 45min, corresponding to sub-lethal or lethal heat shock, 
respectively. At 4, 6, 12, 24 and 48 hrs following heat shock cells were harvested, 
protein isolated and hsp expression determined by western blot analysis using an 
antibody specific for the inducible form of hsp70 (Figure 3.6B). K1735 cells heat 
shocked under sub-lethal conditions (42®C for 20min) upregulated expression of 
Hsp70 within 4 hrs of heat shocking and maintained high hsp70 expression levels 
until 24hrs post heat-shock. By 48 hrs hsp70 levels had reduced significantly. In
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contrast, under lethal heat-shock conditions (45^C for 45min) K1735 cells upregulated 
hsp70 expression more slowly. No hsp70 could be detected at 4 and 6 hrs following 
heat-shock, while significantly elevated levels of the protein could be detected by 
12hrs and were maintained at least until 48hrs. K1735 cells that had not been heat- 
shocked expressed no detectable hsp70. This data suggested that the optimal 
timepoints for harvesting K1735 cells following sub-lethal or lethal heat-shock which 
would result in highly upregulated levels of hsp70 expression were 4-6hrs and 16- 
24hrs respectively.
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Figure 3.6: Western blot analysis of hsp70 expression in allogeneic K1735 
modified cells.
A: Puro resistant K1735 cells infected with pBabe-hsp70 retroviral vector were 
expanded and protein extracted for Western blot analysis with an anti-hsp70 
(inducible) antibody. Lanel- K1735; Lane 2- K1735-pBabePuro; Lane 3- K1735- 
rhsp70 (passage 8); Lane 4- K1735-rhsp70 (passage 1); Lane 5- positive control for 
hsp70. B: K1735 cells were exposed to lethal (Lanes 1-5) or sublethal (Lane 6-10) 
heat shock and protein was extracted at 4 (lanes 1 & 6), 6 (lanes 2 & 7), 12 (lanes 3 & 
8), 24 (lanes 4 & 9) and 48 hrs (lanes 5 & 10) following heat shock for western blot 
analysis as in A. Lane 11- K1735; Lane 12- K1735-rhsp70.
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3.5 Genetic modification of K l735 cells to express hsp70 does not enhance the 
efficacy of the allogeneic vaccine against a B16 challenge
K1735 overexpressing hsp70 or sub-lethally or lethally heat-shocked K1735 cells 
were used as a vaccine against B16 in a prophylactic vaccination protocol identical to 
the ones previously described. Hsp70 over-expression, either by genetic modification 
(Figure 3.7) or induced by heat-shock (Figure 3.8) had no effect on the 
immunogenicity of an allogeneic K1735 vaccine in our model and had no protective 
effect against B16 development.
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Figure 3.7: Irradiated allogeneic K1735-hsp70 cells as a vaccine against the 
development of B16 melanoma.
Groups of 8 C57BL/6 mice received 3 sequential subcutanous injections of 5x10^ 
irradiated (lOOGy) K1735, K1735-hsp70 or PBS at days 1, 8 and 15. At day 22 (day 0 
on the graph) micç received an injection of 2x10^ live B16 cells at the opposite flank 
and animal survival was followed.
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Figure 3.8: Sub-Iethally or lethally irradiated allogeneic K1735 cells as a vaccine 
against the development of B16 melanoma.
Groups of 8 C57BL/6 mice received 3 sequential subcutanous injections of 5x10^ 
irradiated (lOOGy) K1735, K1735-hsp70 or PBS at days 1, 8 and 15. At day 22 (day 0 
on the graph) mice received an injection of 2x10^ live B16 cells at the opposite flank 
and animal survival was followed.
3.6 Summary
IL-12, GM-CSF or IFN-y expression by allogeneic K1735 melanoma cells did not 
enhance the immunogenicity of the allogeneic vaccine in a prophylactic vaccination 
model against the autologous B16 melanoma tumour. Similarly, hsp70 over­
expression by the allogeneic vaccine was ineffective as a treatment against B16 
development in the same experimental model.
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Chapter 4
M e c h a n is m  o f  I m m u n o g e n ic it y  o f  t h e  K1735 a l l o g e n e ic  M e l a n o m a  C e l l
L in e
The data presented in Chapter 3 suggested that the K1735 cells are, at best, only very 
poorly immunogenic as vaccines against B16 tumours, either when used as 
parental/unmodified cells or following genetic modification with potentially 
immunostimulatory genes. To understand the reasons behind this apparent lack of 
immunogenicity of the allogeneic K1735 cells in our model system, the 
immunological profile of K1735 cells was analysed. Expression of important 
immunological markers by the K1735 and the B16 cells was studied. These markers 
included MHC class 1 and MHC class II molecules, co-stimulatory molecules, 
adhesion molecules, and TAA. In addition, the host immune response against the 
K1735 vaccine was studied by analysing the cytokine profile, as well as the profile of 
infiltrating immune cells, at the site of injection of the K1735 vaccine.
4.1 Comparative analysis of immunological markers expressed by K1735 and 
B16 cells
Molecules involved in direct antigen presentation (MHC Class I and Class II), co- 
stimulatory molecules and adhesion molecules play an important role in the 
immunotherapeutic potential of a cell-based vaccine. The two melanoma cell lines 
used in our studies, K1735 and B16, were analysed by FACS for constitutive cell 
surface expression of MHC Class I and Class II (Figure 4.1). K1735 expressed high 
levels of the H-2K'^ and lower levels of the H-2D'  ^ MHC Class I molecules (Figure
4.1 Aiv and iii respectively). B16 expressed neither of the two MHC I molecules (H- 
2K^ and H-2D^) tested (Figure 4.1AÜ and i respectively). Neither of the two murine 
melanoma cell lines showed any expression of MHC Class II on the cell surface 
(Figure 4.1B). Constitutive surface expression of the co-stimulatory molecules B7.1 
and B7.2 was also analysed. K1735 cells expressed very low levels of B7.1, but no 
B7.2 on the cell surface (Figure 4.1Ciii and iv respectively), while B16 cells 
expressed neither (Figure 4.1Ci and ii). Finally, constitutive expression of the
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intracellular adhesion molecule (ICAM-1) was analysed and neither of the two cell 
lines expressed any detectable levels on their cell suface (Figure 4.1Di and ii).
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Figure 4.1: Constitutive cell surface expression of immunological markers on 
K1735 and B16 cells.
FACS analysis of surface expression of A: MHC Class I, B: MHC Class II, C: Co­
stimulatory molecules and D: ICAM-I on B16 (Ai, Aii, Bi, Ci, Cii and Di) and K1735 
(Aiii, Aiv, Bii, Ciii, Civ and Dii) tumour cells. Dashed lines: control antibody 
staining; solid lines: surface markers. Green lines: FITC conjugated antibody; Red 
lines: PE-conjugated antibody
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4.2 Com parative analysis of melanoma associated antigen expression by 
K1735 and B16 cells
Expression of melanoma associated antigens against which a cell mediated immune 
response can be raised is a key feature of a successful melanoma vaccine. K1735 and 
B16 cells were screened by rtPCR for expression of a panel of known melanoma 
associated antigens, which included Tyrosinase, TRP-1, TRP-2, gplOO, MAGE-1, 
MAGE-2, MAGE-4 and MAGE-7. Table 4.1 shows a qualitative measure of the 
presence or absence of TAA expression in each cell line. B16 cells constitutively 
expressed Tyr, TRP-1, TRP-2, gplOO, MAGE-2 and MAGE-4. No MAGE-1 or 
MAGE-7 expression could be detected by rtPCR. In contrast, K1735 cells expressed 
fewer of the antigens tested. No Tyr, TRP-1, MAGE-1 or MAGE-7 expression could 
be detected. TRP-2, gplOO, MAGE-2 and MAGE-4 were expressed. These data 
suggest that a relative paucity of shared antigens between the cell lines may contribute 
to the poor vaccine efficacy of the K1735 cell vaccine. The results of MHC, ICAM-1 
and TAA expression by K 1735 and B16 cells are in agreement with previous studies 
(Knight, Souberbielle et al. 1996; Peter, Mezzacasa et al. 2001).
Melanoma Antigen B16 K1735
Tyr +
TRP-1 +
TRP-2 + +
gp100 + +
Mage A1 - -
Mage A2 + +
Mage A4 + +
Mage A7 - -
Table 4.1: Analysis of melanoma associated antigen expression by K1735 and 
B16 cells.
Total RNA was isolated from cells, cDNA generated and expression of TRP-1, TRP- 
2, Tyr, gplOO, MAGE-1, MAGE-2, or MAGE-3 analysed by PCR using specific 
primers for each of these molecules. GAPDH signal was used to confirm integrity of 
RNA. (+ = presence of appropriate band, - = absence of appropriate band).
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4.3 Histological examination of injection sites following subcutaneous 
injection of irradiated K1735 cells
To investigate how vaccine preparations of K1735 cells are recognised by the host 
immune system, irradiated (lOOGy) K1735 cells (5x10^ cells/injection) were injected 
subcutaneously into the flank of C57BL/6 mice and the boundaries of the injection 
site, covering an area of approximately 1x1 cm, were marked. At 0.5, 6, 24, 48, 72 
and 96 hrs following injection animals were sacrificed, the injection site harvested 
and processed appropriately for histology. For generating frozen sections, the tissues 
were immersed in OCT medium immediately after harvesting and snap frozen. The 
frozen blocks of tissue were then sent to the Pathology Department (Mayo Clinic) and 
5 pm sections were cut and stained for H&E for general structural observations. 
Although repeated attempts were made, we were unable to obtain sections that 
maintained good tissue morphology. This was likely due to the mixed consistency of 
the harvested tissue, which contained both the dense skin layer and the softer 
subcutaneous space of the injection site. We were therefore unable to obtain frozen 
sections for staining with a variety of cell markers for different cell types, such as 
CD4^ T cells, CDS^ T cells, DC, M(j), or NK cells.
Maintenance of very good tissue morphology has been well documented with 
paraffin-embedded tissue (Gendelman, Moench et al. 1983; Whiteland, Nicholls et al. 
1995), although often this is at the expense of preserving antigenic epitopes 
(Whiteland, Nicholls et al. 1995). As an alternative to frozen sectioning, paraffin- 
embedded sections were prepared. Tissue was harvested at 0.5, 24, 48 and 72 hrs 
following injection, fixed in 10% neutral buffered formalin immediately following 
harvesting for a minimum of 24hrs, paraffin embedded and sectioned (5 pm thick 
sections). The tissue was then stained with H&E or with a variety of antibodies to 
different cell-surface markers. Specifically, antibodies against CD4, CD8, DEC-205 
and CDl lb were used to detect the presence of CD4^ T cells, CD8^ T cells, DC and 
M(|) respectively. Although very good tissue morphology could be obtained, as 
determined by H&E staining, no reproducible staining could be achieved using any of 
the above-mentioned antibodies in any of the conditions attempted. This is consistent 
with literature reports that in formalin-fixed, paraffin-embedded tissue, critical
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antigenic epitopes are very commonly lost, and that successful staining for immune 
cells could be obtained only under very specialized fixing, embedding, and processing 
conditions (McLean and Nakane 1974; Codings, Poulter et al. 1984; Brenes, Harris et 
al. 1986; Whiteland, Nicholls et al. 1995).
Nonetheless, careful examination of the H&E stained sections revealed meaningful 
information about the local inflammatory environment generated at the site of 
injection of the allogeneic K1735 vaccine. Analysis was performed on the basis of 
morphology of the cells as revealed by H&E. Figure 4.2 shows that irradiated K1735 
cells attracted an increasingly larger mononuclear cell infiltrate as time progressed. 
Furthermore, analysis of B16 injection sites showed that irradiated B16 cells attracted 
an immune infiltrate also, although at a less marked level compared to K1735 cells. 
PBS injection site showed the basal levels of immune cells at the injection sites at the 
different timepoints.
4.4 Allogeneic K1735 cells are progressively cleared from the injection site 
following subcutaneous injection and stimulate a pro-inflam m atory cytokine 
response
Irradiated (lOOGy) K1735-Neo cells were injected subcutaneously as described above 
and the injection site was harvested at 0.5, 24, 48, 72 and 96 hrs following injection. 
Total RNA was extracted from the tissue, cDNA generated and used as a template for 
an PCR reaction for the detection of the Neo marker gene in the harvested tissues. 
This was an indirect method of determining the rate of clearance of the allogeneic 
K1735 cells by the host immune system. As it can be seen in Figure 4.3 the Neo 
signal disappeared by 72 hrs suggesting that the allogeneic cells were progressively 
cleared from the injection site within a timeframe of approximately 72 hrs. In 
addition to determining the presence of the allogeneic cells, the injection sites were 
analyzed for expression of a panel of pro- and anti-inflammatory cytokines. Primers 
specific for murine IE-10, TNF-a and INF-y were designed based on the published 
sequence for these molecules. rtPCR analysis revealed that a significant pro- 
inflamatory cytokine response was induced at the subcutaneous injection site against 
the K1735-Neo cells, with induction of TNF-a and INF-y at 24-96 hrs following 
vaccination. No induction of IL-10 was observed up to 4 days following vaccination.
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Induction of pro-inflammatory cytokine expression correlated well with the time 
course of clearance of the allogeneic cells from the site of injection, suggesting that 
activated infiltrating immune cells are mediating the clearance of the vaccine cells.
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Figure 4.2: Histological analysis of injection sites.
5x10" irradiated (lOOGy) K1735 or B16 cells or PBS were injected subcutaneously 
into the flank of mice. At 0.5, 24, 48 and 72 hrs the injection site was harvested, fixed 
in 10% neutral buffer formalin and paraffin-embedded. 5pm sections were cut from 
each tissue and stained for H&E (Magnification: 63X).
72 hrs
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Figure 4.3: Subcutaneous vaccination with allogeneic K1735 cells induces local 
expression of pro-inflammatory cytokines.
RNA recovered from vaccination sites was used for rtPCR to screen for expression of 
murine cytokines at 0.5, 24, 48, 72 or 96 hrs following vaccination with 5x10" 
irradiated K1735-neo cells or PBS. Equal loading of RNA was assessed by expression 
of GAPDH (data not shown).
4.5 K1735 vaccination induces infiltration of NK cells, M(|), and granulocytes
The histological and rtPCR analyses strongly suggested that irradiated K1735 cells 
can attract immune cells at the site of injection and can be cleared in an 
immunostimulatory fashion. Since our attempts to identify the profile of immune 
infiltrates at the injection site with immuno staining of histological sections of the 
injection site were unsuccessful, we designed an indirect method of studying the 
infiltrates (Figure 4.4). Gelfoam absorbable gelatin sponges were surgically 
implanted into the subcutaneous space on the backs of mice (two sponges of 
1.5x1.5x0.5cm each were implanted per mouse) and the animals were allowed to 
recover from the procedure for a period of three days. At day three, 5x10^ irradiated 
(lOOGy) K1735 or B16 cells were injected directly into the sponges and 48 hrs later 
the sponges were surgically removed for analysis. Sponges were treated with 
collagenase for 3 hrs to dissolve them and release any infiltrating cells. Red blood 
cells were depleted, cells counted and phenotyped by FACS analysis using a 
combination of antibodies to specific cell surface markers of immune cells. To
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determine the basal levels o f infiltrating cells in this system, sponges from animals 
that received a PBS injection were also analysed in each experiment.
Gelfoam Gelatin Sponge
3 days
Tum our cells 
or PBS
48 hrs
iCollagenase3hrs
Red Blood Cell Depletion
i
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Figure 4.4: Diagrammatic description of sponge experiments in mice.
Gelfoam absorbable gelatin sponges of approximately 1x1x0.5cm were surgically 
implanted at the back of animals. 3 days later tumour cells or PBS were injected into 
sponges and 48 hrs later sponges were harvested and digested with collagenase to 
release cells from sponge matrix. Red blood cells were removed and cells quantified, 
stained with a panel o f cell surface markers and analysed by FACS.
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Figure 4.5 shows a typical FACS dot plot and the statistical analysis of the results. 
The final number of each specific infiltrating cell type was calculated by multiplying 
the percentage total positive-staining cells by the total number of cells harvested from 
the sponge. Numbers of CDS T cells (CDS/CD3^), CD4 T cells (CD4VCD3^), NK 
cells (NK1.1VCD3'), macrophages (MacSVCDllc'), DCs (CD11c*/I-A'’*), 
granulocytes (Ly6GVCD14') and total leukocytes (CD45^) were determined by 
costaining and multicolor FACS analysis. Irradiated K1735 vaccine cells injected 
into a sponge attracted a significantly higher number of NK cells, M(j) and 
granulocytes (Figure 4.6) compared to the PBS control, confirming that irradiated 
K1735 cells can are recognised by the host immune system under these conditions. In 
addition, CDS^ and CD4^ T cell, and DC infiltration was increased. The autologous 
B16 cells attracted an increased level of leukocytes compared to the PBS controls. 
Infiltration observed in the K1735 sponges was consistently higher compared to that 
observed in the B16 sponges for all the cells types examined. These data are 
consistent with the histological analysis showing immune infiltration of the injection 
site, as well as the cytokine analysis showing the generation of a pro-inflammatory 
environment.
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Figure 4.5: Dot plots and statistical analysis of sponge infiltrating cells.
Cells extracted from the sponges were stained with antibodies to surface molecules 
conjugated to FITC (FL-1), PE (FL-2) or PerCP (FL-3), and analysed using FACS. 
Typical dot plots and corresponding statistical analysis are shown.
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Figure 4.6: Irradiated K1735 cells attract immune cells at site of injection.
K1735 or B 16 or PBS was injected into implanted sponges in mice and 48 hrs later 
the sponges were harvested and infiltrating cells were analysed as described in Figure
4.3 and Figure 4.4. To calculate number of infiltrating cells in each sponge,% total 
cells obtained for each sponge analysed were multiplied by the total number of cells 
harvested from that sponge. The trends shown here are representative of three 
individual experiments (* P<0.05; ** P<0.01).
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4.6 Vaccines consisting of mixtures of allogeneic K1735 and syngeneic B16 
cells have no significant protective effect against a B16 challenge
The data thus far have shown that K1735 cells express allogeneic MHC class I on 
their surface, express some melanoma associated antigens and can attract immune 
cells at a subcutaneus injection site and stimulate a pro-inflammatory immune 
response. Syngeneic B16 cells express no detectable MHC class 1 on their surface, 
express a wide range of melanoma associated antigens tested and can attract some 
immune infiltrate at the injection site. Based on this information, we decided to 
investigate what would be the effects of providing relevant tumor antigens to an 
allogeneic vaccine, by adding autologous cells to the vaccine. Alternatively, what 
would be the effects of providing allogenicity to a syngeneic vaccine, by adding 
allogeneic cells to the vaccine.
Mice received three subcutaneous consecutive injections of 5x10^ 1 OOGy-irradiated 
K1735 cells or 5x10^ 1 OOGy-irradiated B16 cells or different mixtures of the two cell 
lines as shown in Figure 4.7. Survival of animals following a B16 tumour challenge 
was monitored. The results shown in Figure 4.7 are from a single experiment, 
representative of three separate experiments, and for purposes of clarity they were 
separated into two individual graphs, A and B. Addition of increasing numbers of 
autologous B16 cells had no significant effect on the immunogenicity of the K1735 
cells against a B16 challenge (Figure 4.7.A). Likewise, addition of increasing 
numbers of allogeneic cells had no significant effect on the immunogenicity of the 
B16 cells against a B16 challenge (Figure 4.7.B). These data suggest that providing 
TAA with an allogeneic K1735 vaccine or providing potentially immunstimulatory 
molecules, such as the allogeneic MHC, with an autologous B16 vaccine has no effect 
on the immunogenicity of the allogeneic or the syngeneic vaccine respectively in the 
model used.
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Figure 4.7: Semi allogeneic vaccines do not protect mice from a B16 challenge.
Mice received three consecutive vaccination, 7 days apart, of 5x10^ irradiated K1735 
cells or different ratios of irradiated K1735 and B16 cells or PBS. Seven days 
following the last vaccination mice were challenged with 2x10^ live B16 cells and the 
percentage of mice surviving following the challenge are shown (8 mice per group). 
For clarity, the separate groups of a single experiment are shown in the two individual 
graphs (A. and B.). (P=0.0018 5x10’B16 v s  PBS; P=0.0198 5xlO^B16 vs 
5xl0^B16+10^K1735).
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4.7 Summary
Allogeneic K l735 cells are MHC Class I positive, Class II negative, ICAM-I 
negative, B7.1 low expressing and B7.2 negative. They express some melanoma 
associated antigens, such as TRP-2, gplOO, MAGE-2 and MAGE-7 and irradiated 
cells can attract immune cells at a subcutaneous injection site. B16 cells express no 
MHC Class I or II molecules on the cell surface, and no B7.1, 87.2 or ICAM-I. They 
express a wide panel of melanoma associated antigens, including TRP-1, TRP-2, Tyr, 
gplOO, MAGE-2, and MAGE-4. Sponge experiments revealed that irradiated 
allogeneic K1735 cells attract higher levels of NK cells, M(|), granulocytes, CD8^ and 
CD4^ T cells at the injection site when compared to B16 or PBS control injection 
sites. To address the issue of whether the weak immunogenicity of the allogeneic 
K1735 vaccine could be attributed to a relative paucity of TAA expressed by the 
vaccine cells, mice were vaccinated with different mixtures of K1735 and B16 cells. 
The immunogenicity of the allogeneic K1735 vaccine could not be enhanced when 
different amounts of B16 cells were mixed in the vaccine. Furthermore, the 
immunogenicity of a B16 vaccine could not be enhanced when different levels of 
K1735 cells were mixed in the autologous vaccine.
These data suggest that K1735 cells can be immunostimulatory when injected as a 
whole tumor cell vaccine, but the immune response generated against such a vaccine 
is not appropriate or sufficient to generate a systemic protective immunity against a 
syngeneic melanoma challenge. Modification of the allogeneic K1735 vaccine to 
express potentially immunostimulatory molecules, such as IE-12, GM-CSF, hsp70 
and INF-y (Chapter 3), does not enhance the immunogenicity of the allogeneic 
vaccine any fiirther.
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Chapter 5
V S V G -G -M e d ia t e d  F u s io n  E n h a n c e s  im m u n o t h e r a p e u t ic  P o t e n t ia l  o f  a
S e m i-A l l o g e n e ic  V a c c in e
Allogeneic K1735 melanoma cells, although they can not vaccinate against a syngeneic B16 
challenge, can induce a local proinflamatory environment and enhance the infiltrate of 
immune cells at the site of vaccination. We aimed to enhance this effect by controlling the 
destruction of the allogeneic cells in the vaccination site via expression of cytotoxic genes. 
We have previously shown that expression of viral FMG genes in tumour cells leads to very 
potent local tumor cell killing through fusion of tumor cells to each other (Bateman, Bullough 
et al. 2000; Diaz, Bateman et al. 2000; Fielding, Chapel-Femandes et al. 2000). The fusion 
event leads to the formation of large multinucleated syncytia which subsequently die through 
non-apoptotic, autophagic-like mechanisms which are immune potentiating (Suhy, Giddings 
et al. 2000; Bateman, Harrington et al. 2002). In addition, death of syncytia is associated 
with the induction of stress related proteins (Bateman, Bullough et al. 2000) which are 
potently immunostimulatory (Melcher, Todryk et al. 1998; Gough, Melcher et al. 2001). 
Finally, we (Bateman, Bullough et al. 2000) and others, have observed that the expression of 
viral immunogens can act as potent adjuvants in vaccinating against tumor related antigens 
through various immunological mechanisms (Schirrmacher, Haas et al. 1999; Eslahi, Muller 
et al. 2001; Mandelboim, Lieberman et al. 2001). Therefore, we reasoned that using FMG to 
fuse tumor cells to each other along with the immune stimulatory mechanisms associated 
with FMG-mediated cell killing may provide an effective method to liberate relevant tumour 
antigens from vaccine cells in an immunologically effective context.
5.1 Transient expression of the gene for Vesicular Stomatitis Virus G 
glycoprotein leads to the formation of extensive syncytia
We used transfection of the gene for VSV-G to fuse murine tumor cells to each other. 
VSV-G is non-fusogenic until the ambient pH is lowered to pH 5.5-5.7, which is 
believed to induce a conformational change that converts the protein into a fusogenic 
confbrmation(Fredericksen and Whitt 1995; Han, Bushweller et al. 2001). Since 
expression of the VSV-G envelope protein may be a potent adjuvant of itself (in the
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absence of tumor cell fusion) (Schirrmacher, Haas et al. 1999; Bateman, Bullough et 
al. 2000; Eslahi, Muller et al. 2001; Mandelboim, Lieberman et al. 2001), we also 
used a mutant VSV-G in which a single amino acid mutation at position 124 of the 
protein reduces the amount of cell fusion induced by expression of the gene by over 
90% (Fredericksen and Whitt 1995). Transfection with this mutant VSV-G also 
served as a control for the transient pH drop to which all fusing vaccine preparations 
were exposed. Transfection of tumour cells with VSV-G followed 24 hours later by a 
2 minute drop in pH to 5.5-5.7 caused fusion of cells such that between 60-90% of the 
cells in vitro were involved in syncytia 24-48 hours following the pH drop (Figure 
5.1). Transfection with VSV-G G-E124 or mock transfection routinely fused minimal 
numbers of cells (Figure 5.1 and (Fredericksen and Whitt 1995)).
VSV-G (Ipg)
I  24hrs
pH 7.5
B16 (or 1735)
(No fusion)
VSV-G (Ipg) 
I 24hrs
pH 5.5-5.7
^  24hrs
VSV-G* (Ipg)
I 24hrs
pH 5.5-5.7
^  24hrs
(60-90% fusion) (0-5% fusion)
Figure 5.1: Extensive tumour cell fusion mediated by VSV-G expression and low 
pH acid shock.
B16 tumour cells transfected with VSV-G or the VSV-G G-E124 mutant (VSV-G*). 
24 hours later cells were either left in normal pH media (pH 7.5) or briefly exposed to 
media of pH 5.7 for 2 min. 24-48 hours later cells transfected with VSV-G and acid 
shocked formed large multinucleated syncytia. In constrast cells transfected with 
VSV-G but not exposed to low pH or cells transfected with VSV-G* showed minimal 
amounts of fusion.
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5.2 VSV-G mediated tumour cell fusion does not enhance the efficacy of an 
autologous or an allogeneic tumour cell vaccine
We tested the effects of vaccination of C57/BL mice with VSV-G-mediated fusing 
cell vaccines in the prophylactic protection model previously described in chapters 3 
and 4. In one experiment, fusion of B16 cells to each other with VSV-G generated a 
moderately more effective vaccine compared to an irradiated B16 whole tumour cell 
vaccine, which is non-immunogenic in the experimental conditions used in these 
studies, or no vaccination (Figure 5.2A). In the same experiment, transfection of B16 
with the non-fusing VSV-G, had a similar effect to the fusing B16 vaccine (Figure 
5.2A), suggesting that expression of the VSV-G envelope protein in B16 cells slightly 
enhances their immunogenicity. However, to show any statistical significance of the 
observed effect, an analysis of much larger experimental group sizes would have to be 
done over several experiments. Fusion of the allogeneic K1735 cells to each other by 
VSV-G had no effect on the immunogenicity of the vaccine compared to naïve 
(untreated) animals (Figure 5.2B). Similarly, expression of VSV-G in the absence of 
fusion had no effect on the immunogenicity of the K1735 (Figure 5.2B).
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Figure 5.2: Irradiated fusing allogeneic or autologous vaccines are very poor 
immunogens against a B16 challenge.
Groups of 10 C57BL/6 mice received 3 sequential subcutaneous injections of 
irradiated vaccine cells followed by a live B16 challenge. The percentage of mice 
surviving are shown following the B16 challenge. Mice were sacrificed once tumour 
size exceeded 1cm in diameter. A. vaccine cells: VSV-G transfected fusing B16 
(B16-VSVG); VSV-G G-E124 transfected non-fusing B16 (B16-VSVG*); parental 
B16 (B16); no vaccination (Naïve). B. vaccine cells: VSV-G transfected fusing 
K1735 (K1735-VSVG); VSV-G G-E124 transfected non-fusing K1735 (K1735- 
VSVG*); no vaccination (Naïve).
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5.3 VSV-G mediated tumour cell fusion enhances the efficacy of 
autologous/allogeneic tumour cell vaccines
The data so far suggested that a purely autologous or a purely allogeneic fusing 
vaccine had no significant therapeutic effect against a B16 melanoma challenge in our 
protection model. Next we decided to investigate if a mixed allogeneic/autologous 
fusing vaccine would have a different effect. We hypothesized that the autologous 
cells would provide all the immunologically relevant antigens, the allogeneic cells 
would provide a strong adjuvant effect and the VSV-G mediated cell death would be 
a immunostimulatory mechanism of release of antigens accompanied by the induction 
and release of stress and danger signals. Figure 5.3 shows that fusion of a 1:1 
mixture of K1735:B16 cells with VSV-G generated a very effective vaccine with up 
to 70% of mice surviving rechallenge long term (>60 days) depending upon the 
individual experiment (the therapeutic effect ranged from 30% to 70%). These effects 
were not due to the adjuvant effect of the VSV-G immunogen alone, nor were they 
due to vector related components or to the brief exposure of cells to low pH, since the 
fusion defective mutant VSV-G G-E124 (VSV-G*) gave only minimal therapeutic 
gains (not statistically significant).
To understand the immunological significance of the mechanism by which the tumour 
cells are fused, the prophylactic vaccination experiments of Figure 5.3 were also 
carried out by fusing the K1735:B16 cells using polyethylene glycol (PEG) (Wang, 
Saffold et al. 1998). PEG fusion of tumour cells leads to the formation of 
disorganised cell aggregates rather than organised fusing cell monolayers obtained 
with VSV-G induced fusion. PEG-mediated fusion of tumour cells gave no delay in 
the appearance of tumours on rechallenge compared to controls, whereas fusion 
induced by VSV-G protected some mice long term firom tumour growth (Figure 5.4). 
This indicates that the mechanism of VSV-G mediated fusion is crucial to the 
immunogenicity of fusing tumour cell vaccines.
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Figure 5.3: Irradiated fusing allogeneic/autologous vaccines are potent 
immunogens against B16 challenge.
Groups of 10 C57BL/6 mice received 3 sequential subcutaneous injections of a 1:1 
mixture of irradiated K1735 and B16 cells transfected with VSV-G and fusing 
(K1735/B16-VSVG), or transfected with VSV-G*, non-fusing (K1735/B16-VSVG*), 
followed by a live B16 challenge. The percentage of mice surviving are shown 
following the B16 challenge. Mice were sacrificed once tumour size exceeded 1cm in 
diameter. Non vaccinated, naïve mice are shown as control. K1735/B16-VSVG was 
significantly better than K1735/B16-VSVG* or naïve groups, P<0.0003.
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Figure 5.4: The mechanism of fusion is critical for vaccination efficacy.
A 1:1 mixture of K1735 and B16 cells fused by VSV-G (K1735/B16-VSV-G) or by 
polyethelene glycol (PEG) (K1735/B 16-PEG) were used as irradiated cell vaccines in 
the prophylactic vaccination model similar to those described in Figures 5.2 and 5.3. 
The percentage of mice surviving are shown following the B16 challenge. Mice were 
sacrificed once tumour size exceeded 1cm in diameter. Non vaccinated, naïve mice 
are shown as control. K1735/B16-VSVG was significantly better than the 
K1735/B 16-PEG (P<0.0001) or naïve (P=0.0002) groups.
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5.4 Fusing tumor cell vaccines are effective in a therapy model of disease
We also tested the fusing tumour cell vaccines in a model of established disease 
(Castleden, Chong et al. 1997). Mice were seeded with B16 tumours on one flank, 
then treated with three consecutive vaccine treatments, 24 hours apart, on the 
contralateral flank once the B16 tumours became palpable (tumour diameter ~ 
0.1cm), typically 3-5 days after seeding. Fusing B16:K1735 vaccines were able to 
cure up to 80% of mice with established disease in this model (Figure 5.5). Both 
K1735:K1735 and B16:B16 fusing vaccines consistently produced a significant delay 
in growth of the tumour and, depending on the experiment, cured between 20-40% of 
the mice (Figure 5.5A). Other vaccines produced no therapeutic effect (Figure 5.5).
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Figure 5.5: Fusing allogeneic/autologous cells are potent immunogens against 
established disease.
Fusing cell vaccines were tested in a therapy model. Groups of 10 C57BL/6 mice 
were injected with 2x10^ live B16 cells. Once the B16 tumours became palpable, the 
mice received three vaccines separated by 24 hours. The percentage of mice surviving 
the lethal tumour challenge following treatment with different irradiated fusing 
(VSVG) or non-fusing (VSVG*) cell vaccines is shown post initial B16. Mice were 
sacrificed once tumour size exceeded 1cm in diameter. The K1735/B16-VSVG group 
was significantly better than any o f the other groups (P<0.0001).
142
5.5 The long term vaccinating capability of fusing tumour cell vaccines is 
both tumour specific and T cell dependent
In the experiment shown in Figure 5.5, we rechallenged the 8 mice which had been 
cured of their tumours by treatment with K1735:B16 fusing tumour vaccines. Of the 
4 mice rechallenged with CMT93 tumour cells -  an unrelated colorectal tumour 
syngeneic with C57/BL mice -  all 4 developed tumours (Table 5.1). In contrast, only 
1 of 4 mice rechallenged with parental B16 cells developed a tumour (Table 5.1). 
These data show that the immunological mechanisms that led to effective rejection of 
the established B16 tumours by the K1735:B16 fusing vaccine were able to contribute 
significantly to the development of long term immunity against the tumour. 
Moreover, this long term protective effect is tumour specific.
Initial vaccination Survival Rechallenge Survival 25 days post
rechallenge
K1735/B16-VSVG 8/10 B16 (4/8) 3/4
CMT (4/8) 0/4
Table 5.1: Tumour specific, long term vaccinating capability of fusing tumour 
cell vaccines.
In the experiment shown in Figure 5.5, 8 of 10 mice were cured of the established 
tumours when treated with a fusing K1735/B16 vaccine. These 8 mice were 
rechallenged with either parental B16 or parental CMT93 colorectal tumour cells. 25 
days later, all the animals challenged with CMT93 cells had succumbed to 
progressively growing tumours. Only 1 of the 4 mice rechallenged with B16 
developed a tumour and was sacrificed.
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We also repeated the vaccination protocol of Figure 5.3 in athymic nude mice. 
Figure 5.6 shows that the vaccinating ability of the fusing cell vaccines was 
completely eradicated in animals lacking functional T cells, suggesting that T cells 
play an important role in the immune response mounted against the autologous B 16 
cells.
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Figure 5.6: The long term vaccinating capability of fusing tumour cell vaccines is 
T cell dependant.
The prophylactic vaccination experiments of Figures 5.2 & 5.3 were repeated in 
athymic nude mice which lack T cells. As previously, mice were vaccinated with 
irradiated fusing (VSVG) or non-fiising (VSVG*) vaccines, PBS or no vaccine at all. 
The percentage of mice surviving are shown following the lethal B16 challenge. Mice 
were sacrificed once tumour size exceeded 1 cm in diameter. There was no statistically 
significant difference between any of the groups.
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5.6 Sum m ary
Despite improvements in slowing tumour development in some cases, neither pure 
autologous nor pure allogeneic fusing vaccines alone were able to protect animals 
against development of disease. However, an irradiated mixture of autologous and 
allogeneic tumour cells fused by VSV-G was extremely effective at protecting mice 
from subsequent rechallenge with B16 cells. Furthermore, a similar vaccine was also 
very potent at curing small established disease. This protective immunity was not 
attributable to the expression of the immunogenic VSV-G alone, or to the possible 
effects of low pH exposure, since cells transfected with a mutant, non fusing VSV-G 
differing in only a single amino acid, were only weakly immunogenic. The protection 
effects observed here were long term, tumour specific and T cell dependent. Finally, 
fusion of a similar autologous/allogeneic vaccine by chemical means (polyetheline 
glycol-PEG) did not result in the generation of a potent immunogen, suggesting that 
the mechanism of fusion plays an instrumental role in the efficacy of a fusing vaccine.
It should be noted that, although the experiment in athymic nude mice is an indication 
on the possible importance of T cells in the immune response observed following the 
K1735/B16-VSVG fusing vaccination, these mice have a more complex 
immunocompromised phenotype that in not solely attributed to the absence of T cells. 
Hence, further experiments need to be done in models where the role of T cells can be 
examined in the absence of any other immunological defects, for example in CD4 or 
CD8 knockout animals or animals depleted of CD4+ or CD8+ T cell populations with 
specific antibodies. Along this line, experiments need to be done to investigate the 
role of non-specific immune effector cells such as NK cells in the potent immune 
response observed.
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Chapter 6
M e c h a n is m s  o f  I m m u n o g e n ic it y  o f  F u s in g  T u m o u r  C e l l  V a c c in e s
The data in Chapter 5 clearly demonstrate that expression of the VSV-G gene by a 
mixed autologous/allogeneic melanoma cell vaccine followed by fusion dramatically 
enhances the potency of such a vaccine. To understand the immunological 
mechanisms by which FMG-induced syncytial killing leads to the anti tumor effect 
we have observed in these studies we decided to study the host immune response 
against the fusing K1735/B16 vaccine, as well as the interaction of immune cells with 
the fusing vaccine in vitro.
6.1 VSV-G-mediated fusion enhances infiltration of immune cells at the site 
of vaccination.
We investigated the host response to the irradiated vaccine cells shortly after 
vaccination by utilising the gelfoam absorbable gelatine sponge model we had 
previously established (Chapter 4; Figure 4.4). K1735/B16-VSVG, K1735/B16-
VSVG* and K1735/B16 vaccines were prepared as described in chapter 5, irradiated 
to lOOGy and injected into previously implanted gelfoam sponges at the flank of 
mice. 48 hrs later the sponges were removed from the animals and the cell infiltrates 
analysed. Numbers of CD8 T cells (CD3^CD8^, CD4 T cells (CD3^CD4^), NK cells 
(CD3'NK1.1^, M(j) (Mac3^CDllc'), DC (CDllc^I-Ab^ and granulocytes 
(Ly6G^CD14‘) were determined by costaining and multicolour FACS analysis, as 
previously described in Chapter 4, paragraph 4.5. Figure 6.1 shows that expression 
of VSV-G* by the K1735/B16 vaccine did not significantly influence the profile of 
infiltrating cells when compared to the unmodified K1735/B16 vaccine. In contrast, 
K1735/B16-VSVG fusing cells consistently attracted significantly higher levels of 
NK cells, CDS T cells, macrophages and granulocytes compared to K1735/B16 cells 
or K1735/B16-VSVG*. In only one of three experiments CD4 T cell infiltration was 
significantly higher in the fusing K1735/B16-VSVG group than the K1735/B16 or 
K1735/B16-VSVG* groups. The data shown in Figure 6.1 are representative of at 
least three different experiments (except for CD4^CD3^ cells). VSVG expression and 
fusion did not seem to affect DC infiltration.
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Figure 6.1: VSV-G-mediated fusion enhances infiltration of immune cells at the 
site of vaccination.
Irradiated K1735/B16-VSVG, K1735/B16-VSVG*, or K1735/^16 vaccine cells were 
injected into implanted sponges in mice, 48 hrs later the sponges were harvested and 
infiltrating cells were analysed as previously described (Chapter 4). The trends shown 
here (except for CD4+/CD3+) are representative of three individual experiments
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These data suggest that VSVG-induced fusion creates a more inflammatory local 
environment leading to enhanced recruitment of APC and effector cells, which may 
contribute to the enhanced in vivo efficacy of the fusing K1735/B16 vaccine 
compared to the non-fusing VSVG-expressing or the unmodified vaccines.
6.2 Allogeneic MHC Class I is a critical factor in the immunogenicity of 
syncytial cell killing.
Based on our observation that the presence of K1735 allogeneic cells as the fusion 
partner is necessary for vaccine potency in our fusing tumour cell vaccines (Chapter 
5), we investigated the role of allogeneic MHC Class I molecules in the 
immunogenicity of a fusing vaccine. For these studies we utilized B16-derived cell 
lines expressing no detectable syngeneic MHC I on their surface (B16-neg), or 
engineered to express high levels of autologous H-2D^ (B16-syng) or allogeneic H- 
2L  ^ (B16-allo) (Figure 6.2) (Thomas, Greten et al. 1998). Fusing and non-fusing 
vaccines of each of these cell lines were prepared as previously described (Chapter 5 
and materials and methods), irradiated with lOOGy and tested in a protection 
vaccination model in C57BL/6 mice. Mice were challenged with live B16-syng cells 
and animal survival post challenge was followed. Expression of VSVG without any 
fusion and a syngeneic MHC I molecule by B16 cells (B16syng-VSVG*) had no 
significant effect on the immunogenicity of the vaccine (Figure 6.3). Similarly, 
expression of VSVG without any fusion by B16 expressing no MHC I (B16neg- 
VSVG*) did not enhance the immunogenicity of such a vaccine. Expression of 
VSVG without any fusion in combination with allogeneic MHC 1 (B16allo-VSVG*) 
however, significantly enhanced the immunogenicity of the vaccine compared to 
either B16neg-VSVG* (P<0.002) or B16syng-VSVG* (P<0.002). Fusion of B16- 
neg to each other by VSV-G expression (B16neg-VSVG) generated a significant 
therapeutic benefit relative to B16neg-VSVG* (P<0.002) and fusion of B16-syng to 
each other by VSV-G led to an enhanced yet not statistically significant therapeutic 
effect relative to B16syng-VSVG*. But most importantly, the fusion of B16-allo 
cells to each other by VSV-G led to potent enhancement of the therapeutic effect, 
with 90% of mice surviving tumour challenge long term (>60 days) (P=0.04 relative 
to B16allo-VSVG*), comparable to protection observed with B16/K1735 fusing 
vaccine. Although the extent to which allogeneic MHC or VSVG-mediated fusion
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contribute individually to the immunogenicity of a tumour cell vaccine needs further 
investigation, the data in figure 6 3 show that expression of an allogeneic MHC 
molecules on the surface of fusing tumour cells significantly enhances the efficacy of 
such a vaccine. This suggests that allogeneic MHC molecules expressed by K1735 in 
the fusing K1735/B16 vaccines contribute significantly in the immunogenicity of this 
vaccine.
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Figure 6.2: Profile of MHC Class I surface expression by B16 Class I variants.
1-5x10* B 16-neg, B16-syng and B16-allo tumour cells were stained with antibodies 
against H-2K* (solid red line) or H-2L^ (solid blue line) and analysed by multicolor 
FACS analysis. Appropriate control IgG staining shown as dashed lines.
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Figure 6.3: Allogeneic MHC Class I is a critical factor for the immunogenicity of 
syncytial cell killing.
Fusing (VSVG) and non-fusing (VSVG*) vaccines of B16-neg, B16-syng and B16- 
allo were prepared, irradiated with lOOGy and injected into groups of 10 C57BL/6 
mice as previously described. Mice were then inoculated with live B 16-syng cells and 
animal survival was monitored post tumour challenge. Control groups received PBS 
as a vaccine or no treatment. K1735/B16-VSVG vaccine was used as a comparison 
for efficient protection.
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6.3 Syncytial cell killing enhances uptake of tumour derived material by both 
macrophages and immature dendritic cells.
Previous data from our laboratory has demonstrated an important role for 
macrophages in coordinating immune responses to tumour vaccines (Gough, Melcher 
et al. 2001). In view of the data described in Chapter 4 and Figure 6.1 where 
elevated macrophage numbers infiltrate the fusing K1735/B16 vaccine site, we 
hypothesised that these cells may play an important role in mediating the efficacy of 
this approach. Peritoneal macrophages were prepared as described in Materials and 
Methods. Co-culture of labelled macrophages (Figure 6.4.Ai) with labelled tumour 
cells (Figure 6.4.AÜ) showed that macrophages can take up tumour derived material 
to a small degree from actively growing cultures (seen as a right shift of staining of 
the macrophages in Figure 6.4.Aiii). When autologous B16 tumour cells were killed 
through syncytial formation, uptake of labelled material by the macrophages was 
occasionally enhanced (Figure 6.4.Av). However, uptake of tumour derived material 
was consistently optimal when the target cells contained allogeneic cells (K1735 
alone or K1735/B16), (Figure 6.4.Aiv). No secretion of either IFN-y or IL-10 could 
be detected from macrophages co-cultured with syncytia. TNF-a was produced at 
low levels by macrophages in response to K1735/B16 mixtures in the absence of cell 
fusion (Figure 6.5.Aiii) or B16 cells in the presence of fusion (Figure 6.4.Av). 
However, TNF-a production was consistently seen at highest levels in response to 
fusing cells containing allogeneic cells (Figure 6.4.Aiv).
Similar experiments with immature murine dendritic cells showed enhanced levels of 
uptake of tumor material from fusing cells compared to normal cultured cells, but 
there was no distinction between fusing cell mixes which contained only autologous 
or allogeneic components (Figure 6.4.B). Incubation of immature DC with syncytia 
did not induce TNF, IL-10 or INF-y secretion under any conditions tested.
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Figure 6.4: Syncytial killing enhances uptake of tumour derived material by both 
macrophages and IDC.
A. Red labeled peritoneal macrophages (i) or green labeled tumour cells (ii) were co­
cultured (iii) or were co-cultured following transfection with VSV-G and acid shock 
to induce syncytial fusion and cell killing (iv and v). The resulting populations were 
analysed by FACS for populations of single or double labeled cells. The release of 
TNF-a was measured by ELISA and figures are shown per 10^  fresh C57BL/6 
peritoneal macrophages/ml/24 hrs. B. As for A except that tumour cells were co- 
cultured with IDC.
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6.4 Syncytial cell killing leads to cross presentation by dendritic cells of a 
model tumour antigen from both autologous and allogeneic tumour cells.
We investigated further the immunological mechanisms by which syncytial killing 
leads to the anti tumour immunity that we have observed in these studies. T cells from 
OTl transgenic mice recognise the SIINFEKL epitope of the ovalbumin antigen in 
the context of H-2*^  (Hogquist, Jameson et al. 1994). DC loaded with SIINFEKL 
peptide are recognised by OTl cells leading to INF-y release (Figure 6.5.A). Due to 
low levels of MHC Class 1 expression B16ova-transfected cells cannot present 
sufficient SIINFEKL epitope to OTl cells from endogenous expression of ova 
(Figure 6.5.A) (unless pre-treated with INF-y to upregulate Class I MHC expression, 
data not shown) for detectable cytokine release. Similarly, B 16-ova incubated with 
DC in the absence of killing do not release sufficient ova epitopes for presentation 
(Figure 6.5.A). Lysates of B16ova cells killed by freeze thawing or osmotic shock 
were also unable to load DC with the appropriate epitope of ova for cross presentation 
to OTl cells (data not shown). In one of three experiments, B16ova cells killed by 
irradiation (lOOGy ) were able to serve as a source of ova antigen for DC in a cross 
presentation assay (Figure 6.5.B). However, B16ova cells fused by VSV-G were a 
reproducible and potent source by which the ova epitope could be supplied to DC for 
subsequent presentation to OTl cells (Figure 6.5.B). This presentation did not occur 
in the absence of DC to cross-present the antigen. This demonstrates that fusion of 
tumour cells leads enhanced cross presentation of tumour derived antigens by DC and 
thus enhanced crosspriming of T cells.
Despite repeated attempts using both plasmid and retroviral-mediated gene transfer of 
the ova gene, we were unable to generate a K1735 cell line expressing ova. We were, 
however, able to generate NIH3T3 cells expressing ova which could serve as an 
allogeneic source of the protein (NIH3T3 cells are unable to present ova to OTl cells 
even with INF-y stimulation due to a lack of H2b MHC). To a lesser degree than with 
fusing B16ova cells, NIH3T3ova cells expressing fusogenic VSV-G loaded H-2^+ve 
DC with ova which led to presentation of the SIINFEKL epitope to OTl cells (Figure 
6.5.C). In these experiments, irradiation (Figure 6.5.C), freeze thaw or osmotic 
shock (data not shown) of the allogeneic ova expressing line, were ineffective at 
promoting cross presentation of the ova antigen by H2^ DC.
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Figure 6.5: Syncytial cell killing leads to cross presentation by dendritic cells of a 
model tumour antigen from both autologous and allogeneic tumour cells .
A. OTl T cells were co-cultured for 24 hours with various mixes of tumour and 
dendritic cells as shown. As controls, OTl cells were co-cultured with immature 
C57BL/6 dendritic cells (DC) either alone or pre-loaded with the SIINFEKL peptide 
as a positive control for recognition; or with B16ova tumour cells or with mixtures as 
indicated. IFN-y release from the OTl cells was measured by ELISA as shown. B. As 
for A except that B16ova were VSV-G transfected and fused in some samples. C. As 
for B except that the tumour cells in this case were NIFI3T3ova allogeneic cells.
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6.5 Summary
Irradiated VSV-G fusing tumour cell vaccines attract NK, CD8^ T cells, 
macrophages, neutrophils and possibly CD4 T cells, compared to VSV-G expressing, 
but non-fusing, vaccines or just irradiated vaccines. This observation further supports 
the suggestion that the mechanism of syncytial death is more immunostimulatory than 
irradiation alone despite the presence of the potential viral immunogen. More 
evidence to support this comes from our observations that syncytial killing enhances 
the uptake of tumour derived material by macrophages and dendritic cells and also 
leads to efficient cross-priming of T cells by DC in vitro.
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Chapter 7
Transcriptional Control of FMG Expression for the Development of Stable Cell
Lines Expressing FMGs.
We have shown that FMGs are able to potently enhance the immunogenicity of a 
combined autologous and allogeneic cell vaccine. To develop this for therapeutic 
application we aimed to develop allogeneic cells stably expressing FMGs as an “off 
the shelf’ reagent either to combine with patient derived tumour material or to inject 
directly within established tumour nodules. As previously demonstrated however, 
expression of a FMG gene under the control of a strong constitutive promoter, such as 
CMV, in cells expressing the appropriate FMG-receptor leads to potent direct and 
bystander cytotoxic effects (Chapter 5, (Bateman, Bullough et al. 2000; Diaz, 
Bateman et al. 2000; Fielding, Chapel-Femandes et al. 2000)). Therefore, for the 
purposes of generating stable FMG-expressing cells lines it is essential to regulate 
gene expression
The “Tet-On” transcription regulation system (Gossen, Freundlieb et al. 1995; Baron, 
Gossen et al. 1997; Rossi and Blau 1998) (as described in Introduction) was utilised 
in these studies to regulate expression of FMGs. Briefly, the system is composed of 
two critical components and gene expression is regulated by the tetracycline analogue 
Dox (Figure 7.1). The first component is the reverse tetracycline-controlled 
transcativator (rtTA), a hybrid transcription factor that can specifically bind to the 
second key component, the TRE. The TRE contains sequences from the tetracycline 
operator and is coupled to a minimal CMV promoter, forming a tet-responsive 
promoter. A FMG gene is placed under the control of this promoter but in the 
absence of Dox, the rtTA is unable to bind to the TRE and activate transcription. 
Addition of Dox leads to conformational changes in the rtTA which enable it to bind 
to the TRE and consequently induce transcription.
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7.1 Cloning of the hyperfusogenic GALV envelope gene in the Tet-On system 
regulation plasmids.
The Tet-On system (Clontech) was used to regulate expression of the GALV FMG in 
a panel of different human cell lines. The GALV envelope gene used in these studies 
expresses a hyperfusogenic C-terminally truncated mutant of the wild type envelop 
protein (Fielding, Chapel-Femandes et al. 2000). Expression of GALV on human 
cells expressing the receptor for GALV, PitI, leads to extensive syncytia formation 
and potent direct and bystander cytotoxic effects within 24 hrs. The key plasmids 
used in these studies are shown in Figure 7.2A. pTet-On plasmid (Gossen, Freundlieb 
et al. 1995) expresses the rtTA regulator protein from the strong immediately early 
promoter of CMV. In addition, this plasmid contains a neomycin resistance gene for 
selection of transduced cells. The pTRE response plasmid (Resnitzky, Gossen et al. 
1994) contains the TRE coupled to the minimal CMV promoter (Figure 7.2B). 
Immediately downstream of this Tet-responsive promoter is a multiple cloning site 
(MCS) consisting of unique restriction enzyme sites for cloning of the gene of interest 
in the plasmid. Generation of cell lines expressing GALV under the control of Tet 
involves the development of double-stable cell populations transduced initially with 
the pTet-On regulator plasmid for stable expression of the rtTA, followed by 
transduction with the pTRE response plasmid carrying the GALV gene for Tet- 
regulated expression of GALV.
For the purposes of cloning of the GALV envelope gene into the pTRE plasmid, 
BamHI sites were created on either end of the GALV gene using PCR and 
appropriately designed primers (see Materials and Methods). The 2.2 Kb PCR 
product corresponding to the GALV gene containing BamHI sites on either side was 
inserted into the shuttle plasmid pCR3.1 (Invitrogen) to create plasmid pCRS.l- 
GALV. The GALV gene was subsequently excised from pCR3.1-GALV by BamHI 
digestion and ligated to a 5<3wM-linearised pTRE plasmid, to yield plasmid pTRE- 
GALV (Figure 7.2C). Sequencing of the GALV gene contained in pTRE-GALV 
confirmed the correct orientation of the GALV, as well as the integrity of the gene in 
the final plasmid.
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A. pTet-On (7.4 kb)
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w
rtetR VP16 SV40
AD pA
Amp
B. pTRE (3.1 kb)
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) — C D - —
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C. pTRE-GALV (5.3 kb)
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pA
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Figure 7.2: Maps of plasmids used in the Tet-On system.
A: pTet-On regulator plasmid. B: original pTRE response plasmid. C: modified 
pTRE-GALV response plasmid. Pcwrimmediate early cytomegalovirus promoter; 
rtetR: reverse tetracycliic repressor; VP 16 AD: activation domain of VP 16 protein of 
herpes simplex virus; pA: poly A signal; Amp: ampicilin resistance gene; Neo: 
neomycin resistance gene; TRE: tetracycliiEresponse element; Pmincw- minimal CMV 
promoter; MCS: multiple cloning site.
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7.2 Regulation of GALV expression in 293 cells.
To demonstrate the proof-of-principle of using the Tet-On system for regulating gene 
expression in human cells, a modified human primary kidney embryonal cell line, 
293-On, was initially used in the studies. The 293-On cell line (Clontech) is a 
subclone of 293 cells stably transformed with the pTet-On regulator plasmid and 
expressing high levels of rtTA. To verify the inducibility potential of the 293-On 
cells, the cells were transfected with a pTRJE plasmid expressing the reporter gene for 
luciferase, pTRE-Luc (Clontech), using the Effectene transfection system as described 
in Materials and Methods. For Tet-induced gene expression, Ipg/ml of Dox was 
provided in the media of the transfected cells immediately following transfection and 
luciferase expression was monitored over 72 hrs by a luciferase assay. To determine 
the basal level of gene expression from the pTRE plasmid in this cell line, the cells 
were transfected with pTRE-Luc in the absence of Dox. No transfection or 
transfection with “empty” pTRE plasmid were used as controls. Figure 7.3 shows 
that in the presence of Dox luciferase expression can indeed be induced to high levels 
compared to the negative controls. However, relatively high levels of basal luciferase 
expression were observed in the absence of Dox and overall luciferace expression 
upon Dox administration could only be induced 3-4 fold higher than the background 
expression. These data demonstrate that although Dox can significantly induce gene 
expression in the 293-On cell line, gene expression is not completely silent in the 
absence of Dox.
Since the relevance of basal gene expression is a function of the gene selected, we 
next proceeded to test the pTRE-GALV and determine the basal level of GALV 
expression plasmid in the same transient transfection system used above. 293-On 
cells were transfected with pTRE-GALV and the level of GALV expression was 
determined by level of syncytia formation. pCR3.1-GALV was used as a positive 
control for GALV fusion. The levels of syncytia formation were determined by 
visual observation under the microscope (Figure 7.4) and are summarised in Table 
7.1. Transfection of 293-On cells with pCR3.1-GALV led to rapidly progressive 
fusion (Figure 7.4A). Approximately 60% of the cells were fusing at 12 hrs, and by 
24 hrs almost 100% fusion could be observed. However, syncytia formation was also
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observed in the cells transfected with the pTRE-GALV in the absence of any Dox 
(Figure 7.4B). Although the extent of fusion was limited at the initial timepoints 
(approximately 15% at 24 hrs), it significantly increased at the later timepoints of the 
experiment and by 96 hrs approximately 80% of the cells had formed syncytia. No 
syncytia formation was observed in the mock transfected cells (Figure 7.4C). The 
results of this experiment confirm that the GALV gene cloned in the pTRE-GALV 
plasmid is functional, but, most importantly, they demonstrate the existence of 
significantly high basal levels of GALV expression in the absence of Dox from the 
Tet-responsive plasmid at the level of transient expression in 293-On cells. This 
apparent “leakiness” of the Tet-On system in regulating GALV expression following 
transient transfection may present a significant hurdle in the development of cellular 
or viral vectors expressing GALV or other FMG genes.
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Figure 7.3: Luciferace expression in 293-On cells transiently transfected with 
pTRE-Luc.
293-On cells were transfected with plasmid pTRE-Luc in the presence or absence of 1 
pg/ml of Dox, plasmid pTRE or nothing. 24, 48 and 72 hrs post transfection protein 
was isolated from cells and analysed for Luciferase activity.
Timepoints (hrs)
Sam ples 12 24 48 72 96
pCR3.1-Galv -f-H - + + + -E + + + -H --E - H -+ + + -f-E-h-f-t-
pTR E-Gal V - 4-+ +++ -H-E-f-E
untransfected - - - - -
no DNA - - - - -
Table 7.1: Level of fusion of 293-On cells transiently transfected with pTRE- 
GALV.
293-On cells were transfected with the indicated plasmids and the extent of syncytia 
formation was monitored over 72 hrs. The extent of syncytia formation was used as a 
measure of GALV gene expression levels. -: 0% fusion; +: 1-20%; ++: 21-40%; 
41-60%; ++++: 61-80%; +++++: 81-100%.
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7.3 Generation o f  double-transfected 293-On cell lines expressing GALV.
Since our goal is the generation of long-lived stable cell lines conditionally expressing 
GALV, we decided to investigate if it was possible to isolate clonal populations of 
293-On cells transformed with pTRE-GALV that exhibit low background, yet high 
induction potential of GALV expression. Plasmid pTRE expresses no drug selectable 
marker for selection of stable drug-resistant populations. 293-On cells were therefore 
co-transfected with pTRE-GALV and pBabePuro, the latter plasmid conferring 
puromycin resistance, at a ratio of 20:1 respectively and 48 hrs following transfection 
the cells were subjected to puromycin selection (Ipg/ml Puro). The use of 20 times 
more response plasmid compared to selection plasmid significantly enhances the 
likelihood that cells resistant to puromycin have also integrated a copy or copies of 
the response plasmid. Approximately 2 to 3 weeks later puromycin-resistant 
transformed colonies could be isolated and further expanded in individual cultures. A 
total of 48 sub-clones were analysed for induction of GALV expression and syncytia 
formation in the presence or absence of Dox. Cells were plated in duplicates and the 
first set of cells was kept in normal tissue culture media while the second set was kept 
in Ipg/ml of Dox. Light microscopy was used to monitor extent of fusion over 96 hrs 
and results from 22 representative clones are summarised in Table 7.2. 10 of the 22 
sub-clones exhibited no background and no induction of GALV expression as 
demonstrated by the lack of syncytia formation in the absence or presence of Dox. 
Six of the sub-clones exhibited very low background and low levels of induced 
GALV expression. Two of the sub-clones exhibited medium to high levels of GALV 
induction, but the levels of background expression were also high, while two 
subclones exhibited low background expression and medium induced expression. 
Finally, two of the sub-clones exhibited very low levels of background GALV 
expression with high induction potential. In the absence of Dox less than 5% of cells 
of sub-clones 26 and 2S were involved in syncytia at any timepoint. By 72 hrs of Dox 
stimulation approximately 90% of cells of sub-clone 26 were forming syncytia, while 
by the same timepoint approximately 80% of the cells of clone 2S were forming 
syncytia. These results demonstrate that upon continuing puromycin selection clones 
of 293-On cells with minimal background levels of GALV expression and high 
induction potential can be developed.
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_______________- Dox_______________   +_Dox______________
Sub-clone 24 hrs 48 hrs 72 hrs 96 hrs 24 hrs 48 hrs 72 hrs 96 hrs
7 + + + + + +++ +++ +++
8 ++ ++ ++ ++ ++ +++ ++++ ++++
12
16 + + + + + + + + + + +
17 + + + + + + + +
19 - - - - - + + +
20 ++ ++ ++ ++ ++ ++ ++ +++
22 - - - - + + + +
23 - - - - - - - -
24 - - - - - - - -
26 + + + + + ++ +++- +++++
27 _ -
28 - + + + - ++ +++ +++++
40 + + + + + + + +
41 - + + + - + + +
4 2  — -  -  -  -  — —
46 - + + + - +4- + +  + + +
4 8 — - - — - — — —
Table 7.2: Level of syncytia form ation in double-transform ed 293-On sub-clones 
expressing GALV.
To determine the levels o f induction of GALV expression in each individual 293-On 
GALV-expressing sub-clone, 1 pg/ml of Dox was administered to the cells and fusion 
was monitored by phase contrast light microscopy. Basal levels of GALV expression 
was determined by monitoring fusion in the absence o f Dox. -: 0% fusion; +: 1-20%; 
4-h: 21-40%; +++: 41-60%; ++++: 61-80%; +++++: 81-100%.
Gene expression from the Tet-response plasmid is dependent on the concentration of 
Dox. Although Ipg/ml of Dox is well documented in the literature as being an 
optimal dose for inducing gene expression in various models, we determined whether 
the lack of fusion induction observed in some of our clones was due to sub-optimal 
levels of Dox. Clones 1,9, 7, 23, 26 and were plated in increasing amounts of Dox 
and the extent of fusion was assessed 72 and 96 hrs later (Table 7.3). 100 pg/ml of 
Dox was toxic to all the cells and cells died within 24 hrs of exposure to this 
concentration. Although 10 pg/ml of Dox was not potently cytotoxic a reduction in 
the growth rate of the cells was observed. The remaining Dox concentrations had no
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apparent direct toxic effect on the cells. 10 pg/ml of Dox did not further enhance the 
extent of fusion compared to 1 pg/ml of Dox in any of the clonal cell lines. Induction 
of fusion was therefore determined to be optimal at 1 pg/ml of Dox and lack of fusion 
in the clones tested was not due to sub-optimal Dox levels.
72 hrs Dox concentrarion  ( pg/ml)
clone 0 0.01 0.1 1 10 100
1 - - - - cells dead
9 - - - - cells dead
23 - - - - cells dead
7 + 4- + +++ 4-4-4" cells dead
26 + + + +++ 4-4-4- cells dead
28 + + ++ +++ 4-4--E cells dead
96 hrs Dox concen trarion  ( iig/ml)
clone 0 0.01 0.1 1 10 100
1 - - - - cells dead
9 - - - - cells dead
23 - - - - cells dead
7 + + + +++ ++++ cells dead
26 + + ++ +++++ +++++ cells dead
28 + + +++ ++++ +++++ cells dead
Table 7.3: Effect of Dox concentration on levels of fusion in 293-On cell lines 
transformed with pTRE-GALV.
293-On sub-clones were plated in 0, 0.01, 0.1, 1, 10 and 100 pg/ml of Dox. 72 and 96
hrs later extent of fusion was determined by light microscopy. -: 0% fusion; +: 1-
20%; ++: 21-40%; +++: 41-60%; +++-H: 61-80%; 81-100%.
7.4 Regulation of GALV expression in Hela cells.
The specificity and efficiency of the Tet-dependent regulation systems are known to 
be cell line specific (Gossen and Bujard 1995), with background levels of gene 
expression and maximal induction levels varying widely between different cell lines. 
Concurrent to our studies in the 293-On cells, the efficiency of the Tet-On system was 
investigated in an additional human cell line. Hela-On cells are a sub-clone of a
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human cervical carcinoma cell line, transformed to express high levels of rTA. To 
determine the background levels of gene expression obtained in this cell line, Hela-On 
cells were transfected with pTRE-GALV and the extent of syncytia formation was 
determined at 48 hrs post transfection (Figure 7.5). A high level of background 
fusion was also observed in the bulk transfected Hela-On cells in the absence of Dox. 
Extent of fusion reached 50-60% by 48 hrs compared to zero fusion in the un­
transfected control.
Figure 7.5: Syncytia formation in Hela-On cells transiently transfected with 
pTRE-GALV.
Phase contrast microscopy of A. parental, unmodified Hela-On cells or B. pTRE- 
GALV transfected Hela-On cells 48 hrs post transfection.
The feasibility of generating double-stable transformed cell lines expressing GALV 
under the control of Dox was also investigated using this cell line. For these studies 
the pTRE-GALV vector was modified to carry the Puro resistance gene yielding 
plasmid pTRE-GALV-Puro. This modification served to enhance the efficiency of 
the trai^ormation of the target cells and increase the number of resulting Puro 
resistant clones. Hela-On cells were transfected with pTRE-GALV-Puro and 48 hrs 
later they were selected with 0.5 pg/ml Puro. 2-3 weeks later individual Puro- 
resistant colonies were isolated and further expanded. As previously described for the 
293-On clones, the Hela-On clones were screened for GALV expression in a fusion 
induction assay by plating each clone in duplicate samples and adding 1 pg/ml Dox to 
one set of the cells. Fusion induction was monitored over 96 hrs and the results of 
representative clones are summarised in Table 7.4. Clones 1, 6 and 21 exhibited no 
background fusion yet significantly high levels of fusion upon Dox administration 
(Table 7.4 and Figure 7.6) and were regarded as “highly positive” clones. Clone 6
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responded the fastest to Dox stimulation compared to the other 2 clones as shown by 
the high levels of fusion observed by 24 hrs. Clone 9 exhibited no background fusion 
in the absence of Dox and low fusion induction in the presence of Dox and was 
regarded as a “weakly positive” clone. The remaining clones exhibited minimal to no 
fusion induction upon Dox stimulation at any of the timepoints tested.
Sub- - D o x + D o x
Clone 24 hrs 48 hrs 72 hrs 96 hrs 24 hrs 48 hrs 72 hrs 96 hrs
1 - - - - ++ +++ +++++ +++++
2
O
- - - - + + + +
O
6 - - - - ++++ ++++ ++++ +++
9 - - - - + + + + + + + +
10 - - - - - - - -
13 - - - - + + + +
16 - - - - - - - -
2 1 . . - - + +++ ++++ +++++
Table 7.4: Level of fusion of double-stable Hela-On sub-clones expressing 
GALV.
To determine the levels of induction of GALV expression in each individual Hela-On 
GALV-expressing sub-clone cells were cultured in 1 pg/ml of Dox and syncytia 
formation was monitored by phase contrast light microscopy. Basal levels of GALV 
expression were determined by monitoring fusion in the absence of Dox. -: 0% 
fusion; +: 1-20%; +T: 21-40%; 41-60%; ++++: 61-80%; +++++: 81-100%.
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Figure 7.6: Syncytia formation in Hela-On double-stable sub-clones following 
Dox administration.
Hela-On sub-clones 1, 3, 6 and 9 were cultured in 1 pg/ml Dox or in Dox-free media 
and fusion was monitored over 96 hrs by light microscopy. Representative pictures 
are shown.
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GALV expression levels in the presence or absence of Dox in the Hela-On-TRE- 
GALV clones were confirmed by a Northern Blot. Cells from selected clones (the 
negative clone 3, the weakly positive jone 9 and the highly positive clones 1 and 6) 
were cultured in media containing 1 pg/ml Dox or left untreated and RNA was 
extracted at 24, 48, 72 and 96 hrs following onset of Dox treatment and analysed by 
northern blot using a cDNA probe specific for GALV. No GALV expression could 
be detected in any of the clones in the absence of Dox treatment at any timepoint 
(Figure 7.7). As expected, in the presence of Dox no expression could be detected by 
clone 3, while high levels of GALV expression could be detected in clones 1, 6 and 9 
at all timepoints tested. These results confirm the absence of background gene 
expression in the absence of Dox in these clones, as well as the high levels of 
inducibility in clones 1, 6 and 9.
The difference in the fusion levels observed among the transformed clones obtained 
after single cell clonal expansion may reflect a difference in the number of integrated 
copies of the pTRE-GALV-Puro plasmid from which gene expression could be 
induced. To determine the number of integrated copies of the GALV gene, genomic 
DNA was isolated from clones 1, 3, 6 and 9 and treated with the restriction 
endonuclease Xhol. This enzyme will cut the pTRE-GALV-Puro plasmid 
immediately upstream of the TRE (Figure 7.2C). The DNA was then analysed by 
Southern Blot using a cDNA probe specific for GALV. As expected, the parental 
non-transformed Hela-On cells did not carry any copy of the pTRE-GALV-Puro 
plasmid (Figure 7.8). Cells from clones 1, 6 and 9 all carried one copy of the 
response plasmid based on the single banding obtained. Interestingly, clone 3, which 
exhibited no fusion upon Dox stimulation, also carried one copy of the response 
plasmid. The difference in the expression levels and induction of GALV-mediated 
fusion among the clones analysed would therefore more likely be explained by 
differences in the site of integration of the plasmid: integration near highly active 
chromatin may result in higher gene expression levels whereas integration near a 
silent site may result in lower to absent gene expression. Alternatively, the integrated 
copy of TRE-GALV in clone 3 is not intact.
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Figure 7.8: Southern Blot analysis of Hela-On sub-clones.
Genomic DNA from parental Hela-On cells and sub-clones 1, 3, 6 and 9 was isolated, 
treated with Xhol endonuclease and analysed by Southern Blot using a cDNA probe 
specific for GALV.
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7.5 Reduction of basal levels of gene expression using a transcriptional 
silencer.
Basal levels of gene expression in the Tet-On system can be reduced by incorporation 
of a third component in the system, the tetracycline transcriptional silencer (tTS) 
(Freundlieb, Schirra-Muller et al. 1999). tTS can bind to the TRE in the response 
plasmid in the absence of Dox and actively inhibit initiation of transcription from the 
Tet-responsive promoter. As Dox is added in the cells, it binds tTS and induces a 
conformational change such that the silencer is no longer able to bind the TRE. At 
optimal Dox levels, the rtTA will be converted to its active form, associate with the 
TRE and stimulate transcription. 293-On cells were transiently transfected with 
pTRE-Luc alone or pTRE-Luc plus ptTS, a plasmid expressing the tTS, in the 
presence or absence of Dox and luciferase expression was monitored for a total of 72 
hrs following transfection. As shown in Figure 7.9 the basal levels of luciferase 
expression in the absence of Dox were reduced in the presence of tTS. Moreover, 
levels of gene expression upon Dox activation were higher in the presence of the tTS, 
resulting in significantly higher fold induction compared to the samples where tTS 
was absent.
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Figure 7.9: Expression of tTS reduces basal levels of gene expression in 293-On 
cells.
Protein from 293-On cells transfected as indicated was analysed for luciferase 
expression in a luciferase assay. + Dox: cells cultured in 1 pg/ml Dox; - Dox: cells 
cultured in 0 pg/ml Dox.
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To investigate if the same effect could be obtained when the highly cytotoxic GALV 
gene was expressed, 293-On cells were transfected with pTRE-GALV alone or 
pTRE-GALV plus ptTS in the presence or absence of Dox. Cells were also 
transfected with pCR3.1-GALV as a positive control or pEGFP as a negative control. 
Fusion levels were monitored over 96 hrs and the results are summarised in Table
7.5. In the absence of Dox background levels of fusion were reproducibly reduced 
when cells were co-transfected with tTS and by 96 hrs only approximately 10% of the 
cells were forming syncytia, compared to approximately 80% of cells in the pTRE- 
GALV alone samples. Furthermore, levels of Dox-induced fusion in the tTS 
expressing cells were similar to those obtained in the positive control.
Sam ple
Timepoints (hrs)
24 48 72 96
pTRE-GALV + ++ +++ ++++
pTRE-GALV + ptTS - Dox - + + +
pTRE-GALV + ptTS + Dox +++ ++++ ++++ +++++
pCR3.1-GALV ++++ +++++ +++++ +++++
pEGFP - - - -
untransfected - - - -
Table 7.5: tTS expression reduces background fusion in 293-On cells transiently 
transfected with pTRE-GALV.
293-On cells were transfected with indicated plasmid and syncytia formation was 
monitored over 96 hrs. + Dox: cells cultured in 1 pg/ml Dox; - Dox: cells cultured in 
0 pg/ml Dox.
-: 0% fusion; +: 1-20%; ++: 21-40%; +++: 41-60%; ++++: 61-80%; +++++: 81- 
100%.
7.6 Development of a human melanoma cell line expressing GALV under the 
control of the Tet-On system.
Our results thus far demonstrate the feasibility of developing stable GALV-expressing 
tumour cell lines utilising the Tet-On system of transcriptional regulation. Based on 
these results, and the results of chapter 5 showing that FMG-mediated fusion
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significantly enhances the immunogenicity of syngeneic/allogeneic vaccine we 
decided to develop a human melanoma cell line that would conditionally express 
GALV upon Dox stimulation. This cell line could serve as an “off the shelf’ fusion 
partner to patient-derived material for the generation of fusing human tumour cell 
vaccines for clinical use. The human melanoma cell line A375M was sequentially 
modified as shown in Figure 7.10 to express the key components of the regulation 
system.
A375M cells were initially transfected with the pTet-On plasmid alone or pTet-On 
plus ptTS and grown in 1 mg/ml Neomycin. Individual transformed colonies were 
isolated, further expanded and tested for basal levels of gene expression and 
inducibility of gene expression. A total of 33 out of 48 colonies initially picked from 
the plates survived the expansion process. The clones were transfected with pTRE- 
Luc in the presence or absence of Ipg/ml Dox and 48 hrs later luciferase expression 
levels were determined. Results from representative clones are shown in Figure 
7.11 A. In addition, the fold increase in the levels of luciferase expression in the 
presence of Dox compared to expression levels in the absence of Dox is shown in 
Figure 7.11B. Clones 2:14, 2:22 and 2:30, expressing both the pTet-On and ptTS 
plasmids, were chosen as the clones with the lowest basal level of gene expression 
and highest induction potential.
A375M-On clones 2:14, 2:22 and 2:30 were subsequently transfected with pTRE- 
GALV-Puro and grown in 0.4 pg/ml of Puro. As before, individual transformed 
colonies were isolated and expanded. A total of 60 sub-clones survived the expansion 
process and were screened for GALV expression and fusion induction in the presence 
of Dox. Results from representative clones are shown in Table 7.6. High levels of 
fusion could be induced in several sub-clones upon Dox treatment, all of which 
originated from A375M-On clone 2:14. By day 3 of Dox treatment, approximately 
80% of cells of sub-clone 21 and approximately 60% of cells of sub-clones 12, 17 and 
23 were forming syncytia. Syncytia formation reached very high levels by day 6 of 
Dox treatment, with 90-100% of cells of sub-clones 17 and 21 and 70-80% of cells of 
sub-clones 2, 6, 10, 12, 22 and 23 forming syncytia.
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Figure 7.10: Outline of strategy used to generate double-stable A375M cells.
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Figure 7.11: Screening of A375M-On clones for low basal gene expression and
high induction potential. ^
A. A375M-On clones cultured in 0 or 1 i^g/ml Dox were transfected with pRTbLuc 
and 48 hrs later protein was extracted and analysed for luciferase activity. B. fold 
induction of luciferase expression in A375M-On clones.
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A375M-ON pTRE-Galv Dav 3 Day 6
clone sub-c lone + Dox - Dox + Dox -Dox
14 2 ++ - ++++ -
6 + - ++++ -
9 - - + -
10 + - ++++ -
12 +++ - ++++ -
14 - - ++ -
17 +++ - +++++ -
21 ++++ - +++++ -
22 ++ - ++++ -
23 +++ - ++++ _
22 21 + - - -
22 + - - _
30 1 + - + -
3 + - + -
8 - - - -
9 - - - _
15 - - - _
20 + - + -
Table 7.6: Induction of fusion in double-stable A375M-On sub-clones expressing 
GALV.
A375M-On-TRE-GALV double stable sub-clones were cultured in media containing 
0 pg/ml Dox or 1 pg/ml Dox and extent of syncytia formation was assessed 3 and 6 
days later. 0% fusion; +: 1-20%; ++: 21-40%; -H-+: 41-60%; -H-++: 61-80%; 
+++++; 81-100%.
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7.7 Sum m ary
The Tet-On system for transcriptional regulation of gene expression was employed in 
these studies to regulate expression of the GALV envelope gene. Transient 
transfection of 293-On or Hela-On cells lead to high basal levels of gene expression 
as demonstrated by Luc or GALV expression in the absence of Dox. Following stable 
selection of transduced cells, 293-On and Hela-On cell lines could be developed that 
exhibited minimal to no basal levels of syncytia formation and high levels of Dox- 
induced fusion. Co-expression of tTS in the cells expressing the itTA and TRE- 
GALV led to significant reduction of the levels of basal gene expression. These 
results demonstrate that it is possible to generate stably-transduced human cell lines 
expressing the GALV FMG under the control of Dox.
Based on the results shown in chapters 5 and 6 we decided to pursue the development 
of fusing tumour cell vaccines for therapeutic application in humans. “Off the shelf’ 
fusing cell lines could be used to fuse with patient derived tumour material ex vivo 
and the fusing vaccine would be irradiated and administered to the patient. 
Alternatively, an “off-the-shelf’ fusing tumour cell vaccine could be directly 
administered into a patients tumour nodule. Utilising the Tet-On system we were able 
to demonstrate the feasibility of generating conditionally fusing human melanoma cell 
lines. These cell lines expressed all three components of the Tet-On system, the rtTA, 
the TRE-GALV and the tTS, and expression of high levels of GALV was induced 
only following treatment with effective concentrations of Dox.
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Chapter 8 
Discussion
Employing immunotherapy strategies for the treatment of patients with cancer has 
gained significant respect over the last two decades. This has come as a direct result 
of advances in the understanding of the molecular basis of immunological responses 
to cancer, along with a better understanding of cellular immunology. The ultimate 
goal of cancer immunotherapy is the induction of a strong tumour-specific immune 
response against the primary tumour, as well as metastatic disease, ideally leading to 
the establishment of immune memory and prevention of further tumour recurrence. A 
hallmark in the evolution of cancer immunotherapy has been the realisation that 
tumour cells express a range of tumour associated antigens against which an immune 
response can be raised. Advances in the molecular characterisation of tumours led to 
the identification of numerous such TAA, including tissue-specific differentiation 
antigens, shared tumour-specific antigens and unique tumour antigens (Van den 
Eynde and Brichard 1995; Rosenberg 1997; Gilboa 1999). However, the majority of 
these antigens are centered around a limited selection of tumour types and the 
dominant immunogenic epitopes have been identified only for a restricted set of MHC 
haplotypes. This makes the generalised application of specialised TAA-based active 
specific immunisation for cancer treatment a limited approach for the majority of 
cancer types.
As an alternative approach tumour cell vaccines have been widely applied in animal 
models and in human studies, where the need for characterisation of individual TAA 
is obviated. First generation tumour cell based vaccines consisted primarily of 
irradiated autologous whole tumour cells or tumour cell lysates combined with non­
specific adjuvants such as BCG or C. parvum (Nawrocki and Mackiewicz 1999; 
Schadendorf, Paschen et al. 2000; Moingeon 2001). The study of such vaccines in 
various experimental systems has demonstrated the feasibility of therapeutic anti­
tumour vaccination in animal models. Early clinical trials in melanoma and renal cell 
cancer with such vaccines have demonstrated that it is possible to break immune 
tolerance to TAA and induce a specific anti-tumour immune response in human 
(McCune, O'Donnell et al. 1990; Hoover, Brandhorst et al. 1993; Greten and Jaffee
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1999), although the overall response rates were low and occurred in patients with low 
tumour burden (similar to animal data).
Although autologous tumour cell vaccines offer the advantage of possessing all the 
relevant patient specific TAA against which an immune response needs to be raised, 
the large-scale generation of such individualised cell vaccines is currently limited by 
the difficulties in routinely and successfully establishing stable cell lines from biopsy 
material of patients tumours. This is particularly acute when genetic modification of 
the vaccine cells is desirable. An alternative approach which eliminates this difficulty 
is the use of long term established cell lines, called allogeneic cancer cells lines since 
they do not originate fi-om the patient in which they are going to be used. The use of 
allogeneic cell lines for purposes of vaccination is feasible given that TAA are often 
shared among a large number of patients and antigens from tumour cells can be 
efficiently cross-presented by host APCs to cross-prime host T-cells (Mitchell, Kan- 
Mitchell et al. 1988; Huang, Golumbek et al. 1994; Ochsenbein, Klenerman et al. 
1999). Allogeneic cell lines offer the great advantage that they can easily be further 
enriched with specific tumour antigens or genetically modified to express 
immunostimulatory molecules (see below).
Encouraging results on the efficacy of allogeneic vaccines have been obtained in the 
clinic. Morton .and colleagues (Morton, Foshag et al. 1992) have developed a 
polyvalent melanoma cell vaccine (Cancer-Vax) developed from three human 
melanoma cell lines. This is an antigen-enriched vaccine containing at least 11 
tumour-associated antigens found in melanoma and other tumours and 8 melanoma 
associated antigens (Chan and Morton 1998). In Phase II trials with stage IV 
melanoma patients, Cancer-Vax plus BCG yielded an overall response rate of 15- 
20%, significantly improved compared to historical controls. A randomised phase III 
trial is underway to confirm the effectiveness of the allogeneic vaccine to induce 
melanoma specific anti-tumour immune responses.
Another example of an allogeneic vaccine is the allogeneic vaccine developed by 
Mitchell and colleagues. Melacine consists of lysates from two mechanically 
disrupted human melanoma cells lines (Mitchell, Harel et al. 1993). Vaccination of 
patients with Melacine plus the adjuvant DETOX resulted in 20 objective responses
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in 106 patients (Mitchell, Harel et al. 1993). However, a randomised phase III study 
of a lyophilised version of MelaciiC.in 140 Stage IV melanoma patients failed to 
demonstrated enhanced clinical benefit of the vaccine when compared to four-drug 
standard chemotherapy, although significantly lower adverse effects were observed 
with the vaccine (Mitchell 1998).
Animal studies have shown that successful vaccination is intimately associated with 
the induction of host cellular immune responses, with CD8 +ve and CD4 +ve T cells 
playing a key role (Toes, Ossendorp et al. 1999). The immunogenicity of tumour 
cells used in the vaccines could be enhanced by genetic modification of the tumour 
cells to express immunostimulatory cytokines, co-stiniulatory molecules, or MHC 
molecules (Nawrocki and Mackiewicz 1999; Bocchia, Bronte et al. 2000). Such 
genetic modifications have been shown to help overcome immune tolerance or anergy 
and mediate tumour rejection in both CD4 +ve T helper cell dependent and 
independent manner (Fearon, Pardoll et al. 1990; Baskar, Ostrand-Rosenberg et al. 
1993).
8.1 Genetic Modification of Allogeneic Tumour Cell Vaccines with the Genes 
for IL-12, GM-CSF, IFN-y or hsp70 Does Not Enhance the Immunogenicity of 
the Allogeneic Vaccines.
Cytokine gene modification of tumour cell vaccines has been a very popular approach 
for enhancing anti-tumour immune responses, partly due to the pleotropic mechanism 
of action of the majority of cytokines (Pardoll 1998; Mach and Dranoff 2000; 
Schadendorf, Paschen et al. 2000). Importantly, sustained release of cytokines in the 
local tumour environment mediates dramatic local inflammatory effects without any 
systemic or toxic effects often associated with systemic administration of cytokines. 
The aim of the first part of the thesis was to investigate the effect of cytokine 
modification on the immunogenicity of the allogeneic melanoma vaccine, K1735, and 
the induction of an anti-tumour immune response against the syngeneic and poorly 
immunogenic B16 melanoma.
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GM-CSF is one of best studied cytokines in strategies of genetic modification of 
tumour cell vaccines. GM-CSF up-regulates surface expression of MHC and co­
stimulatory molecules, stimulates macrophages and DCs and enhances the antigen 
presenting capacity of APCs (Dranoff, Jaffee et al. 1993; Chiodoni, Paglia et al. 
1999). In combination these effects lead to enhanced T cell reactivity against tumour 
cells. GM-CSF has been shown to effectively generate systemic immunity against a 
number of poorly immunogenic tumours. The first study to show clear evidence of 
the effectiveness of GM-CSF modification was that of Dranoff et al who 
demonstrated that expression of GM-CSF by the very poorly immunogeneic B16 
melanoma enhanced the immunogneicity of an autologous vaccine and lead to 
significant protection of mice from subsequent tumour challenges (Dranoff, Jaffee et 
al. 1993). Other studies in melanoma and other tumour models have shown similar 
results (Castleden, Chong et al. 1997; Ali, McLean et al. 2000; Kinoshita, Kono et al. 
2001; Todryk, Birchall et al. 2001). In the clinic, vaccination of patients with 
metastatic melanoma with an irradiated autologous melanoma vaccine secreting 
human GM-CSF stimulated potent antitumour cellular and humoral immunity as 
demonstrated be dense infiltration of metastatic lesions with CD4^ and CD8^ T cells 
and plasma cells post vaccination, leading to significant destruction (at least 80%) of 
the tumour cells in the infiltrated metastasis, and enhanced IgG antimelanoma 
antibody production post vaccination (Soiffer, Lynch et al. 1998).
IL-12 is a critical element in the host defence against cancer and the mechanisms 
behind its potent anti-tumour effects involve components of both innate and adaptive 
immunity. It is produced by activated macrophages, DCs and B cells. It stimulates 
proliferation of NK cells and T cells and induces expression of a range of cytokines, 
promoting Thl responses (Trinchieri 1995). IL-12 has been shown to promote the 
destruction of the tumour vasculature and the inhibition of angiogenesis (Voest, 
Kenyon et al. 1995) which may contribute to the direct anti-tumour effect of IL-12. 
Several pre-clinical studies have demonstrated the ability of IL-12 to induce potent 
local immune responses, to promote regression of pre-established tumours and to 
enhance systemic protective immunity against poorly immunogenic tumours (Brunda, 
Luistro et al. 1993; Tahara, Zitvogel et al. 1995; Brunda, Luistro et al. 1996; 
Hendrzak and Brunda 1996; Cavallo, Signorelli et al. 1997).
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INF-y plays a central role in tumour surveillance by rendering tumour cells more 
immunogenic (Kaplan, Shankaran et al. 1998). It upregulates surface expression of 
MHC class I and class II molecules, molecules involved in antigen processing, and 
co-stimulatory molecules thereby promoting antigen presentation, recognition and 
elimination by tumour-specific T cells (Boehm, Klamp et al. 1997; Kaplan, 
Shankaran et al. 1998). Furthermore, IFN-y plays a key role in promoting innate 
antitumour immunity by recruiting and activating cells such as NK cells, 
macrophages and neutrophils, while it can have direct anti-tumour effects by 
inhibiting tumour angiogenesis (Qin and Blankenstein 2000). IFN-y expression by 
tumour cells leads to potent and long-term antitumour immunity in mouse models 
(Gansbacher, Banneiji et al. 1990; Abdel-Wahab, Dar et al. 1996; Yang, Vervaert et 
al. 1999).
Based on these findings and on previous work in our laboratory and by others 
demonstrating the feasibility and value of using allogeneic tumour cell vaccines for 
cancer treatment (Kim, Russell et al. 1992; Thomas, Greten et al. 1998; Kayaga, 
Souberbielle et al. 1999; Melcher, Todryk et al. 1999; Chang, Chen et al. 2000; 
Kircheis, Kupcu et al. 2000; Habal, Gupta et al. 2001) we investigated the effect of 
modifying an allogeneic melanoma vaccine with the genes for GM-CSF, IL-12 or 
IFN-y. We hypothesised as with syngeneic vaccines, modification of an allogeneic 
vaccine with these cytokine genes could significantly enhance the immunogenicity of 
the vaccine, leading to immunity against the autologous tumour. The model used in 
these studies was a well-established mouse melanoma model in which K1735 
melanoma cells (H-2*^ ) (Kripke 1979), derived from C3H mice, were used as the 
allogeneic tumour cell vaccine in a model of protection against the development of 
B16 melanoma (H-2^ (Fidler 1975), originating from C57BL/6 mice, in C57BL/6 
mice (H-2^. This serves as a very good model to investigate mechanisms to enhance 
the immunogenicity of a vaccine, since irradiated unmodified K1735 are very poor 
immunogens, leading to poor protection against a B16 challenge in C57BL/6 mice 
(Figure 3.1) (Knight, Souberbielle et al. 1996; Kayaga, Souberbielle et al. 1999; 
Melcher, Todryk et al. 1999; Todryk, Birchall et al. 2001). Despite the poor 
immunogenicity, K1735 cells can become effective vaccines under appropriate
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immunological conditions (Kayaga, Souberbielle et al. 1999; Melcher, Todryk et al. 
1999).
C57BL/6 mice were vaccinated with irradiated K1735 that had been previously 
modified to express murine-GM-CSF, -IL12 or -IFN-y. Animals received 2-3 
consecutive vaccinations 7 days apart and were then challenged with a lethal dose of 
live B16 cells. As shown in Figures 3.2, 3.3 and 3.4 vaccination of mice with 
irradiated K1735-IL-12, K1735-GM-CSF or K1735-IFN-y did not induce systemic 
immunity against the B16 tumour. This result was reproducible, suggesting that 
expression of IL-12, GM-CSF or IFN-y could not enhance the immunising potential 
of irradiated K1735 cells under the conditions used. Although the dose of vaccine 
cells was not varied in these experiments to rule out the possibility that the vaccine 
dose was not sufficient to prime an immune response, previous experience in the 
laboratory had indicated that this dose was effective when combined with adoptively 
transferred DC (Melcher, Todryk et al. 1999). In addition, the dose used in our 
studies falls well within the range of K1735 vaccine doses published in the literature 
(Knight, Souberbielle et al. 1996; Kayaga, Souberbielle et al. 1999; Todryk, Birchall 
et al. 2001 ; Todryk, Birchall et al. 2001).
The level of cytokine release in the local microenvironment is a very important 
parameter in the effectiveness of cytokine-modified tumour cell vaccines. Indeed, 
Chang et al. have demonstrated that the success of their GM-CSF-secreting antigen 
specific allogeneic vaccine in inducing systemic protective immunity against a lethal 
tumour challenge was proportional to the GM-CSF level secreted by the allogeneic 
tumour cell vaccine, with cells releasing higher levels (-200 ng/10^ cells/24 hrs) 
being far more effective in inducing antitumour immunity than cells releasing lower 
levels (-60 ng/10^ cells/24 hrs) (Chang, Chen et al. 2000). This suggests that there 
may be a minimum cytokine secretion level necessary for a tumour cell-based vaccine 
to efficiently induce antitumour immunity. Similarly, Kayaga et al. (Kayaga, 
Souberbielle et al. 1999) have found in their studies that their irradiated B16-GM-CSF 
vaccine was ineffective in protecting mice from a 3 day established B16 tumour, in 
direct contrast to the findings of Dranoff et al. (Dranoff, Jaffee et al. 1993) who 
demonstrated that an irradiated B16-GM-CSF vaccine was capable of protecting
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100% of the animals from pre-established B16 tumours in a similar vaccination 
protocol. One possible explanation for this dramatic difference could be the 
difference in the level of GM-CSF secreted by the tumour cell-based vaccine. In the 
former study GM-CSF secretion was much lower compared to that secreted by the 
tumour cell-based vaccine in the later study (32.75 ng/10*^  cells/48 hrs compared to 
300 ng/10^ cells/48 hrs). It is challenging to compare the levels of cytokine secreted 
by cytokine-modified tumour cell-based vaccines in the different studies and 
determine an effective level of cytokine secretion as most studies use different tumour 
models and different dose and vaccination regiments. In the studies presented in this 
thesis the modified K1735 cells secreted relatively low levels of cytokines, with 
K1735-IL-12 cells secreting 8.3 ng/4xl0^ cells/48 hrs of IL-12, the K1735-GM-CSF 
cells secreting 1.4 ng/4xl0^ cells/48 hrs and the K1735-IFN-y secreting 3.7 ng/4xl0^ 
cells/48 hrs. Although in the lower range, these levels are comparable to other 
published levels for autologous or allogeneic cytokine modified tumour cell-based 
vaccines (Chong, Todryk et al. 1998; Dunussi-Joannopoulos, Runyon et al. 1999). 
However, lack of effectiveness of our cytokine-modified allogeneic vaccines could be 
due to the relatively low levels of cytokine secretion.
Irradiation of cytokine secreting vaccine cells has been shown to have an effect on the 
levels of cytokine released by the vaccine cells (Ali, McLean et al. 2000) and on their 
efficacy (Simova, Bubenik et al. 1998). In our hands, irradiation of the K1735-IL-12, 
-GM-CSF or -IFN-y vaccine cells had no significant effect on the production and 
release of any of the three cytokines by the modified K1735 cells as shown in Figure
3.5. The levels of IL-12 and GM-CSF release remained constant following irradiation 
and were comparable to those obtained by the non-irradiated K173 5-IL-12 and 
K1735-GM-CSF cells respectively. Release of IFN-y, although lower compared to 
that obtained by live cells, remained constant following irradiation.
These data showing a lack of efficacy of cytokine modified K1735 vaccines are in 
agreement with recent literature. Specifically, using a tumour model very similar to 
the one used in this thesis Todryk et al. have recently demonstrated that the efficacy 
of cytokine modified K1735 vaccines varies significantly depending on the model 
used (Todryk, Birchall et al. 2001). When a K1735-GM-CSF vaccine was used as an
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allogeneic vaccine to immunise against a B16 tumour challenge in a protective 
vaccination model in C57BL/6 mice the efficacy was the same as the unmodified 
parental vaccine. In contrast, when used as a syngeneic vaccine in C3H mice to 
immunise against a K1735 tumour challenge significantly better protection was 
observed compared to K1735 alone. The authors suggested that although an immune 
response was occurring against the allogeneic K1735 cells that could potentially lead 
to cross-priming of allogeneic tumour cell-derived antigens by the host APC, cytokine 
secretion by the allogeneic cells could not further enhance the alio MHC-induced 
immune response.
In another study by Kircheis et al. (Kircheis, Kupcu et al. 2000) K1735-IL-2 or B16- 
IL-2 modified irradiated allogeneic vaccines were capable of eliciting significant 
immunity and cross-protect DBA/2 mice from an M-3 syngeneic melanoma (H-2^) 
challenge. However, when K1735-IL-2 or M3-IL-2 allogeneic vaccines were used to 
immunise against the syngeneic B16F10 melanoma in C57BL/6 mice no cross­
protection was observed. Similar observations were made by these authors with a 
K1735-GMCSF allogeneic vaccine in the C57BL/6 model.
Expression of allogeneic MHC on the surface of an allogeneic vaccine leads to 
immune stimulation, “rejection” and rapid clearance of the allogeneic cells as shown 
in chapter 4. We hypothesise that combination of immunostimulatory cytokines such 
as IL-12, GM-CSF or IFN-y, with a potent allo-response will lead to considerably
faster elimination of the vaccine cells, not allowing enough time for efficient immune 
stimulation. Therefore, this could be a contributing factor to the failure of our 
cytokine-modified K1735 vaccines.
Hsp70, a member of the highly conserved family of heat shock proteins, has been 
shown to enhance the immunogenicity and consequently vaccine potency of 
autologous B16 melanoma cells when constitutively overexpressed (Todryk, Melcher 
et al. 1999). Hsp70 over-expression by B16 tumour cells is associated with increased 
immune cell infiltration at the tumour site, a THl profile of intratumoural cytokine 
production and enhanced antigen uptake by DC (Melcher, Todryk et al. 1998; Todryk, 
Melcher et al. 1999). Furthermore, hsp70 has been shown to play an important role in
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the priming of efficient anti-tumour imrhune responses via its ability to chaperone 
tumour antigens to subsets of APCs (Blachere, Li et al. 1997; Castellino, Boucher et 
al. 2000). We therefore looked at the ability of hsp70 to enhance the immunogenicity 
of the allogeneic K1735 cell vaccine in our allogeneic prophylactic vaccination 
model. Overexpression of hsp70 was achieved by either genetic modification of the 
tumour cells to constitutively overexpress hsp70 or by various conditions of heat 
shock, which we show lead to overexpression of hsp70 (Figure 3.6). Vaccination of 
C57BL/6 mice with irradiated K1735-hsp70 cells however did not lead to enhanced 
protection of the animals from subsequent B16 tumour challenge, suggesting that 
hsp70 overexpression had no significant effect on the immunogenicity of the 
allogeneic K1735 cells. We hypothesise that similar to cytokine modified allogeneic 
cells, hsp70 modified allogeneic cells are cleared by the immune system too quickly 
and presumably in a non specific manner such that hsp70 modification is not effective 
in enhancing any antigen-specific immune responses.
Great variation exists between the models of allogeneic tumour cell-based vaccination 
in the mouse system and this most certainly accounts to a great extent for the 
significant variation observed in the effectiveness of allogeneic vaccination. Several 
studies of allogeneic vaccination for melanoma have utilised the K1735/B16 model in 
C57BL/6 mice. This model described by Knight et al. (Knight, Souberbielle et al. 
1996) is one of the few models where completely allogeneic tumour cells (K1735- 
M2) carrying only the natural tumour antigens have been shown to induced cross­
protection (although very weak) against an autologous tumour (B16-F10). This cross­
protection could be fiirther enhanced by transfection of the allogeneic cells with the 
GM-CSF gene (Kayaga, Souberbielle et al. 1999). The data in chapter 3 as well as 
data by Todryk et al. (Todryk, Birchall et al. 2001) and Kircheis et al. (Kircheis, 
Kupcu et al. 2000) however demonstrate that variation in the effectiveness of 
allogeneic vaccines exists even when the same model of study is used. The diversity 
of the different K1735 sublines used in these studies have probably contributed to this 
effect. Furthermore, differences in the in vitro manipulation of the same cell line may 
lead to changes in its characteristics, such as antigen expression and surface MHC 
expression, and this may significantly affect its immunogenic characteristics. To 
obtain a better understanding of the cell lines used as the basis of the allogeneic 
vaccines in our studies we characterised the immunological features of the K1735 as
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well as the B16 cell lines used. Several tumour markers were studied including TAA 
expression, MHC expression and costimulatory molecule expression.
One of the most important parameters for the induction of cross-protection by 
allogeneic vaccines is the expression of TAA by the allogeneic cells that are present 
in the target tumour. In human melanoma a number of the different melanoma- 
associated antigens identified thus far are knovsfito be shared by more than 50% of 
melanoma patients. In murine melanoma however, little information is known about 
the expression of immunologically relevant melanoma-derived tumour antigens or the 
frequency of shared expression of such potential tumour rejection antigens between 
the different melanoma cell lines. To address these issues in our model system we 
screened the K1735 and B16 cell lines for TAA expression using rtPCR. The analysis 
showed that of the eight melanoma antigens tested, only four were shared between the 
two cell lines (Table 4.1). Although expression of a wider panel of melanoma 
antigens could be tested, the data suggest that a relative paucity of shared antigens 
exists between the two cell lines used in our vaccination system and this may 
contribute to the poor vaccine efficacy. However, it is important to mention that 
K1735 express TRP-2 and gplOO, two known tumour rejection antigens for B16 in 
vivo, although at a lower level than B16 (Zhai, Yang et al. 1996; Bloom, Perry-Lalley 
et al. 1997). Our data are in some agreement with the findings of Peter et al. (Peter, 
Mezzacasa et al. 2001) who showed a limited antigen match between K1735 and B16. 
Shared expression of relevant tumour antigens between the allogeneic vaccine and the 
autologous tumour alone, however, is probably not sufficient to induce effective 
cross-protection. This is best demonstrated in the study of Kircheis et al. (Kircheis, 
Kupcu et al. 2000) where the efficacy of cross-protection generated between two 
melanoma cell lines, M3 and B16, varied depending on the mouse model used. Their 
studies suggested that the MHC content of the host may play an important role in the 
effective presentation of relevant antigenic epitopes. Antigens deriving from one cell 
line may not be suitable for presentation by the MHC molecules of the host APC and 
therefore may not be exploited for tumour rejection by the host.
Surface expression of MHC molecules by the two melanoma cell lines was tested 
using surface staining with antibodies specific for MHC Class I or Class II and 
cytofluorometric analysis (Figure 4.1). K1735 cells expressed moderate to high levels
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of the MHC class I molecules tested (H-2D'  ^ and H-2K*^ ) while B16 cells did not 
express any detectable levels of H-2D*’ or H-2K^ under the experimental conditions 
used (Figure 4.1 A). This high surface expression of MHC class I may contribute to a 
more rapid clearance of the K173 5 when used as an allogeneic vaccine. As expected, 
none of the two tumour cell lines expressed any of the MHC Class II molecules tested 
(Figure 4.1B).
Subcutaneous injection of irradiated K1735 cells in C57BL/6 mice led to the 
generation of a proinflammatory environment at the injection site, with high levels of 
IFN-y and TNF-a detected by rtPCR analysis of the injection site at 24 hrs and 48 hrs 
post injection respectively (Figure 4.3). No IL-10 expression was detected up to 4 
days post injection. Induction of a proinflammatory local environment correlated 
well with the clearance of the K1735 cells from the injection site (Figure 4.3), 
suggesting that clearance of the allogeneic cells from the injection site was mediated 
by activated infiltrating immune cells. The presence of IFN-y in the modified 
allovaccine site may potentially explain the lack of effect of adding further IFN-y, or 
the IFN-y inducer IL-12, to the vaccine site via gene modification of the allovaccine. 
To further understand the mechanism of clearance of the allogeneic vaccine cells the 
injection sites were analysed for the types of infiltrating immune cells. Analysis of 
the data showed that by 48 hrs post injection K1735 injection sites were heavily 
infiltrated by NK cells, macrophages and granulocytes. The infiltration of the 
allogeneic cell injection sites was significantly higher than that observed in syngeneic 
B16 cell injection sites. Although a proinflammatory environment was created 
following injection of irradiated allogeneic cells, the infiltrate into K1735 may reflect 
clearance of the allogeneic tumour cells via non-specific effector cells, such as NK 
cells. It appears that this clearance occurs without generating a specific memory T 
cell response to the tumour antigens, such that subsequent rechallenge with antigen- 
expressing B16 cells is not affected. Together these data showing inflammation and 
cell infiltration to the unmodified vaccine site may explain why modifying the 
vaccine environment with the molecules described in Chapter 3 did not enhance allo- 
vaccination.
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8.2 VSVG-Induced Fusogenic Cell Death Is Highly Immunogenic and 
Enhances the Efficacy of a K1735/B16 Vaccine.
Previously in the lab we had described a novel class of therapeutic genes for the 
control of tumour growth (Bateman, Bullough et al. 2000; Diaz, Bateman et al. 2000). 
Expression of genes encoding viral FMGs in tumour cells leads to very potent local 
cell killing, with fusion of neighboring tumour cells to each other and the formation of 
large multinucleated syncytia. Syncytia formation is associated with subsequent 
nonapoptotic, autophagic-like mechanisms of death that are immune potentiating 
(Bateman, Harrington et al. 2002) through the induction of stress related proteins and 
expression of the viral immunogen that could act as potent adjuvants (Melcher, 
Todryk et al. 1998; Bateman, Bullough et al. 2000; Gough, Melcher et al. 2001). We 
therefore decided to investigate whether FMG-induced fusion with all its 
immunological consequences would provide an effective method to liberate relevant 
tumour antigens from allogeneic cells and additional immune-potentiating signals 
sufficient to stimulate an effective antitumour immune response. Once again the 
K1735 allogeneic melanoma vaccination model was studied against the development 
of B16 melanoma in C57BL/6 mice. To induce fusion in murine tumour cells a novel 
FMG gene, VSV-G, was characterised and utilised. Phosphdtidylserine is the 
receptor for VSV-G expressed widely on the surface of murine cells in abundant 
levels. As mentioned previously (Introduction and Chapter 5), VSV-G is 
nonfusogenic in normal ambient pH (approximately pH 7.5). Fusion can only be 
induced when the ambient pH reaches pH 5.5-5.7. This condition of acidic 
environment triggers a conformational change in the VSV-G molecule that converts 
the protein into a fusogenic conformation (Fredericksen and Whitt 1995). VSV-G 
transfection of murine tumour cells, followed 24 hrs later by a transient pH drop, 
leads to extensive syncytia formation by 24-48 hrs following the pH drop (Figure 
5.1).
To investigate the effect of VSV-G-induced fusion on the immunogenicity of 
allogeneic or syngeneic tumour cell vaccines K1735 or B16 fusing tumour cell 
vaccines were prepared and used to vaccinate mice in a prophylactic vaccination 
protocol. To control for the adjuvant effect expression of VSV-G on vaccine cells 
may have and also to control for the effects of the transient pH drop we used a mutant
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VSV-G (VSV-G*) in which a single amino acid mutation reduces the amount of cell 
fusion induced by gene expression and pH drop by >90% (Figure 5.1) (Fredericksen 
and Whitt 1995). Mice were vaccinated weekly with 2-3 consecutive vaccinations of 
irradiated fusing tumour cells and approximately a week after the last vaccination 
they were challenged with live B16 tumour cells as before. Fusion of K1735 cells 
generated no statistically significant therapeutic benefit relative to K1735 cells 
transfected with VSV-G* or naïve mice (Figure 5.2B). Fusion of B16 cells to each 
other was only moderately a more effective vaccine than irradiated B16 cells (Figure 
5.2A).
Several groups have investigated the use of allogeneic/autologous vaccine 
preparations as therapeutic vaccines for cancer with significant success. Staib et al. 
have demonstrated that a mixture of autologous B16-derived melanoma cells with 
allogeneic S91 melanoma cells was able to vaccinate mice against growth of cerebral 
B16 metastasis in C57BL/6 mice (Staib, Harel et al. 1993; Staib, Harel et al. 2001). 
This vaccine required IFN-y-mediated up-regulation of Class I molecules on the 
vaccine cells, as well as the co-administration of the non-specific adjuvant, to be most 
effective. In our hands vaccines composed of mixtures of allogeneic and autologous 
melanoma cells induced no significant therapeutic effect against tumour growth 
(Figure 4.7) regardless of the relative proportion of allogeneic or autologous cells in 
the vaccine preparations. Several studies in the literature have demonstrated the use 
of semi-allogeneic or even semi-xenogeneic hybrid cells for generating potent 
antitumour vaccines (Kim 1979; Payelle, Poupon et al. 1981; Toffaletti, Darrow et al. 
1983; Newton, Romano et al. 2000; Newton, Aciemo et al. 2001). Enhanced 
immunity in these studies was probably a result of an association of TAA with 
allogeneic molecules, while TAA and alloantigens needed to be on the same cell for 
effective vaccination.
Hybrid cells between tumour cells in the literature have thus far been produced 
mainly using polyethylene glycol-mediated fusion and subsequent in vitro selection of 
the fused cells in appropriate selection media. However this approach is time 
consuming and relatively inefficient. We therefore investigated the use of FMG as a 
novel and very efficient mechanism to generate allogeneic/autologous tumour cell
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hybrids and to determine the potency of such a vaccine in inducing protective 
antitumour immunity. FMG expression in a population of cells expressing the 
appropriate receptor for the FMG leads to very efficient and rapid generation of fused 
multinucleated cells (Figure 5.1 and (Bateman, Bullough et al. 2000; Galanis, 
Bateman et al. 2001)). We hypothesised that a combination of expression of relevant 
TAA, allogeneic MHC and other alloantigens, immunogenic cell death associated 
with syncytia formation and the potential adjuvant effect of FMGs in the same 
vaccine may generate the appropriate environment for the induction of short term 
rejection of tumour, as well as long term T-cell mediated responses leading to 
protection of mice from a subsequent tumour rechallenge. K1735/B16 fusing tumour 
cell vaccines were generated by mixing each melanoma cell line at a 1:1 ratio, 
transfecting the mixed population with the VSV-G gene and inducing fusion by a 
transient pH drop. Mice were vaccinated with irradiated K1735/B16 fusing cells in a 
prophylactic vaccination protocol. Vaccination was very effective at protecting mice 
from a subsequent B16 tumour challenge with up to 80% of mice surviving 
rechallenge long term (>60 days), depending on the individual experiment (Figure 
53). The range of protection observed in the experiments carried out with the 
K1735/B16-VSVG vaccine was from 30 to 80% of the animals in the treatment 
group. Overall the experiment was carried out seven times and 30% protection was 
obtained only once, while protection in the remaining experiments was consistently 
between 70 an 80%. These effects were not solely due to the adjuvant effect of the 
VSV-G immunogen, or vector-related components, or the effects of the transient 2 
min pH drop, as a K1735/B16 vaccine expressing the fusion defective VSV-G 
(K1736/B16-VSVG*) (and exposed to the short drop in pH) gave only small 
therapeutic gains.
The mechanism by which tumour cells are fused (and subsequently die) seems to be a 
critical factor in the efficacy of the fusing allogeneic/syngeneic tumour cell vaccines, 
as demonstrated by the lack of efficacy of a PEG fused K1735/B16 vaccine (Figure 
5.4). K1735/B16 cells were fused using the standard PEG-mediated fusion protocols, 
which generate small, disorganised clumping aggregates rather than large, organised 
syncytial structures that are characteristic of VSV-G fusion. Although further 
experiments are required to characterise the two different mechanisms of fusion of the 
K1735/B16 vaccine cells (i.e. level of fusion and induction of stress response signals),
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the significant difference observed in the in vivo efficacy between the two different 
fusion preparations suggests that the mechanisms of cell fusion and its consequences 
are key factors determining the potency of a fusing semiallogeneic vaccine.
The irradiated K1735/B16-VSVG fusing vaccine was very effective in a therapeutic 
vaccination model where up to 80% of mice were cured of small established B16 
tumours (Figure 5.5). Subsequent rechallenge of animals cured from the initial B16 
tumour demonstrated that the fusing K1735/B16-VSVG vaccine was able to generate 
immunity which was long term and tumour specific (Table 5.1). Repetition of the 
experiment in athymic nude mice showed that the antitumour immunity was T cell 
dependent (Figure 5.6).
To investigate the precise contribution of allogeneicity compared to fusion we 
designed prophylactic vaccination experiments similar to the ones described above 
using B16 variants expressing either no MHC class I molecules or a single type of 
syngeneic or allogeneic MHC class I (Thomas, Greten et al. 1998). These data 
demonstrated that vaccines in which VSV-G induced fusogenic cell death was 
combined with allogeneic MHC and relevant tumour antigens were most potently 
immunogenic and induced long term protection (>60 days) of mice against syngeneic 
tumour growth (Figure 63). Furthermore, the protective immunity provided by 
fusing B16 MHC class I loss variant (B16neg-VSVG) and the B16 expressing a single 
type of MHC class I molecule (H-2K*  ^(B16syng-VSVG) was similar (approximately 
50% of the mice were protected long term from tumour challenge), suggesting that 
the anti tumour immune response is a result of cross priming of the relevant TAA by 
host APC and not a result of direct priming by the vaccine cells.
In the experiments described in this section of the thesis, a single gene modification, 
VSV-G-induced tumour cell fusion, is effective in generating both rejection of 
established tumour as well as long term T cell mediated protection responses. 
Considering that the immunological mechanisms involved in generation of short-term 
therapy may be different from those involved in long term protection (Prehn 1993; 
Castleden, Chong et âl. 1997; Melcher, Todryk et al. 1998), syncytia of K l735 and 
B16 cells are likely to have several immunological consequences. The adjuvant 
effects of allo-reactivity, as well as the immunogenicity of the VSV-G antigen, are
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likely to enhance the potency of fusing cell vaccines, by making them good targets for 
NK and other non-specific immune effector killing mechanisms. This is 
demonstrated to some extent by the analysis of the immune infiltrates at injection sites 
of irradiated K1735 or B16 cells which showed that the allogeneic cells induce a 
higher non-specific immune infiltration compared to the autologous cells (Figure 
4.6). Furthermore, similar examination of injection sites of irradiated VSV-G 
expressing K1735/B16 vaccines showed that the presence of the VSV-G immunogen 
in the absence of any fusion in a vaccine preparation adds, although to a limited 
extent, to the observed infiltrate compared to tumour cells alone. However the effects 
of cell fusion clearly add significant immunological potency to the efficacy of the 
fusing vaccines over and above that provided by the adjuvant effects of alio- or anti- 
VSV-G reactivity alone. This is reflected very well in the enhanced recruitment of 
NK cells, macrophages, neutrophils and T cells, as well as in the levels of protection 
seen in vivo with fusing K1735/B16-VSVG vaccines compared to the those obtained 
with the non-fusing K1735/B16-VSVG* vaccines.
In addition, direct syncytial-mediated cell killing will also release immune stimulatory 
molecules at the vaccine site which will recruit and activate host APC (Gallucci, 
Lolkema et al, 1999; Todryk, Melcher et al. 1999), and stress proteins expressed 
within the syncytia (Bateman, Bullough et al. 2000) contribute directly to immune 
stimulation (Melcher, Todryk et al. 1998; Basu, Binder et al. 2000; Gough, Melcher et 
al. 2001). Based on previous work in the laboratory demonstrating the importance of 
macrophages in co-ordinating immune responses to tumour cell killing (Gough, 
Melcher et al. 2001) and in view of the observations in vivo of activation of a 
macrophage response to allogeneic cell vaccines (Figure 4.6) as well as VSV-G- 
fused semi-allogeneic vaccines (Figure 6.1), we hypothesised that macrophages are 
important mediators of the response to fusing cell killing. In vitro experiments 
demonstrated that macrophages can phagocytose tumour material released from dying 
syncytia of K1735/B16 cells much more efficiently than that released from 
K1735/B16 cell mixtures or entirely syngeneic B16-VSV-G fusing cell preparations 
(Figure 6.5), and that these macrophages are activated by allofusion (represented by 
TNF-a secretion, F i^ re  6.5) support our hypothesis. Taken together these data 
show that macrophages and dendritic cells can phagocytose tumour material released
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from dying syncytia. Furthermore, they show that macrophages (but interestingly not 
dendritic cells) can sense allogenicity within fusing mixtures of autologous and. 
allogeneic cells which stimulates both phagocytic uptake of antigens and activation of 
macrophage of TNF-a secretion. Therefore, macrophages recruited to the 
subcutaneous site of allogeneic cell-containing vaccination (as seen in Figure 6.5) 
will be significantly more activated in situ in the presence of fusing cells, permitting 
initiation of a more effective anti tumour immune response. Furthermore, 
experiments utilising a model tumour antigen, OVA, showed that syncytial cell death, 
but not other forms of cell death, promotes cross presentation by immature DC 
(Figure 6.6). Similar results have been obtained in experiments using a human 
tumour antigen, gplOO, and human dendritic cells, demonstrating the relevance of the 
results described here in tlic context of a known melanoma antigen in the human 
system. Enhanced cross-presentation may be mediated by stress proteins such as heat 
shock proteins released by the dying fusing cells that are able to potentiate antigen 
uptake by DCs (Tamura, Peng et al. 1997; Castellino, Boucher et al. 2000). Other 
routes for antigen uptake from dying tumour cells and subsequent cross-presentation 
by DCs have also been reported that rely upon levels and routes of antigen release 
(Kurts, Miller et al. 1998; Mitchell, Nair et al. 1998).
Further investigation of the mechanism of cell death in syncytial structures has shown 
that syncytia-associated cell death occurs through pathways that lack the 
morphological, cytogenetic or biochemical markers of classical apoptosis (Bateman, 
Harrington et al. 2002). This is an important observation as it further demonstrates 
that fusogenic cell death is highly immunogenic as it is likely associated with 
activation of stress response programs (characteristic of non-apoptotic cell death) that 
led to efficient activation of anti tumour immune responses (Melcher, Gough et al. 
1999; Todryk, Melcher et al. 1999; Basu, Binder et al. 2000; Gough, Melcher et al. 
2001).
Overall, we hypothesise that the VSV-G-mediated syncitial death, in the presence of 
alio MHC, may resemble a highly pathogenic event. The simultaneous release of cell 
material from non-apoptotic death, while immune cells are non-specifically
196
stimulated by foreign MHC-peptide structures, would thus be a highly 
immunologically relevant event (Matzinger 1994).
8.3 Generation of FMG Gene Modified Human Melanoma Allogeneic Cell 
Lines Can Be Successfully Attained Using a Small Drug Inducible System for the 
Regulation of Gene Expression.
Clinically, we believe that the data presented in Chapters 5 and 6 are very significant 
for the design of tumour cell vaccines. By modifying either patient recovered tumour 
explants, or established allogeneic cell lines, with a gene for a FMG, fusing tumour 
cell vaccines can be produced in vitro for patient use. In addition, as a more direct 
translation of the observations of Chapter 5, a stable allogeneic cell vaccine could be 
engineered to undergo FMG-mediated fusion which could be boosted by the addition 
of patient-derived tumour cells prepared over a very short period of time following 
surgery to obtain the allogeneic/autologous mix that was shown to be most effective 
in our studies. In this respect the last chapter of this thesis focuses on optimising a 
method that could be employed to generate stable human FMG-expressing cell lines. 
FMGs are highly cytotoxic genes and, as expected, expression of these genes under 
standard constitutive promoters, such as CMV, in any cell line that expresses the 
appropriate FMG receptor would lead to uncontrolled syncytia formation and 
fusogenic cell death in a very short period of time. To obtain cell lines in which 
initiation of fusion is a tightly controlled event, which can reproducibly yield 
extensive syncytia formation, a gene expression regulation mechanisms is required, 
that will allow effective silencing of gene expression as well as very potent and 
immediate induction of gene expression. Such a gene regulation switch can be 
ofifered by the Tet-On transcription regulation system (Gossen, Freundlicb et al. 1995; 
Baron, Gossen et al. 1997; Rossi and Blau 1998), which is a bi-component system 
composed of the tetracycline-controlled transactivator (rtTA) and the tetracycline- 
responsive expression cassette (pTRE). Utilising this system we were able to 
demonstrate that expression of the very potent GALV gene in human cell lines can be 
controlled and subsequently stable cell lines expressing this gene could be generated.
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Initial experiments utilising two human cell lines which are stably transduced with 
rtTA (293-On and Hela-On) and have the potential of high levels of gene expression 
upon Dox stimulation, demonstrated that at the transient transfection level expression 
of GALV under the control of the TRE promoter was leaky (Table. 7.1; Figure 7.4; 
Figure 7.5) leading to significant fusion in the absence of any Dox. Similar 
leakyness in gene expression was also observed using a non-toxic gene, luciferase, 
suggesting that the basal gene expression in this system was not a function of the 
toxicity or the strong bystander effect of the GALV gene. Several reports in the 
literature have indicated the existance of background levels of gene expression using 
the Tet-On system, particularly when polyclonal pools of cells are studied. For 
example Bohl et al. (Bohl, Naffakh et al. 1997) studied the control of production of 
the therapeutic protein erythropoetin (EPO) in mice by transplanting engineered 
primary myoblasts. Using two retroviruses, one encoding rtTA downstream of a 
skeletal-muscle-specific promoter, and the other encoding mouse EPO under the TRE 
the authors modified mouse primary myogenic cells and following selection of a 
polyclonal population of transduced cells found that introduction of the TRE-EPO 
containing vector alone led to low-level EPO secretion that was further increased 
three-fold by adding the rtTA vector in the absence of Dox. This observation 
demonstrated that in the polyclonal pool studied the TRE-EPO promoter had some 
basal activity and rtTA activated to an extent irrespective of Dox induction. Addition 
of Dox led to a significant, 70 fold, induction of EPO secretion by transduced 
myoblasts in vitro. Background levels of gene expression in the absence of induction 
has been observed with several other inducible systems (Clackson 1997). Intrinsic 
effects, such as retention of the active form in the absence of inducing agent, and/or 
the effect of the integration site on the activity of the basal promoter of the target gene 
(position effect) are likely to play a significant role in the generation of the basal 
activity. The observations that basal expression can be detected even in the absence 
of the appropriate transactivator molecules (Bohl, Naffakh et al. 1997), and that stable 
cell clones can be obtained that exhibit very low background expression and high 
induction ratios, suggest that position effects are probably the major contributing 
factor to the variations observed in different experiments. In the case of expression of 
toxic genes such as the FMGs, where background levels of transcription in the 
uninduced state need to be negligible, optimisation of basal promoters will be
198
essential to obtain a stringent system of gene expression regulation (Hoffmann, 
Villalbaetal. 1997).
Single cell selection for generation of cell lines exhibiting only very low basal gene 
expression is a strategy that has been employed by the majority of researchers 
utilising the Tet-inducible gene expression regulation system. In our studies we were 
able to select several 293-On and Hela-On subclones transduced with both rtTA and 
TRE-GALV. Screening of these double-stable cell lines for GALV expression in the 
presence or absence of 1 pg/ml Dox by assessing extent of syncytia formation using 
light microscopy revealed several subclones that exhibited no or very minimal 
background fusion in the absence of the inducer, Dox, and high levels of syncytia 
formation following the addition of the inducer (Table 7.2 & 7.4). GALV expression 
levels in the presence or absence of the inducer were confirmed by Northern Blot in 
the case of the Hela-On subclones.
Incorporation of a third component, the transcriptional silencer -  tTS, in ±e Tet-On 
system has also been shown to significantly improve the performance of the system 
by reducing the basal level of expression without affecting the fully induced level 
(Freundlieb, Schirra-Muller et al. 1999). tTS has the reverse DNA binding properties 
from those of rtTA, i.e. it can bind the TRE in the absence of Dox and can therefore 
be used in the presence of the rtTA to actively suppress gene expression from the 
TRE-containing promoter without affecting rtTA function. Very importantly, rtTA 
and tTS have been designed such that they bear different dimérisation domains, 
preventing heterodimer formation between the two molecules. In transient expression 
experiments transfection of 293-On with pTRE-Luc and ptTS led to significantly 
lower basal levels of luciferase expression compared to that obtained in cells 
transfected with just the pTRE-Luc vector (Figure 7.9). Addition of Dox in the 
double transfected cells led to a 10-fold induction of luciferase expression by 48 hrs. 
Similar observations were made when GALV expression was tested in a similar 
experiment. Background fusion was significantly reduced when the tTS was co­
expressed in the cells (Table 7.5). In addition, fusion of the polyclonal pools in the 
presence of the inducer appeared to be induced more rapid and to a higher extent. 
These observations demonstrate that for the purposes of our studies (generation of cell
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lines expressing the highly toxic FMG genes) the tTS would be an essential 
component that can significantly improve our system.
The data obtained thus far demonstrated that stable GALV-expressing cell lines could 
be obtained utilising the Tet-On system of trancriptional regulation. We therefore 
decided to develop a human melanoma cell line which would conditionally express 
GALV and which could be used as an allogeneic fusion partner in the generation of 
allogeneic/autologous fusing tumour cell vaccines for use in human systems. Very 
few allogeneic melanoma cell lines exist that have been approved by the FDA for use 
in clinical trials in patients with melanoma. One example of an extensively studied 
vaccine is CancerVax, an antigen enriched polyvalant vaccine created by Morton and 
colleagues (Morton, Foshag et al. 1992). Access to this or other approved allogeneic 
human melanoma cell lines for the purposes of our studies was not possible during the 
time-course of this thesis. We therefore decided to use a widely studied human 
melanoma cell line available in the laboratory. A375 is a human melanoma cell line 
established from a female melanoma patient (Giard, Aaronson et al. 1973) and 
expresses some of the known melanoma antigens (Cormier, Hijazi et al. 1998). 
Following sequential transfection of this cell line with plasmids carrying rtTA, tTS 
and TRE-GALV and extensive in vitro screening of over 90 clones at least 8 stably 
transfected subclones could be obtained in which no background fusion could be 
detected while very high levels of fusion could be induced upon addition of Dox 
(Table 7.6). These GALV expressing human melanoma cell lines provide a very 
useful tool for the generation of fusing hybrid melanoma vaccines. Although 
extensive characterisation of these cells lines would be vital prior to any clinical use, 
they can potentially form the platform of a vaccine which can be further enriched with 
fusion of other allogeneic melanoma cells or patient-derived autologous melanoma 
cells. This would lead to the generation of potentially potently immunogenic 
polyvalant fusing melanoma cell vaccines for use in human studies.
One very important observation as far as the technical aspect of generating all of these 
stable cell lines mentioned thus far is concerned has been that development of double­
stable, or triple-stable in the cases where the tTS was also used, cell lines expressing 
all the necessary Tet-On system components in satisfactory levels was particularly 
time-consuming, labour intensive and technically challenging. Transduction of the
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cell lines with three separate plasmids expressing rtTA, tTS and TRE-GALV was 
inefficient, and screening of a large number of subclones was necessary to obtain a 
few that exhibited very stringent control of GALV expression. The limitations of 
DNA transduction procedures significantly restrict the use of the two-plasmid-based 
(or three-plasmid-based) Tet system. Sequential transduction of the cell lines means 
that the laborious screening process needs to be repeated two or three times, adding 
considerable length (in the range of months) to the time required to obtain the final 
cell lines. To overcome these problems several groups have incorporated the Tet 
system into viral vectors that can be produced at high titer and infect cells with very 
high efficiency, allowing for more efficient and rapid generation of populations of 
cells with regulatable gene expression (Bohl, Naffakh et al. 1997; Hu, Ji et al. 1997; 
Buhl, Salvetti et al. 1998; Corti, Sabate et al. 1999; Corti, Sanchez-Capelo et al. 1999; 
Pitzer, Schindowski et al. 1999; Kafri, van Praag et al. 2000). Generation of stable 
cells lines such as the ones described in this thesis requires stable, sustained gene 
expression. Retroviral or lentiviral vectors expressing the different components of the 
Tet system would therefore be best suited for this application. Several groups have 
developed all-in-one retroviral vectors containing the two key component of the Tet 
system, the transactivator and the TRE-gene. Application of such vectors in the 
generation of stable cell lines expressing GALV would considerably reduce the length 
of time and labour required to obtain the final product and would allow the 
application of this system to a wider range of cells. Within the time course of this 
thesis it was not possible to develop suitable viral vector expressing GALV under the 
control of the Tet-On system for use in generating stable cell lines, although this 
represents a critical part of the future work arising from this thesis.
8.4 Conclusion
In conclusion, work presented in this thesis describes a way to generate effective 
allogeneic tumour cell-containing vaccines, enable of inducing potent protective as 
well as therapeutic antitumour immunity, Of the three different gene modifications 
(cytokine expression, hsp expression and FMG-mediated fusion) investigated for their 
potency to augment the therapeutic potential of an allogeneic-based tumour cell 
vaccine in a mouse model of melanoma, FMG-induced fusion is shown to be the most 
effective one. We have begun analysing the important features that make the
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allogeneic-containing FMG-fused tumour cell vaccines potently immunogeneic and 
set the ground for further, more detailed, characterisation of the key molecular 
cellular responses supporting this effect. Finally, we have developed a strategy to 
generate relevant human tumour cell vaccines for clinical use using a regulated gene 
expression system.
8.5 Future Work Stemming From This Thesis.
1. Comparison of effectiveness of fusing tumour cell vaccines when different 
melanoma allogeneic cell lines (such as the 891-M3 melanoma) are used as the 
allogeneic partner in the allogeneic/syngeneic vaccines.
2. Comparison of the effectiveness of fusing tumour cell vaccines in different 
melanoma models, e.g. when K1735 are used as the autologous tumour in C3H 
mice or when 891-M3 cells are used as the autologous tumour in DBA mice.
3. Determine whether the allo-effect can be incorporated into syngeneic tumour 
vaccines to enhance immunogenicity, for example modify B16 tumour cells to co­
express V8V-G and D*' and test as a vaccine against B16 challenge.
4. Investigation of the role of FMG-mediated fusion of tumour cells with DCs in the 
efficacy of such hybrid vaccines. Fusion hybrids between tumour cells and DCs 
have been successfully used in preclinical and clinical studies to induce 
antitumour immunity (Gong Jianlin 1997, May; Wang, 8affold et al. 1998; Gong, 
Nikrui et al. 2000; Kugler, 8tuhler et al. 2000). | |
5. Extended characterisation of the A375 parental and Tet system modified cell lines 
and development of a protocol for the efficient fusion of these allogeneic 
melanoma cell lines with patient derived material.
6. Generation o f viral vectors expressing rtTA, TRE-GALV and tTS for application 
in the development of stable cell lines expressing GALV.
7. Investigation of the effectiveness of FMG-fusing allogeneic/syngeneic human 
tumour cell vaccines in Phase I/E clinical trials.
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